

DEFINITIONS	
Class I	Reimbursed for active cancer or approved treatment or approved indication only.
Restricted Funding (R)	Reimbursed for approved indications only. Completion of the BC Cancer Compassionate Access Program Application is necessary to provide the appropriate clinical information for each patient.
NOTES	

- 1. BC Cancer will reimburse, to the Communities Oncology Network hospital pharmacy, the actual acquisition cost of a Benefit Drug, up to the maximum price as determined by BC Cancer, based on the current brand and contract price. Please contact the OSCAR Hotline at 1-888-355-0355 if more information is required.
- 2. Not Otherwise Specified (NOS) code only applicable to Class I drugs where indicated.
- 3. Intrahepatic use of chemotherapy drugs is not reimbursable unless specified.
- 4. For queries regarding other indications not specified, please contact the BC Cancer Compassionate Access Program Office at 604.877.6000 x 6277 or cap_bcca@bccancer.bc.ca

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
abemaciclib	tablet	Breast	Treatment of Adjuvant Breast Cancer using Abemaciclib and Aromatase Inhibitor With or Without LHRH Agonist	UBRAJABEAI	R	
			Treatment of Adjuvant Breast Cancer using Abemaciclib and Tamoxifen With or Without LHRH Agonist	UBRAJABET	R	
abiraterone	tablet	Genitourinary	Therapy for Metastatic Castration-Sensitive Prostate Cancer using Abiraterone and Prednisone	GUMCSPABI	ı	
			Palliative Therapy for Metastatic Castration Resistant Prostate Cancer Using Abiraterone and prednisone	UGUPABI	R	
			Therapy for Castration Sensitive Very High-Risk Non-Metastatic Prostate Cancer using Abiraterone and predniSONE	UGUPAJABI	R	
acalabrutinib	capsule/tablet	Lymphoma	Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma using Acalabrutinib	LYACAL	ı	
			Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma using Acalabrutinib	LYFACAL	I	
acitretin	capsule	Lymphoma	reversal of early dysplastic and neoplastic stem changes	LYNOS		
afatinib	tablet	Lung	first-line treatment of epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer with afatinib	LUAVAFAT	I	
aldesleukin	injectable	Skin & Melanoma	Treatment of In-Transit Melanoma with Intralesional Aldesleukin IL-2	SMILALD	I	
		Pediatric	pediatric patients with high risk neuroblastoma treated on the ANBL0032 study		I	
			treatment of pediatric patients with high-risk neuroblastoma who achieve a response to prior first-line multi-agent, multimodal therapy using dinutuximab in combination with sargramostim, aldesleukin and tretinoin		I	
alectinib	capsule	Lung	treatment of ALK-positive advanced non-small cell lung cancer with alectinib	LUAVALE	ı	
alemtuzumab	injectable	Lymphoma	treatment of fludarabine-refractory B-chronic lymphocytic leukemia and T- prolymphocytic leukemia	LYALEM	I	
alitretinoin	tablet	Lymphoma	Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides/ Sézary Syndrome)	LYALIT	1	
aminolevulinic acid (LEVULAN® KERASTICK®)	topical solution	Skin & Melanoma	topical therapy for skin cancer with PDT (Photodynamic Therapy)	SMPDT	ı	Only reimbursable when prescribed by physicians in the Skin Tumour Group within the BC Cancer Skin PDT Program
amsacrine	injectable	Leukemia & BMT		LKNOS		
anagrelide	capsule	Leukemia & BMT	patients with thrombocytosis related to a myeloproliferative disorder who have had an inadequate response to or are intolerant of hydroxyurea and/or interferon	LKANAG	ı	

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
anastrozole	tablet	Breast	Treatment of Adjuvant Breast Cancer using Abemaciclib and Aromatase Inhibitor With or Without LHRH Agonist	UBRAJABEAI	R	
			neoadjuvant or adjuvant therapy for breast cancer using anastrozole in postmenopausal women	BRAJANAS	ı	
			Neoadjuvant or Adjuvant Ovarian Suppression and Aromatase Inhibitor in Premenopausal Women or In Men with High Risk Early Stage Breast Cancer	BRAJLHRHAI	I	
			first or second line hormonal treatment for advanced breast cancer in postmenopausal women	BRAVANAS	l	
			therapy for advanced breast cancer using a LHRH agonist and an aromatase inhibitor	BRAVLHRHAI	l	
			therapy of advanced breast cancer using palbociclib and aromatase inhibitor with or without LHRH agonist therapy of advanced breast cancer using ribociclib and aromatase inhibitor with or	BRAVPALAI	l .	
			without LHRH agonist hormonal treatment for advanced endometrial cancer in postmenopausal women	BRAVRIBAI	l	
		Gynecology	with contraindications to tamoxifen or intolerant of tamoxifen therapy for advanced ovarian cancer using an aromatase inhibitor	GOENDAI GOOVAI	l i	
apalutamide	tablet	Genitourinary	- 1 <i>2</i>	GUMCSPAPA	ı	
			Treatment of Non- Metastatic Castration Resistant Prostate Cancer Using Apalutamide	UGUPAPA	R	
arsenic trioxide	injectable	Leukemia & BMT	first-line induction and consolidation therapy of acute promyelocytic leukemia using arsenic trioxide and tretinoin	LKATOATRA	-	
			arsenic trioxide and treatment first-line induction and consolidation therapy of acute promyelocytic leukemia using arsenic trioxide, tretinoin and daunorubicin	LKATOP	ı	
			induction and consolidation therapy of relapsed acute promyelocytic leukemia using arsenic trioxide and tretinoin (All-Trans Retinoic Acid)	LKATOR	1	
		Pediatric	Treatment of Pediatric Patients with De Novo Acute Promyelocytic Leukemia using Arsenic Trioxide In Combination with Tretinoin and with or without Idarubicin and Dexamethasone on the COG AAML1331 Study		1	
asciminib	tablet	Leukemia & BMT	Treatment of Chronic Myeloid Leukemia using Asciminib	LKCMLA	1	
asparaginase (KIDROLASE®)	injectable	Leukemia & BMT		LKNOS, LYNOS	I	
asparaginase-erwinia (ERWINASE®)	injectable	Leukemia & BMT	treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma using asparaginase-Erwinia (Erwinase®) in patients allergic to asparaginase (Kidrolase®) or pegaspargase (Oncaspar®)	LKNOS, LYNOS	1	
atezolizumab	injectable	Gastrointestinal	First-Line Treatment of Advanced Hepatocellular Carcinoma using Atezolizumab and Bevacizumab	GIATZB	_	
		Lung	Treatment of Resected Non-Small Cell Lung Cancer using Atezolizumab Treatment of Advanced Non-Small Cell Lung Cancer Using Atezolizumab	ULUAJATZ LUAVATZ	R I	
			Treatment of Advanced Non-Small Cell Lung Cancer Using 4-Weekly Atezolizumab	LUAVATZ4	1	
			Treatment of Extensive Stage Small Cell Lung Cancer (SCLC) with Atezolizumab, Platinum and Etoposide	LUSCATPE	I	
avelumab	injectable	Genitourinary	Maintenance Therapy of Locally Advanced or Metastatic Urothelial Carcinoma using Avelumab	GUBAVE	l .	
		Skin & Melanoma	second-line treatment of recurrent or metastatic merkel cell carcinoma using avelumab	SMMCCAVE	I	
axicabtagene ciloleucel (YESCARTA)	CAR T-cell	Lymphoma	Third line treatment of adults with diffuse large B cell lymphoma (DLBCL) and high- grade B-cell lymphoma (HGBL)	LYCARTDL3	R	
			Third line treatment for adults with primary mediastinal B-cell lymphoma	LYCARTPM3	R	
axitinib	tablet	Genitourinary	therapy for metastatic renal cell carcinoma using axitinib Treatment of Metastatic Renal Cell Carcinoma Using Pembrolizumab and Axitinib	GUAXIT GUAVPEMAX	1	

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
azacitidine	injectable	Leukemia & BMT	Therapy of Acute Myeloid Leukemia using azacitidine and sorafenib	LKAMLAS	_	
			Therapy of Acute Myeloid Leukemia using Azacitidine and Venetoclax	ULKAMLAVEN	R	
			Therapy of Myelodysplastic Syndrome	LKMDSA	I I	
		Pediatric	Treatment of pediatric myelodysplastic syndrome (MDS) prior to hematopoietic		I .	
		Pediatric	stem cell transplant (HSCT)		'	
	tablet	Leukemia & BMT	Maintenance Oral Azacitidine for Acute Myeloid Leukemia	ULKAMLAMTN	R	
bacillus calmette guerin (BCG)	injectable	Genitourinary	Therapy for High- or Intermediate-Risk Non-Muscle Invasive Bladder Cancer using BCG	GUBCG	1	
bendamustine	injectable	Lymphoma	treatment of Non-Hodgkin Lymphoma with bendamustine	LYBEND	1	
			treatment of Non-Hodgkin Lymphoma with bendamustine and rituximab	LYBENDR	i i	
			treatment of relapsed chronic lymphocytic leukemia with bendamustine	LYCLLBEND	I	
			treatment of relapsed/refractory chronic lymphocytic leukemia or small lymphocytic	LVOLLDENDD		
			lymphoma with bendamustine and rituximab	LYCLLBENDR	'	
			treatment of previously untreated chronic lymphocytic leukemia (CLL) with	LVOLLEDD		
			bendamustine and rituximab	LYCLLFBR	1	
			treatment of rituximab-refractory follicular lymphoma with obinutuzumab in	LVODDEND		
			combination with bendamustine	LYOBBEND	1	
			Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Not	LYPOLABR	1	
			Eligible for Transplant using Polatuzumab Vedotin, Bendamustine and Rituximab			
			First-Line Treatment of Advanced Hepatocellular Carcinoma using Atezolizumab			
bevacizumab	injectable	Gastrointestinal	and Bevacizumab	GIATZB		
			palliative therapy of metastatic colorectal cancer using capecitabine and			
			bevacizumab	GIAVCAPB		
			palliative combination chemotherapy for metastatic colorectal cancer using			
			irinotecan, bevacizumab and capecitabine	GICIRB		
			palliative combination chemotherapy for metastatic colorectal cancer using			
			oxaliplatin, bevacizumab and capecitabine	GICOXB		
			palliative combination chemotherapy for metastatic colorectal cancer using			
			irinotecan, fluorouracil, folinic acid (leucovorin) and bevacizumab	GIFFIRB		
			palliative combination chemotherapy for metastatic colorectal cancer using			
			oxaliplatin, fluorouracil, leucovorin, and bevacizumab	GIFFOXB	l I	
		Neuro-Oncology	patients with relapsed malignant gliomas	CNBEV		
			alternative treatment of gynecological malignancies using bevacizumab, carboplatin			
		Gynecology	and paclitaxel NAB (ABRAXANE)	GOCABRBEV	l I	
			Alternative Treatment of Gynecological Malignancies using Bevacizumab, Cisplatin			Note: Biosimilar bevacizumab
			and Paclitaxel	GOCISPBEV	l I	(ZIRABEV®, AYBINTIO®) is funded for
			Maintenance Therapy of Squamous, Adenocarcinoma, or Adenosquamous Cancer			treatment started on or after November
			of the Cervix with Pembrolizumab with or without Bevacizumab	GOCXBP	l I	1st. 2019. AVASTIN® is funded for
						treatment started prior to November
			Maintenance Therapy of Squamous, Adenocarcinoma, or Adenosquamous Cancer	GOCXBP6	1 1	1st. 2019.
			of the Cervix with 6-Weekly Pembrolizumab with or without Bevacizumab	OCONDI O		150, 2010.
			primary treatment of metastatic/recurrent cancer of the cervix with bevacizumab,			
			carboplatin and paclitaxel	GOCXCATB	l I	
			Primary Treatment of Squamous, Adenocarcinoma, or Adenosquamous Cancer of	UGOCXCATBP	R	
			the Cervix with Bevacizumab, CARBOplatin, PACLitaxel and Pembrolizumab	OGOGNOATBI	18	
			Alternative Treatment of Squamous, Adenocarcinoma, or Adenosquamous Cancer			
			of the Cervix with Bevacizumab, CARBOplatin, PACLitaxel NAB (ABRAXANE) and	GOCXCPNBP	1 1	
		ĺ	Pembrolizumab	2 3 3 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	1 '	
			Treatment of Platinum Resistant or Refractory Epithelial Ovarian Cancer with			
			Bevacizumab and Gemcitabine	GOOVBEVG	1	
			Resistant or Refractory Epithelial Ovarian Cancer with Bevacizumab and			
		ĺ	DOXOrubicin Pegylated Liposomal	GOOVBEVLD	1	
			Platinum Resistant or Refractory Epithelial Ovarian Cancer with Bevacizumab and			
			, ,	GOOVBEVP	1	
			PACLitaxel	COOVDEVE	1 '	

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
bevacizumab (cont'd)	injectable	Gynecology	Treatment of Platinum Resistant or Refractory Epithelial Ovarian Cancer with Bevacizumab and Vinorelbine	GOOVBEVV	I	
			primary treatment of invasive epithelial ovarian, fallopian tube and primary peritoneal cancer with high risk of relapse using bevacizumab, carboplatin and paclitaxel	GOOVCATB	I	Note: Biosimilar bevacizumab (ZIRABEV®, AYBINTIO®) is funded for treatment started on or after November
		Pediatric	treatment with bevacizumab as a single agent or in combination with chemotherapy for pediatric patients with low-grade glioma progressing after first-line chemotherapy		l	1st, 2019. AVASTIN® is funded for treatment started prior to November 1st, 2019.
		Sarcoma	therapy for advanced solitary fibrous tumours and hemangiopericytoma using temozolomide and bevacizumab	SATEMBEV	I	
bexarotene (SAP)	capsule	Lymphoma	patients with refractory cutaneous T-cell lymphoma	LYMFBEX	I	Approval from Health Canada Special Access Programme is required for each patient.
bicalutamide	tablet	Genitourinary	Treatment of Prostate Cancer with High-Dose Bicalutamide Non-Steroidal Treatment of Prostate Cancer, at 50 mg po daily	GUPHDBIC GUPNSAA	<u>.</u>	Not reimbursed for vasomotor symptoms (hot flashes)
binimetinib	tablet	Skin & Melanoma	Treatment of BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma using Encorafenib and Binimetinib	SMAVEB	ı	, , , ,
bleomycin	injectable	Gynecology	therapy of non-dysgerminomatous ovarian germ cell cancer using bleomycin, etoposide, and cisplatin	GOBEP	- 1	
		Genitourinary	curative therapy for germ cell cancer using with bleomycin, etoposide, cisplatin for germ cell cancers	GUBEP	ı	
		Kaposi's Sarcoma	palliative therapy for kaposi's sarcoma using vinblastine alternating with vincristine	KSVB	I	
		Lymphoma	treatment of Hodgkin lymphoma with doxorubicin, bleomycin, vinblastine, and dacarbazine	LYABVD	ı	Not reimbursed for pleurodesis
			treatment of Hodgkin's Disease with cyclophosphamide, vinblastine, procarbazine and prednisone	LYCVPPABO	ı	
		Not Otherwise Specified		Other tumour site code followed by 'NOS' (e.g. LYNOS)	I	
blinatumomab	injectable	Leukemia & BMT	Treatment of Philadelphia chromosome (Ph)-positive or Ph-negative refractory or relapsed pre-B-cell acute lymphoblastic leukemia with blinatumomab	ULKBLIN	R	
			Treatment of Pre-B-Cell Acute Lymphoblastic Leukemia with Minimal Residual Disease using Blinatumomab	ULKMRDBLIN	R	
		Pediatric	Treatment of pediatric patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory pre-B-cell acute lymphoblastic leukemia using blinatumomab		R	
			Pediatric patients with Philadelphia chromosome-negative and CD19-positive pre-B- cell acute lymphoblastic leukemia (ALL) in complete hematologic remission (CR) and with minimal residual disease (MRD) positivity		R	

DRUG	DOSAGE	TUMOUR	APPROVED INDICATIONS	PROTOCOL	CLASS	NOTES
	FORM	SITE	Treatment of Previously Untreated Light Chain Amyloidosis and Not-Eligible for	CODES		
bortezomib	injectable	Lymphoma	Stem Cell Transplant using Daratumumab, Cyclophosphamide, Bortezomib and	LYDARCBDF		
	,	_,	Dexamethasone			
		N	Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell	MYBLDF		***************************************
		Myeloma	Transplant using Bortezomib, Lenalidomide and Dexamethasone	WITBLUF	ı	
			Treatment of Multiple Myeloma using Lenalidomide, Bortezomib and	MYBLDPRE		
			Dexamethasone as Induction Pre-Stem Cell Transplant	WIT DEDFINE	_ '	
			Maintenance Therapy of Multiple Myeloma using Bortezomib for Patients with the	MYBORMTN	1 1	
			High-Risk Chromosome Abnormality			
			Treatment of Multiple Myeloma using Bortezomib, Dexamethasone With or Without	MYBORPRE	1	
			Cyclophosphamide as Induction Pre-Stem Cell Transplant			
			Treatment of Relapsed Multiple Myeloma using Bortezomib, Dexamethasone With or Without Cyclophosphamide	MYBORREL	1	
			Treatment of Multiple Myeloma using Bortezomib, Selinexor, and Dexamethasone			
			With or Without Cyclophosphamide	MYBSD	I	
			treatment of relapsed and refractory multiple myeloma with daratumumab in	MYDARBD	1	
			combination with bortezomib and dexamethasone with or without cyclophosphamide			
			Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell			
			Transplant using Daratumumab, Cyclophosphamide, Bortezomib and	MYDARCBDF	1	
			Dexamethasone			
			treatment of multiple myeloma using melphalan, prednisone and weekly bortezomib	MYMPBOR	1 1	
			with the option of substituting cyclophosphamide for melphalan			
		Pediatric	Treatment of Children with T-cell Lymphoblastic Lymphoma with Bortezomib		I	
			Bortezomib with chemotherapy for pediatric patients with T-cell lymphoblastic		1 1	
la a continuita			lymphoma treated with on the AALL1231 study	LIKOMED		
bosutinib	tablet	Leukemia & BMT	treatment of chronic myeloid leukemia using bosutinib Treatment of Previously Untreated, Stage IV Hodgkin Lymphoma with Doxorubicin,	LKCMLB	- 1	
brentuximab vedotin	injectable	Lymphoma	Vinblastine, Dacarbazine and Brentuximab Vedotin	LYAVDBV	- 1	
			treatment of Hodgkin lymphoma and anaplastic large cell lymphoma with			
			brentuximab vedotin	LYBRENTUX	1	
			treatment for consolidation therapy post-autologous stem cell transplant (ASCT) for			
			Hodgkin lymphoma using brentuximab vedotin	LYBV	'	
			Treatment of Previously Untreated, Stage IV Hodgkin Lymphoma with Sequential			
			Brentuximab Vedotin and DOXOrubicin, vinBLAStine and Dacarbazine in Patients	LYBVAVDBV	1	
			60 Years or Older			
			treatment of CD30-positive peripheral T-Cell Lymphoma (PTCL) with doxorubicin,	LYCHPBV		
			cyclophosphamide, prednisone (CHP) and brentuximab vedotin			
			Treatment of Cutaneous T-Cell Lymphoma (CTCL) with Brentuximab Vedotin	LYCTCLBV	l	***************************************
	injectable	Pediatric	pediatric patients following autologous hematopoietic stem cell transplant (HSCT)		1	
	+		for relapsed or refractory Hodgkin lymphoma			
1			Treatment of relapsed B-cell acute lymphocytic leukemia (ALL) within 12-months of			
brexucabtagene autoleucel	CAR T-cell	Leukemia & BMT	first remission, refractory/relapsed after two or more treatments, or after an	LKCARTALL3	R	
(TECARTUS)	0, 1, 1, 00	Zeanema a zm.	allogeneic stem cell transplantation, OR Ph+ disease with intolerance to tyrosine	2.10/11/1220	.,	
			kinase inhibitors (TKIs) or refractory/relapsed after two or more TKIs			
		1 1	Treatment of adults with relapsed or refractory mantle cell lymphoma after 2 or	LVOADTMOO		***************************************
		Lymphoma	more lines of therapy, including a Bruton's tyrosine kinase (BTK) inhibitor	LYCARTMC3	R	
brigatinib	tablet	Lung	First-Line Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer	LUAVBRI	_	
		ŭ	(NSCLC) with Brigatinib	-	'	
bromocriptine	tablet, capsule	Neuro-Oncology	therapy for pituitary adenomas using bromocriptine	CNB		
husulfan	1	Net Otherwis Co. 15		Tumour site code	1	
busulfan	tablet	Not Otherwise Specified		followed by 'NOS' (e.g.		
			myeloablative conditioning therapy prior to hematopoietic stem cell transplantation	LKNOS)		
1	injectable	Leukemia & BMT	for myeloid malignancies	BMTIVBUCY	1	
		Pediatric	pediatric patients who cannot swallow oral busulfan			
	†		palliative therapy for metastatic castration resistant prostate cancer using		<u> </u>	
cabazitaxel	injectable	Genitourinary	cabazitaxel and prednisone	GUPCABA	1	
cabergoline	tablet	Neuro-Oncology	therapy for pituitary adenomas using cabergoline	CNCAB		
			. , ,			

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
cabozantinib	tablet	Gastrointestinal	Treatment of Advanced Hepatocellular Carcinoma using Cabozantinib	UGICABO	R	
		Genitourinary	Therapy for metastatic renal cell carcinoma using cabozantinib	GUCABO	- I	
		Head and Neck	Therapy of Advanced Differentiated Thyroid Cancer using Cabozantinib	HNOTDCABO	- I	
capecitabine	tablet	Breast	therapy of adjuvant breast cancer using capecitabine	BRAJCAP	I	
			metastatic breast cancer as first line treatment if anthracyclines and taxanes contraindicated, or where sidfect profile and/or treatment delivery concerns favour initial use of BRAVCAP; second or third line treatment of metastatic breast cancer that has previously responded to an anthracycline and taxane	BRAVCAP	1	
			therapy for metastatic breast cancer using capecitabine and lapatinib	BRAVLCAP	l	
				BRAVTCAP	ı	
			Canacitahina	UBRAVTTCAP	R	
		Gastrointestinal	adjuvant therapy of colon cancer using capecitabine	GIAJCAP		
			adjuvant combination chemotherapy for stage III and IIB colon cancer with oxaliplatin	GIAJCAPOX	ı	
			first line palliative therapy of metastatic or unresectable colorectal adenocarcinoma in a patient either not suitable for or refusing GIIRFUFA	GIAVCAP	ı	
			palliative therapy of metastatic colorectal cancer using capecitabine and bevacizumab	GIAVCAPB	ı	
			combined modality therapy for metastatic rectal carcinoma using capecitabine and radiation therapy	GIAVCRT	ı	
			palliative therapy of metastatic neuroendocrine cancer using temozolomide and capecitabine	GIAVTZCAP	I	
			Adjuvant Therapy of Biliary Cancer using Capecitabine	GIBAJCAP	I	
			palliative combination chemotherapy for metastatic colorectal cancer using irinotecan and capecitabine in patients unsuitable for GIFOLFIRI	GICAPIRI	ı	
			palliative combination chemotherapy for metastatic colorectal cancer using oxaliplatin and capecitabine	GICAPOX	ı	
			combination with mitomycin and radiation therapy as curative combined modality therapy for carcinoma of the anal canal	GICART	ı	

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
capecitabine (cont'd)	tablet	Gastrointestinal	palliative combination chemotherapy for metastatic colorectal cancer using irinotecan, bevacizumab and capecitabine	GICIRB	I	
			palliative combination chemotherapy for metastatic colorectal cancer using oxaliplatin, bevacizumab and capecitabine	GICOXB	ı	
			curative-intent combined modality therapy for cancer of the anal canal, using cisplatin, capecitabine and radiation therapy	GICPART	I	
			adjuvant chemotherapy in gastric cancer patients with D2 resection (node negative)	GIGAJCOX	ı	
			or ineligible for adjuvant chemoradiation using oxaliplatin and capecitabine adjuvant chemotherapy in gastric cancer patients with completely resected gastric	GIGAJCPRT		
			cancer using cisplatin and capecitabine and radiation therapy palliative therapy of metastatic or locally advanced anal squamous cell carcinoma	GIGAVCC		
			using cisplatin and capecitabine Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal			
			Junction or Esophageal Adenocarcinoma using Cisplatin, Capecitabine and Trastuzumab	GIGAVCCT		
			Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction or Esophageal Carcinoma using Capecitabine and Oxaliplatin	GIGAVCOX	I	
			First-Line Treatment of Locally Advanced or Metastatic Esophageal, Gastroesophageal, or Gastric Cancer using Oxaliplatin, Capecitabine and	GIGAVCOXN	ı	
			Nivolumab First-Line Treatment of Locally Advanced or Metastatic Gastroesophageal Cancer			
			using Oxaliplatin, Capecitabine and Pembrolizumab palliative treatment of metastatic or locally advanced gastric, gastroesophageal	GIGAVCOXP		
			junction, or esophageal adenocarcinoma using capecitabine, oxaliplatin and trastuzumab	GIGAVCOXT		
			treatment of operable cancer of the stomach, stomach-esophagus junction or lower 1/3 esophagus, given before and after surgery, using epirubicin, cisplatin and capecitabine	GIGECC	1	
			adjuvant chemotherapy for resected pancreatic adenocarcinoma using capecitabine and cemcitabine	GIPAJGCAP	I	
			second line treatment of metastatic or unresectable pancreatic adenocarcinoma using capecitabine	GIPAVCAP	I	
			Adjuvant or Neoadjuvant Combination Chemotherapy for Stage III Rectal Cancer using Oxaliplatin and Capecitabine	GIRAJCOX	ı	
			Adjuvant Therapy for Stage II and III Rectal Cancer using Capecitabine in Patients Previously Treated with Preoperative Radiation Therapy Alone	GIRCAP	I	
			combined modality adjuvant therapy for high risk rectal carcinoma using capecitabine and radiation therapy	GIRCRT	1	
			combined modality adjuvant therapy for high risk rectal carcinoma using capecitabine, infusional fluorouracil and radiation therapy	GIRINFRT	I	
		Head and Neck	treatment of recurrent or metastatic squamous cell cancer of the head and neck with capecitabine treatment of recurrent or metastatic nasopharyngeal cancer with capecitabine	HNAVCAP HNNAVCAP		
carboplatin	iniectable	Breast	neoadjuvant or adjuvant therapy for breast cancer using carboplatin, docetaxel and	BRAJDCARBT		
			trastuzumab Alternative Neoadjuvant or Adjuvant Therapy for Breast Cancer using PACLitaxel	BRAJPNCT		
			NAB (ABRAXANE), CARBOplatin and Trastuzumab palliative therapy for metastatic breast cancer using cisplatin and gemcitabine	BRAVGEMP		
			Palliative Therapy for Metastatic Breast Cancer using Pembrolizumab, Gemcitabine, and CARBOplatin	BRAVPGC	1	
			Alternative NEOAdjuvant Therapy for Triple Negative Breast Cancer using CARBOplatin and PACLitaxel NAB (ABRAXANE) Followed by DOXOrubicin and	BRLACPNAC	ı	
			Cyclophosphamide Alternative NEOAdjuvant Therapy for Triple Negative Breast Cancer using Dose Dense Therapy: CARBOplatin and PACLitaxel NAB (ABRAXANE) Followed by	BRLACPNACG	<u>.</u>	
			DOXOrubicin and Cyclophosphamide NEOAdjuvant Therapy for Triple Negative Breast Cancer using Carboplatin and Weekly PACLitaxel Followed by DOXOrubicin and Cyclophosphamide	BRLACTWAC		

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
			Neoadjuvant Therapy for Triple-Negative Breast Cancer using Dose-Dense			
carboplatin (cont'd)	injectable	Breast	Therapy: Carboplatin and Weekly Paclitaxel Followed by Doxorubicin and	BRLACTWACG	1	
			Cyclophosphamide			
			NEOAdjuvant Therapy for Triple Negative Breast Cancer using Pembrolizumab with			
			CARBOplatin and Weekly PACLitaxel, Followed by DOXOrubicin and	BRPCTAC	1	
			Cyclophosphamide NEOAdjuvant Therapy for Triple Negative Breast Cancer using Pembrolizumab,			
			Weekly CARBOplatin and Weekly PACLitaxel, Followed by DOXOrubicin and	BRPCWTAC		
			Cyclophosphamide	BRECWIAC	'	
		Neuro-Oncology	carboplatin and etoposide in the treatment of recurrent ependymoma	CNCARV	···+·····	
			First-Line Palliative Treatment of Metastatic Anal Squamous Cell Carcinoma using			
		Gastrointestinal	Carboplatin and Weekly Paclitaxel	GIAAVCT	1	
			First-line Palliative Treatment of Advanced Biliary Tract Cancer using Durvalumab,	GIAVDURPG		
			Gemcitabine and Platinum	GIAVDURPG	<u>'</u>	
			First-Line Palliative Chemotherapy for Advanced Gallbladder or Pancreatic	GIAVPG	1	
			Carcinoma and Cholangiocarcinoma using Gemcitabine and Cisplatin	OIAVI O		
			neoadjuvant treatment of esophageal and gastroesophageal carcinomas using	GIENACTRT		
			carboplatin, paclitaxel and radiation therapy			
		Gynecology	alternative treatment of gynecological malignancies using carboplatin and paclitaxel NAB (ABRAXANE)	GOCABR	1	
			alternative treatment of gynecological malignancies using bevacizumab, carboplatin			
			and maditaval NAD (ADDAYANE)	GOCABRBEV	1	
			treatment of advanced/recurrent non-small cell cancer of the cervix with carboplatin			
			and docetaxel	GOCXCAD	1	
			primary treatment of advanced/recurrent non-small cell cancer of the cervix with			
			carboplatin and paclitaxel	GOCXCAT	1	
			primary treatment of metastatic/recurrent cancer of the cervix with bevacizumab,	COCYCATR		
			carboplatin and paclitaxel	GOCXCATB		
			Primary Treatment of Squamous, Adenocarcinoma, or Adenosquamous Cancer of			
			the Cervix with Bevacizumab. CARBOplatin. PACLitaxel and Pembrolizumab	UGOCXCATBP	R	
			7 2 2 1 2			
			Primary Treatment of Squamous, Adenocarcinoma, or Adenosquamous Cancer of	UGOCXCATP	R	
			the Cervix with CARBOplatin, PACLitaxel, and Pembrolizumab Alternative Treatment of Squamous, Adenocarcinoma, or Adenosquamous Cancer			
				GOCXCPNBP		
			Pembrolizumab	GOCACFINDE	' '	
			Alternative Treatment of Squamous, Adenocarcinoma, or Adenosquamous Cancer			
			of the Cervix with CARBOplatin, PACLitaxel NAB (ABRAXANE), and	GOCXCPNP		ļ
			Pembrolizumab			
			Neoadjuvant or Adjuvant Treatment of Endometrial Cancer using CARBOplatin and	GOENDAJCAT		
			PACLitaxel	GUENDAJCAT		
			Treatment of Advanced or Recurrent Endometrial Cancer using CARBOplatin and	GOENDAVCAT		
			PACLitaxel			
			treatment of primarily advanced or recurrent endometrial cancer using carboplatin	GOENDCAD	1 1	
			and docetaxel	-		
			treatment of primary advanced or recurrent endometrial cancer using carboplatin	GOENDCAT	1	
			and paclitaxel primary treatment with visible or no visible residual tumour (moderate, high, or			
			extreme risk) or treatment at relapse of invasive epithelial ovarian, fallopian tube,	GOOVCAD		
		1	and primary peritoneal cancer, using carboplatin and docetaxel	33370/ID		
			carboplatin and gemcitabine for the treatment of recurrent platinum-sensitive			
			ovarian cancer	GOOVCAG	'	
			first or second line therapy for invasive epithelial ovarian cancer using single-agent	GOOVCARB		
			carboplatin	GOOVCARB		
			primary treatment of invasive epithelial ovarian, fallopian tube and primary			
			peritoneal cancer with high risk of relapse using bevacizumab, carboplatin and	GOOVCATB	1	
			paclitaxel			

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
			primary treatment of invasive epithelial ovarian, fallopian tube and primary			
carboplatin (cont'd)	injectable	Gynecology	peritoneal cancer, with no visible residual tumour (moderate-high risk) using	GOOVCATM	1	
			carboplatin and paclitaxel			
			second line treatment using paclitaxel and carboplatin for epithelial ovarian cancer	GOOVCATR	1	
			relapsing after primary treatment	OOOVOATI	L	
			primary treatment of visible residual (extreme risk) invasive epithelial ovarian	GOOVCATX		
			cancer in ambulatory care settings using paclitaxel and carboplatin			
			primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian	GOOVDDCAT		
			tube carcinoma using carboplatin and weekly paclitaxel			
			first line treatment of epithelial ovarian cancer using doxorubicin pegylated	GOOVFPLDC	1	
			liposomal and carboplatin			
			primary treatment of stage III less than or equal to 1 cm visible residual invasive			
			epithelial ovarian cancer or stage 1 grade 3 or stage II grade 3 papillary serous	GOOVIPPC		
			ovarian cancer using intravenous and intraperitoneal paclitaxel and intraperitoneal	0001110		
			carboplatin			
			second line treatment for epithelial ovarian cancer relapsing after primary treatment	GOOVPLDC		
			using pegylated liposomal doxorubicin (PLD) and carboplatin		L	
			treatment of small-cell gynecologic cancer with cisplatin and etoposide	GOSCPE	l I	
			treatment of small-cell gynecologic cancer with cisplatin and etoposide with	GOSCPERT		
			radiation therapy	GOSCFERT	L	
		Genitourinary	palliative therapy for urothelial carcinoma using cisplatin and gemcitabine	GUAVPG	I	
			adjuvant therapy for stage I high risk seminoma using carboplatin	GUSCARB	I	
			therapy of genitourinary small cell tumors with a platin and etoposide	GUSCPE	I	
			therapy of genitourinary small cell tumors with a platin and etoposide with radiation	GUSCPERT	ı	
		Head and Neck	treatment of advanced squamous cell carcinoma of the head and neck cancer using	HNAVFUP	······	***************************************
			fluorouracil and platinum			
			treatment for unresectable, locoregionally recurrent or metastatic squamous cell			
			carcinoma of the head and neck using paclitaxel and cisplatin or carboplatin	HNAVPC	I	
			First-Line Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck	HNAVPCPMB	1	
			with Paclitaxel, Carboplatin and Pembrolizumab			
			treatment of recurrent or metastatic squamous cell carcinoma of the head and neck	HNAVPD	1	
			with platinum and docetaxel			
			treatment of recurrent and metastatic squamous cell cancer with platinum and	HNAVPE	1	
			etoposide		L	
l			First-Line Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck	HNAVPFPMB		
			using Platinum, Fluorouracil and Pembrolizumab		<u> </u>	
carboniatin	injectable	Head and Neck	combined chemotherapy (carboplatin and fluorouracil) and radiation treatment for	HNLACAFRT		
	injootatoro		locally advanced squamous cell carcinoma of the head and neck		ļ	
			Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck	HNLACARTW		
			with Concurrent Weekly CARBOplatin and Radiation	INVERTORITY	L	
			Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck	HNLACART3		
			with Concurrent 3-Weekly Carboplatin and Radiation	INTACANIO	L	
			treatment for advanced nasopharyngeal cancer of the head and neck using	HNNAVFUP		
			platinum and fluorouracil	I II VI VA VI OF	L	
			treatment of recurrent and/or metastatic nasopharyngeal cancer with platinum and	HNNAVPE		
			etoposide	IIININAVAVEL		
	T		treatment of locoregionally recurrent and/or metastatic nasopharyngeal cancer with	HNNAVPG		
			platinum and gemoitabine	I IININAVEG	L	
	T		treatment of recurrent or metastatic nasopharyngeal carcinoma with carboplatin and	HNNAVPC		
	<u> </u>		paclitaxel	IIININAVEC	' '	

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
carboplatin (cont'd)	injectable	Lung	Neoadjuvant Treatment of Non-Small Cell Lung Cancer with Nivolumab, CARBOplatin and PACLitaxel	LUAJNIVPC	ı	
			Neoadjuvant Treatment of Non-Squamous Non-Small Cell Lung Cancer with Nivolumab, Pemetrexed and Platinum	LUAJNIVPP	ı	
			adjuvant carboplatin and paclitaxel following resection of stage I, II and IIIA non- small cell lung cancer	LUAJPC	ı	
			first-line treatment of advanced non-small cell lung cancer with carboplatin and pacilitaxel	LUAVPC	ı	
			First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer with Paclitaxel, Carboplatin, Ipilimumab and Nivolumab	LUAVPCIPNI	ı	
			first-line treatment of advanced squamous non-small cell lung cancer with paclitaxel, carboplatin and pembrolizumab	LUAVPCPMB	ı	
			treatment of advanced non-small cell lung cancer with platinum and gemcitabine	LUAVPG	1	
			first-line treatment of advanced squamous non-small cell lung cancer with platinum, gemcitabine and pembrolizumab	LUAVPGPMB	Ι	
			first-line treatment of advanced non-small cell lung cancer with platinum and pemetrexed	LUAVPP	ı	
			First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer with Platinum, Pemetrexed, Ipilimumab and Nivolumab	LUAVPPIPNI	1	
	•••		first-line treatment of advanced non-squamous non-small cell lung cancer with platinum, pemetrexed and pembrolizumab	LUAVPPPMB	ı	
			treatment of locally advanced non-small cell lung cancer using carboplatin and	LULACATRT	ı	
			paclitaxel with radiation therapy treatment of locally advanced non-small cell lung cancer using cisplatin and etoposide with radiation therapy	LULAPERT	ı	
			treatment of locally advanced non-small cell lung cancer using alternative dosing of cisplatin and etoposide with radiation therapy	LULAPE2RT	Ι	
			treatment of thymoma with cisplatin and etoposide	LUOTPE	 	
			treatment of thymoma using cisplatin and etoposide with radiation therapy	LUOTPERT	ti	
			treatment of cancer of unknown primary involving the thorax with cisplatin and etoposide	LUPUPE	l	
			Treatment of Extensive Stage Small Cell Lung Cancer (SCLC) with Atezolizumab, Platinum and Etoposide	LUSCATPE	ı	
			Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC) with Durvalumab, Platinum and Etoposide	LUSCDURPE	ı	
			Treatment of Extensive Stage Small Cell Lung Cancer (SCLC) with Platinum and Etoposide	LUSCPE	ı	
			Treatment of Extensive Stage Small Cell Lung Cancer with Platinum and Oral	LUSCPEPO	ı	
			Treatment of Limited Stage Small Cell Lung Cancer using Platinum and Oral	LUSCPEPORT	ı	
			Treatment of Limited Stage Small Cell Lung Cancer using Platinum and Etoposide	LUSCPERT	ı	
			second line treatment of extensive stage small cell lung cancer (SCLC) with irinotecan with or without platinum	LUSCPI	ı	
		Lymphoma	Treatment of Lymphoma with Dexamethasone, Cytarabine, Platinum and riTUXimab	LYDHAPR	ı	
			treatment of relapsed or refractory advanced stage aggressive B-cell non-Hodgkin's lymphoma with ifosfamide, carboplatin, etoposide and rituximab	LYRICE	1	
		Primary Unknown	primary treatment of cancer of unknown primary origin using carboplatin and paclitaxel	PUCAT	ı	
		Skin & Melanoma	treatment of recurrent or metastatic Merkel cell carcinoma with cisplatin and etoposide	SMMCCPE	ı	
		Not Otherwise Specified		Other tumour site code followed by 'NOS' (e.g. HNNOS)	l	



DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
carfilzomib	injectable	Myeloma	Therapy of Multiple Myeloma using Carfilzomib and Dexamethasone With or Without Cyclophosphamide	MYCARDEX	ı	
			Therapy of Multiple Myeloma using Carfilzomib, Lenalidomide with Dexamethasone	MYCARLD	- 1	
			Therapy of Multiple Myeloma using Carfilzomib, Dexamethasone and Isatuximab with or without Cyclophosphamide	UMYISACARD	R	
carmustine	injectable	Lymphoma	topical therapy in cutaneous T-cell lymphoma	LYCARTOP		
			1	Other tumour site code		
		Not Otherwise Specified		followed by 'NOS' (e.g. LKNOS)	I	
cemiplimab	injectable	Skin & Melanoma	Cemiplimab for Treatment of Cutaneous Squamous Cell Carcinoma	SMAVCEM	ı	
ceritinib	capsule	Lung	treatment of ALK-positive advanced non-small cell lung cancer (NSCLC) with ceritinib	LUAVCER	I	
cetuximab	injectable	Gastrointestinal	palliative third line treatment of metastatic colorectal cancer with wild-type KRAS using cetuximab and irinotecan	GIAVCETIR	I	
		Head and Neck	combined cetuximab and radiation treatment for locally advanced squamous cell carcinoma of the head and neck	HNLACETRT	ı	
		Skin & Melanoma	Treatment of Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma using Cetuximab	SMAVCET	ı	
chlorambucil	tablet	Lymphoma	low grade lymphoma and chronic lymphocytic leukemia	LYCHLOR	- 1	
			treatment of indolent B-cell lymphoma with chlorambucil and rituximab	LYCHLRR	l I	
			treatment of chronic lymphocytic leukemia with chlorambucil and rituximab	LYCLLCHLR	l I	
			lymphoma palliative chemotherapy	LYPALL	l I	
			treatment of previously untreated chronic lymphocytic leukemia using obinutuzumab in combination with chlorambucil	LYOBCHLOR	ı	
				Other tumour site code		
		Not Otherwise Specified		followed by 'NOS' (e.g.	1	
				LKNOS, LYNOS)		
chlormethine	topical gel	Lymphoma	topical chlormethine in cutaneous T-Cell lymphoma	LYMECHLOR		
cisplatin	injectable	Breast	palliative therapy for metastatic breast cancer using cisplatin and gemcitabine	BRAVGEMP	i	
		Neuro-Oncology	adjuvant lomustine, cisplatin and vincristine in adult high-risk medulloblastoma or other primitive neuroectodermal tumour	CNCCV	ı	
		Gastrointestinal	First-line Palliative Treatment of Advanced Biliary Tract Cancer using Durvalumab, Gemcitabine and Platinum	GIAVDURPG	ı	
			First-Line Palliative Chemotherapy for Advanced Gallbladder or Pancreatic Carcinoma and Cholangiocarcinoma using Gemcitabine and Cisplatin	GIAVPG	ı	
			curative-intent combined modality therapy for cancer of the anal canal, using cisplatin, capecitabine and radiation therapy	GICPART	ı	
				GIEMBOL	ı	Note: only funded when prescribed by specialists at BC Cancer Vancouver and Royal Jubilee Hospital
			palliative chemotherapy for upper gastrointestinal tract cancer (gastric, esophageal, gall bladder carcinoma and cholangiocarcinoma) and metastatic anal cancer using infusional fluorouracil and cisplatin	GIFUC	ı	
			combined modality curative therapy for carcinoma of the anal canal using cisplatin, infusional fluorouracil and radiation therapy	GIFUPART	l	
			adjuvant chemotherapy of gastric cancer patients with completely resected gastric	GIGAJCPRT	1	
			cancer using cisplatin and capecitabine and radiation therapy palliative therapy of metastatic or locally advanced anal squamous cell carcinoma	GIGAVCC	l I	
			using cisplatin and capecitabine Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal		!	
			Junction or Esophageal Adenocarcinoma using Cisplatin, Capecitabine and	GIGAVCCT	- 1	
			Trastuzumab palliative treatment of metastatic or inoperable, locally advanced gastric or	CICAVCET		
			gastroesophageal junction adenocarcinoma using cisplatin, infusional fluorouracil and trastuzumab	GIGAVCFT	'	



DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
		V., _	treatment of operable cancer of the stomach, stomach-esophagus junction or lower			
cisplatin (cont'd)	injectable	Gastrointestinal	1/3 esophagus, given before and after surgery, using epirubicin, cisplatin and	GIGECC	1	
. ` ` ′	1		capecitabine			
			palliative therapy of neuroendocrine tumours using cisplatin and etoposide	GIPE	l	
			hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with peritoneal	GIPMHIPEC		
			mesothelioma using doxorubicin, cisplatin and paclitaxel	GIPINITIPEC	<u>'</u>	
		Gynecology	therapy of non-dysgerminomatous ovarian germ cell cancer using bleomycin,	GOBEP	I .	
		Gyriecology	etoposide and cisplatin	GODEF	<u> </u>	
			alternative treatment of gynecological malignancies using cisplatin and paclitaxel	GOCISP	- 1	
			Alternative Treatment of Gynecological Malignancies using Bevacizumab, Cisplatin			
			and Paclitaxel	GOCISPBEV	l	
			treatment of high risk squamous carcinoma, adenocarcinoma, or adenosquamous			
			carcinoma of the cervix with concurrent cisplatin and radiation	GOCXCRT	- 1	
			therapy of dysgerminomatous ovarian germ cell cancer using cisplatin and	GOEP	1	
			etoposide			
			invasive epithelial ovarian cancer	GOOVCIS	!	
			treatment of small-cell gynecologic cancer with cisplatin and etoposide	GOSCPE		
			treatment of small-cell gynecologic cancer with cisplatin and etoposide with	GOSCPERT	1	
			radiation therapy adjuvant therapy for urothelial carcinoma using cisplatin and gemcitabine			
		Genitourinary		GUAJPG	ļ	
			palliative therapy for urothelial carcinoma using cisplatin and gemcitabine	GUAVPG		
			Neoadjuvant Treatment of Urothelial Cancer using Dose-Dense Methotrexate,	GUBDDMVAC	1	
			Vinblastine, Doxorubicin and Cisplatin	OUDED		
			curative therapy for germ cell cancer using bleomycin, etoposide and cisplatin treatment of locally advanced bladder cancer with weekly cisplatin and concurrent	GUBEP		
			radiation	GUBPWRT	1	
			treatment of metastatic adrenalcortical cancer with doxorubicin, etoposide, cisplatin			
			and mitotane	GUEDPM	- 1	
			therapy for nonseminoma germ cell cancer using etoposide-cisplatin	GUEP		
			combined modality therapy for squamous cell cancer of the genitourinary system		·	
			using fluorouracil and cisplatin with radiation	GUFUPRT	1	
			therapy for transitional cell cancers of the urothelium using methotrexate,			
			vinblastine, doxorubicin and cisplatin	GUMVAC	- 1	
			neo-adjuvant therapy for urothelial carcinoma using cisplatin and gemcitabine	GUNAJPG	·	
			therapy of genitourinary small cell tumors with a platin and etoposide	GUSCPE	· I · · · · · · · · · · · · · · · · · ·	
					T	
			therapy of genitourinary small cell tumors with a platin and etoposide with radiation	GUSCPERT	<u> </u>	
			advanced therapy for relapsed testicular germ cell cancer using paclitaxel,	GUTIP	Ī	
			ifosfamide and cisplatin	GUTIF	L'	
			consolidation/ salvage treatment for germ cell cancer using vinblastine, cisplatin,	GUVEIP	I .	
			ifosfamide and mesna		L'	
			nonseminoma consolidation/salvage protocol using etoposide, cisplatin, ifosfamide,	GUVIP2		
			mesna		<u>'</u>	
1		Head and Neck	treatment of advanced squamous cell carcinoma of the head and neck cancer using	HNAVFUP		
		TIOGG AND INCOR	fluorouracii and piatinum		<u>'</u>	
1			palliative chemotherapy for advanced head and neck squamous cell carcinoma with	HNAVP	1 1	
			weekly cisplatin		ļ	
1			treatment for unresectable, locoregionally recurrent or metastatic squamous cell			
1			carcinoma of the head and neck using paclitaxel and cisplatin or carboplatin	HNAVPC		
			sales in and the state and the state and passing passing of and displacing of carbopiating			



DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
cisplatin (cont'd)	injectable	Head and Neck	treatment of recurrent or metastatic squamous cell carcinoma of the head and neck	HNAVPD	1	
			with platinum and docetaxel			
			treatment of recurrent and metastatic squamous cell cancer with platinum and	HNAVPE	1	
			etoposide First-Line Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck			
			using Platinum, Fluorouracil and Pembrolizumab	HNAVPFPMB	1	
			treatment of locally advanced (alternate) head and neck cancer using cisplatin			
			during radiation therapy	HNLAALTPRT	1	
			treatment of locally advanced squamous cell carcinoma of the head and neck with	HNLADCF	1	
			docetaxel, cisplatin and infusional fluorouracil	I INCADOI		
			combined chemotherapy (cisplatin) and radiation treatment for locally advanced	HNLAPRT	1	
			squamous cell carcinoma of the head and neck treatment for advanced nasopharyngeal cancer of the head and neck using			
			platinum and fluorouracil	HNNAVFUP	1	
			palliative chemotherapy for advanced head and neck nasopharyngeal carcinoma			
			with weekly cisplatin	HNNAVP	1	
			treatment of recurrent and/or metastatic nasopharyngeal cancer with platinum and	LININIAN/DE		
			etoposide	HNNAVPE	'	
			treatment of locoregionally recurrent and/or metastatic nasopharyngeal cancer with	HNNAVPG	1	
			platinum and gemcitabine induction treatment of locally advanced nasopharyngeal cancer with cisplatin and			
				HNNLAPG	1	
			gemcitabine treatment of locally advanced nasopharyngeal cancer with concurrent cisplatin and			
			radiation	HNNLAPRT	1	
			treatment of advanced head and neck cancer using cisplatin and fluorouracil	HNSAVFUP		
			treatment of advanced salivary gland cancers with cisplatin and vinorelbine	HNSAVNP		
			treatment of advanced salivary gland cancers with platinum, doxorubicin and	HNSAVPAC		
			cyclophospahmide	IIIIOAVEAC		
		Lung	Neoadjuvant Treatment of Non-Squamous Non-Small Cell Lung Cancer with	LUAJNIVPP	1	
			Nivolumab, Pemetrexed and Platinum			
			adjuvant cisplatin and vinorelbine following resection of non-small cell lung cancer	LUAJNP	1	
			Adjuvant Cisplatin and Pemetrexed Following Resection of Non-Small Cell Lung			
			Cancer	LUAJPP	ı	
			first-line treatment of advanced non-small cell lung cancer with cisplatin and	LUAVDC		
			docetaxel	LUAVDC		
			treatment for advanced non-small cell lung cancer with cisplatin and vinorelbine	LUAVNP	1	
			treatment of advanced non-small cell lung cancer with platinum and gemcitabine	LUAVPG	1	
			first-line treatment of advanced squamous non-small cell lung cancer with platinum,			
			gemcitabine and pembrolizumab	LUAVPGPMB	I	
			first-line treatment of advanced non-small cell lung cancer with platinum and			
			pemetrexed	LUAVPP	'	
			First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer with	LUAVPPIPNI	1	
			Platinum, Pemetrexed, Ipilimumab and Nivolumab			
			treatment of locally advanced non-small cell lung cancer using cisplatin and	LULAPERT	1	
			etoposide with radiation therapy treatment of locally advanced non-small cell lung cancer using alternative dosing of			
1			cisplatin and etoposide with radiation therapy	LULAPE2RT	1	
			treatment of malignant mesothelioma with platinum and gemoitabine	LUMMPG		
			treatment of malignant mesothelioma with platinum and pemetrexed	LUMMPP	i	
			treatment of thymoma with platinum, doxorubicin and cyclophosphamide	LUOTPAC	I I	
			treatment of thymoma with cisplatin and etoposide	LUOTPE	i I	



DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
cisplatin (cont'd)	injectable	Lung	treatment of thymoma using cisplatin and etoposide with radiation therapy	LUOTPERT	1	
			treatment of cancer of unknown primary involving the thorax with cisplatin and etoposide	LUPUPE	ı	
			Treatment of Extensive Stage Small Cell Lung Cancer (SCLC) with Atezolizumab, Platinum and Etoposide	LUSCATPE	ı	
			Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC) with Durvalumab, Platinum and Etoposide	LUSCDURPE	I	
			Treatment of Extensive Stage Small Cell Lung Cancer (SCLC) with Platinum and Etoposide	LUSCPE	ı	
			Treatment of Extensive Stage Small Cell Lung Cancer with Platinum and Oral Etoposide	LUSCPEPO	I	
			Treatment of Limited Stage Small Cell Lung Cancer using Platinum and Oral Etoposide with Radiation Therapy	LUSCPEPORT	I	
			Eloposide with Radiation Interapy Treatment of Limited Stage Small Cell Lung Cancer using Platinum and Etoposide with Radiation Therapy	LUSCPERT	ı	
			will readiation interlapy second line treatment of extensive stage small cell lung cancer (SCLC) with irinotecan with or without platinum	LUSCPI	l	
		Lymphoma	Treatment of Lymphoma with Dexamethasone, Cytarabine, Platinum and riTUXimab		ı	
			treatment of lymphoma with gemcitabine, dexamethasone and platinum	LYGDP	l I	
			rituximah	LYGDPR	ı	
			by stangaids, ifacfamids, signistin and devempth sagns	LYVIPDRT	I	
		Sarcoma	adjuvant therapy for osteosarcoma using doxorubicin and cisplatin	SAAJAP	l I	
			therapy of advanced osteosarcoma using doxorubicin and cisplatin	SAAVAP	i	
			hyporthormic introportional abomatherapy (HIDEC) for national with paritonal	SAHIPEC	I	
		Skin & Melanoma	treatment of recurrent or metastatic Merkel cell carcinoma with cisplatin and etoposide	SMMCCPE	ı	
		Not Otherwise Specified		Other tumour site code followed by 'NOS' (e.g. HNNOS)	1	
cladribine	injectable	Lymphoma	hairy cell leukemia	LYCDA	I	
		Pediatric	salvage treatment of pediatric patients with Langerhans cell histiocytosis (LCH) who are risk organ positive (RO+) or with chronic reactivating disease		I	
clodronate	capsule	Breast	metastatic breast cancer	BRAVCLOD	I	Not reimbursed for hypercalcemia
cobimetinib	tablet	Skin & Melanoma	using vemurafenib and cobimetinib	SMAVVC	I	
cortisone	tablet	Genitourinary	and mitotane	GUEDPM	ı	
				GUMITO	<u> </u>	
		Not Otherwise Specified		Other tumour site code followed by 'NOS' (e.g. GUNOS)	I	



DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
crisantaspase recombinant		Leukemia & BMT,	Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma in Adult			
(RYLAZE)	injectable	Lymphoma	Patients Allergic to Asparaginase (KIDROLASE) or Pegaspargase (ONCASPAR)	LKNOS, LYNOS	1	
(KTEAZE)		Суптриотпа	using Crisantaspase Recombinant (RYLAZE)			
			Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma in			
		Pediatric	Pediatric Patients Allergic to Asparaginase (KIDROLASE) or Pegaspargase		1	
			(ONCASPAR) using Crisantaspase Recombinant (RYLAZE) Treatment of Children with Low-Risk Acute Myeloid Leukemia Who Require Short-			
			Acting Asparaginase per COG AAML 1831 Study using Crisantaspase		1	
			Recombinant (RYLAZE)			
			second-line treatment of ALK-positive advanced non-small cell lung cancer			
crizotinib	tablet	Lung	(NISCLC) with orizotinih	LUAVCRIZ		
			first-line treatment of ALK-positive advanced non-small cell lung cancer (NSCLC)			
			with crizotinib	LUAVCRIZF	I	
			first-line treatment of ROS1-positive advanced non-small cell lung cancer with			
			crizotinib	LUAVCRIZR	1	
			myeloablative conditioning therapy prior to autologous and allogeneic			
cyclophosphamide	tablet, injectable	Leukemia & BMT	hematopoietic stem cell transplantation for myeloid malignancies using IV busulfan	BMTIVBLICY		
Cyclophosphamide	tablet, injectable	Leukeilia & Divil	and cyclophosphamide	DIVITIVOOCT	' '	
		Proof	adjuvant therapy for breast cancer using doxorubicin and cyclophosphamide	BRAJAC		
		Breast	neoadjuvant or adjuvant therapy for breast cancer using doxorubicin and	BRAJAC		
			cyclophosphamide followed by paclitaxel	BRAJACT	1	
			neoadjuvant or adjuvant therapy for breast cancer using dose dense therapy:			
				BRAJACTG	1	
			doxorubicin and cyclophosphamide followed by paclitaxel			
			neoadjuvant or adjuvant therapy for breast cancer using doxorubicin and	BRAJACTT	1	
			cyclophosphamide followed by paclitaxel and trastuzumab			
			neoadjuvant or adjuvant therapy for breast cancer using dose dense therapy:	BRAJACTTG	1	
			doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab			
			neoadjuvant or adjuvant therapy for early breast cancer using doxorubicin and	BRAJACTW	1	
			cyclophosphamide followed by weekly paclitaxel			
			neoadjuvant or adjuvant therapy for breast cancer using cyclophosphamide,	BRAJDAC	1	
			doxorubicin and docetaxel			
			neoadjuvant or adjuvant therapy for breast cancer using docetaxel and	BRAJDC	1 1	
			cyclophosphamide			
1			adjuvant therapy for breast cancer using fluorouracil, epirubicin and	BRAJFEC		
			cyclophosphamide	-		
l			neoadjuvant or adjuvant therapy for breast cancer using fluorouracil, epirubicin and	BRAJFECD		
			cyclophosphamide and docetaxel			
l			neoadjuvant or adjuvant therapy for breast cancer using fluorouracil, epirubicin and	BRAJFECDT		
			cyclophosphamide followed by docetaxel and trastuzumab		ļ	
			neoadjuvant or adjuvant therapy for breast cancer using trastuzumab, docetaxel	BRAJTDC		
			and cyclophosphamide			
			palliative therapy for metastatic breast cancer using doxorubicin and	BRAVAC		
			cyclophosphamide		<u> </u>	
			palliative therapy for advanced breast cancer using cyclophosphamide,	BRAVCMF		
			methotrexate and fluorouracil	DI V V OIVII	1	
			palliative therapy for metastatic breast cancer using metronomic low-dose oral	BRAVCMPO		
			cyclophosphamide and methotrexate	DI VA V CIVIF O	_ '	
	1		treatment of locally advanced breast cancer using doxorubicin and	BRLAACD		
			cyclophosphamide followed by docetaxel	DRLAACD	'	

president of coard of the coard	DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
CARBOplatin and Policiase National Content and Statistical Cancer using Dose Content and Cyclophospharmide Content and	cyclophosphamido (contid)	tablet injectable	Broast	treatment of locally advanced breast cancer using doxorubicin and	RDI AACDT		
CARBOplatin and PACLitaxot NBB (ABRAXANE) Followed by DOXOnubicin and SRLACPNAC I Control Transport (ARRO) Register Breast Cancer using Dose Designation of the Control State of	cyclophosphamide (cont u)	tablet, injectable	Dieasi		DRLAACDI	<u>'</u>	
Oxyclobopspharide Alternative NECAGInant Therapy for Triple Negative Breast Cancer using Dose Dense Therapy. CARSO, plain and PACLizaxon NAB (ARRAZANE) Followed by DOX Oxyclobopspharide Weekly PACLizaxon Followed by DOX Oxyclobopspharide Noosdjuvant Therapy for Triple Negative Breast Cancer using Dose Dense Therapy. Carboplatin and Weekly Paclizaxon Followed by DOX Oxyclobopspharide Noosdjuvant Therapy for Triple Negative Prosest Cancer using Deservation of Cyclobopspharide Noosdjuvant Therapy for Triple Negative Dox DOX Oxyclobopspharide Noosdjuvant Therapy for Triple Negative Breast Cancer using Deservation of Negative Paclizaxon Followed by DOX Oxyclobopspharide Negative Paclizaxon Followed by DOX Doxyclobopspharide Negative Paclizaxon Followed Paclizaxon							
Alternative NECAGUsunal Therapy for Tripic Negative Breast Cancer using Dose December 1000 (ARCA) (A				, , , , ,	BRLACPNAC	I	
Dense Therapy: CARSO-platin and PACLitaxo NAB (ARRAXANE) Followed by DOXON-Duble and Octophosphamide NEOAdjavant Therapy for Triple-Negative Breast Cancer using Carboptain and Weekly PACLitaxo Triple-Negative Breast Cancer using Dese Dense Breakly Carboptain And Weekly PACLitaxol NAB (ARRAXANE) Robusted by DoXOn-Breakly Depote Dense Therapy Packly Carboptain And Packly Packly Medical NAB (ARRAXANE) Robusted by DoXOn-Breakly Carboptain And Packly Carboptain And Packly Packly Medical NAB (ARRAXANE) Robusted by DoXOn-Breakly Carboptain And Packly Carboptain And Packly Medical NAB (ARRAXANE) Robusted by DoXOn-Breakly Carboptain And Packly And Packly And Packly Carboptain And Packly Carboptain And Packly Carboptain And Packly And Packly And Packly And Packly Carboptain And Packly Carboptain And Packly Carboptain And Packly And Packly And Packly And Packly Carboptain And Packly Carboptain And Packly And Packly Carboptain And Packly Carboptain And Packly Carboptain And Packly And Packly And Packly Carboptain And Packly Carbop							
DOXONUSION and Cyclophosphamide RicAdjuvant Therapy for Triple Negative Breast Cancer using Carboplatin and Meekly PACLitaxel Followed by DOXOnubicin and Cyclophosphamide Ricarry Carboplatin and Weekly PACLitaxel Followed by Doxonubicin and BRIACTWACG Ricarry Carboplatin and Weekly PACLitaxel Followed by Doxonubicin and Cyclophosphamide Alternative NEOAdjuvant Therapy for Triple Negative Breast Cancer using Pack Cancer using Pack Cancer using Alternative NEOAdjuvant Therapy for Breast Cancer using Dose Dense Therapy. PACLitaxel NAR (ARRANANE) Followed by DOXOnubicin and Cyclophosphamide Ricarry Carboplatin and Cyclophosphamide Ricarry Carboplatin And Cyclophosphamide Ricarry Carboplatin Therapy for Breast Cancer using Dose Dense Therapy. PACLitaxel NAR (ARRANANE) Followed by DOXOnubicin and Cyclophosphamide Ricarry Carboplatin And Cyclophosphamide Ricarry Carboplatin And Veekly PACLitaxel. Ricarry Carboplatin And Veekly PACLitaxel. Ricarry Carboplatin And Weekly PACLitaxel, Followed by DOXOnubicin and Cyclophosphamide Ricarry Carboplatin And Weekly PACLitaxel, Followed by DOXOnubicin and Cyclophosphamide Ricarry Carboplatin And Weekly PACLitaxel, Followed by DOXOnubicin and Cyclophosphamide Ricarry Carboplatin And Weekly PACLitaxel, Followed by DOXOnubicin and Cyclophosphamide Ricarry Carboplatin And Weekly PACLitaxel, Followed by DOXOnubicin and Cyclophosphamide Ricarry Carboplatin And Weekly PACLitaxel, Followed by DOXOnubicin and Cyclophosphamide Ricarry Carboplatin And Weekly PACLitaxel, Followed by DOXOnubicin and Cyclophosphamide Ricarry Carboplatin And Weekly PACLitaxel, Followed by DOXOnubicin and Cyclophosphamide Ricarry Carboplatin And Weekly PACLitaxel, Followed by DOXOnubicin and Cyclophosphamide Ricarry Carboplatin And Ricarry Carboplatin An							
NECOAdywant Therapy for Triple Negative Breast Cancer using Carboplatin and Weekly PACLitaxel Followed by DOXOnubicin and Cyclophosphamide Nooadywant Therapy for Triple Negative Breast Cancer using Desponsion and Pack Pack Pack Policity Pack Pack Pack Pack Pack Pack Pack Pack				, , , ,	BRLACPNACG	1	
Weekly PACLItate Followed by DOXCOUDION and Cytophosphamide BRACHWAC 1							
Necadjuvant Therapy for Triple-Negative Breast Cancer using Dose-Dense BRLACTWACG 1					BRLACTWAC	1	
Therapy. Carboplain and Weekly Paclitaxel Followed by Doxonubicin and Cyclophosphamide Allernative NEOAdjavant Therapy for Locally Advanced Breast Cancer using Department of the Paclitaxel NAB (ABRAXANE) followed by DoXOnubicin and Cyclophosphamide Allernative NEOAdjavant Therapy for Breast Cancer using Dose Dense Therapy. PACLitaxel NAB (ABRAXANE) followed by DoXOnubicin and Cyclophosphamide Readment of Locally advanced timespi for Inseast Cancer using Dose Dense Therapy. PACLitaxel NAB (ABRAXANE) followed by DoXOnubicin and Cyclophosphamide followed by doxonubicin and cyclophosphamide resiment of Locally advanced breast cancer using Dose therapy. PACLitaxel NAB (ABRAXANE) followed by DoXOnubicin and Cyclophosphamide resiment of Locally advanced breast cancer using doxonubicin and cyclophosphamide oxidophosphamide oxidop							
Cyclophosphamide Cyclophosphamide Cyclophosphamide RILAPNAC I					DDI ACTIVIACO		
Alternative NEOAdjuvant Therapy for Locally Advanced Breast Cancer using Dose Dense Therapy. Alternative NEOAdjuvant Therapy for Breast Cancer using Dose Dense Therapy. ACLItaxel NAB (ABRAXANE) followed by DOXOrubicin and Cyclophosphamide Readywant therapy for breast Cancer using Dose Dense Therapy. ACLItaxel NAB (ABRAXANE) followed by DOXOrubicin and Cyclophosphamide. Readywant therapy for breast cancer using dose dense therapy. BRILATACG Readywant therapy for Dense Cancer using dose dense therapy. BRILATACG Readywant therapy for Triple Negative Breast Cancer using Permorizumab with Carbon Control of Cancer of Cancer using Dense Dense Therapy. Readywant Therapy for Triple Negative Breast Cancer using Permorizumab with Carbon Control of Cancer using Dense Dense Cancer using Permorizumab with Carbon Control of Carbon Cancer using Permorizumab with Carbon Carbon Carbon Cancer using Permorizumab with Carbon C				, , , , , , , , , , , , , , , , , , , ,	BRLACTWACG	'	
PACLITAXION NAS (ABRAXANE) followed by DOXOrubicin and Cyclophosphamide SRLAPNAC							
Alternative NEOAdjuvant Therapy for Breast Cancer using Dose Dense Therapy: PACLitaxel NAG (ABRAVANE) followed by DOXOrubicin and Cyclophosphamide leading the dense of the de					RDI ADNIAC		
PACLITAXE NAB (ABRAXANE) followed by DOXOrubicin and Cyclophosphamide Readily and therapy for breast cancer using dose dense therapy; pacilitaxel followed by doxorubicin and cyclophosphamide followed by doxorubicin and cyclophosphamide Readily advanced breast cancer using doxorubicin and Readily pacilitaxel				PACLitaxel NAB (ABRAXANE) followed by DOXOrubicin and Cyclophosphamide	DINLAFINAC	'	
PACLitaxer NAB (ABRAXANE) followed by DOXOrubicin and Cyclophosphamide Readily and therapy for breast cancer using dose dense therapy; pacilitaxel followed by doxorubicin and cyclophosphamide treatment of locally advanced breast cancer using doxorubicin and BRLATACG 1							
PACLITAXE NAB (ABRAXANE) followed by DOXOrubicin and Cyclophosphamide readment of locally doxorubicin and cyclophosphamide reatment of locally avanced breast cancer using doxorubicin and syclophosphamide followed by weekly paciliaxes NECAdjuvant Therapy for Trijne Negative Breast Cancer using Pernbrolizumab with CARBOplain and Weekly PACLITAXE, Followed by DOXOrubicin and Cyclophosphamide NECAdjuvant Therapy for Trijne Negative Breast Cancer using Pernbrolizumab with CARBOplain and Weekly PACLITAXE, Followed by DOXOrubicin and Cyclophosphamide NECAdjuvant Therapy for Trijne Negative Breast Cancer using Pernbrolizumab. Weekly CARBOplain and Weekly PACLITAXE, Followed by DOXOrubicin and Cyclophosphamide NECAdjuvant Therapy for Trijne Negative Breast Cancer using Pernbrolizumab. Weekly CARBOplain and Weekly PACLITAXE, Followed by DOXOrubicin and Cyclophosphamide. Qrylecolopsy pallative therapy for relapsed/progressing epithelial ovarian, primary pertineal, or fallopian tube carcinoma using metronomic low-dose oral cyclophosphamide and vincristine. The pallative therapy for relapsed/progressing epithelial ovarian, primary pertineal, or fallopian tube carcinoma using metronomic low-dose oral cyclophosphamide and vincristine. Head and Neck doxorubicin and functional decorational de				, , , , , , , , , , , , , , , , , , , ,	BRI APNACG	1	
Infollowed by doxorubicin and cyclophosphamide BRLATIAGS 1				PACLitaxel NAB (ABRAXANE) followed by DOXOrubicin and Cyclophosphamide	5.12.11.100		
Infollowed by doxorubicin and cyclophosphamide BRLATIAGS 1				neoadiuvant therapy for breast cancer using dose dense therapy: paclitaxel			
treatment of locally advanced breast cancer using doxorubicin and cyclophosphamide (followed by weekly pacilitaxe) NEOAdjuvant Therapy for Triple Negative Breast Cancer using Pembrolizumab with CARBOplatin and Weekly PACLitaxel, Followed by DOXOrubicin and Cyclophosphamide NEOAdjuvant Therapy for Triple Negative Breast Cancer using Pembrolizumab, Weekly CARBOplatin and Weekly PACLitaxel, Followed by DOXOrubicin and Cyclophosphamide NEOAdjuvant Therapy for Triple Negative Breast Cancer using Pembrolizumab, Weekly CARBOplatin and Weekly PACLitaxel, Followed by DOXOrubicin and Cyclophosphamide and Verdent of Septembrolizumab, Weekly CARBOplatin and Weekly PACLitaxel, Followed by DOXOrubicin and Cyclophosphamide and Verdent of Septembrolizumab, Weekly CARBOplatin and Weekly PACLitaxel, Followed by DOXOrubicin and Cyclophosphamide and Verdent of Septembrolizumab, Weekly CARBOplatin and Weekly PACLitaxel, Followed by DOXOrubicin and Cyclophosphamide and Verdent of Septembrolizumab, Weekly CARBOplatin and Verdent of V					BRLATACG	ı	
Cyclophosphamide fullowed by weekly paciliaxe SHC WALL I							
NicOAdjuvant Therapy for Triple Negative Breast Cancer using Pembrolizumab with CARBOplatin and Weekly PACLitaxel, Followed by DOXOrubicin and Cyclophosphamide NEOAdjuvant Therapy for Triple Negative Breast Cancer using Pembrolizumab, Weekly CARBOplatin and Weekly PACLitaxel, Followed by DOXOrubicin and Cyclophosphamide Newbox PACLitaxel, Followed by DOXOrubicin and Cyclophosphamide palliative therapy for relapsed/progressing epithelial ovarian, primary peritoneal, or fallopian tube carcinoma using metronomic low-dose oral cyclophosphamide therapy for high-risk Gestational Trophoblastic Neoplasia (GTN) using etoposide, methorexate, leucovorin (folinic acid), dactinomycin, cyclophosphamide and vincristiline palliative therapy for edvanced salivary gland cancers using cyclophosphamide, doxorubicin and fluorouvacil treatment of advanced salivary gland cancers with platinum, doxorubicin and cyclophosphamide and vincristiline treatment of thymoma/thymic carcinoma with cyclophosphamide, doxorubicin and vincristiline treatment of thymoma/thymic carcinoma with cyclophosphamide, doxorubicin and vincristiline treatment of extensive small cell lung cancer with cyclophosphamide, doxorubicin and cyclophosphamide, doxorubicin and vincristiline treatment of extensive small cell lung cancer with cyclophosphamide, doxorubicin and cyclophosphamide, vincristiline treatment of extensive small cell lung cancer with cyclophosphamide, vincristiline and cyclophosphamide, doxorubicin and cyclophosphamide, vincristiline treatment of cyclophosphamide, prednisone (CHP) and brentuximab vedotin cyclophosphamide, vincristiline, prednisone (CHP) and brentuximab vedotin cyclophosphamide, vincristiline, treatment of relapsed chronic (CHP) and brentuximab vedotin cyclophosphamide, vincristiline, treatment of relapsed chronic (Viphophocytic leukewia using cyclophosphamide, vipcristiline).					BRLATWAC	1	
CARBOplatin and Weekly PACLitaxel, Followed by DOXOrubicin and Cyclophosphamide NEOAdjuvant Therapy for Triple Negative Breast Cancer using Pembrolizumab, Weekly CARBOplatin and Weekly PACLitaxel, Followed by DOXOrubicin and Cyclophosphamide Oxplochosphamide or fallopian tube carcinoma in the c			1				
NECAdjuvant Therapy for Triple Negative Breast Cancer using Pembrolizumab, Weekly CARBOplatin and Weekly PACLitaxel, Followed by DOXOrubicin and Cyclophosphamide and Cyclophosphamide unique therapy for relapsed/progressing epithelial ovarian, primary peritoneal, or fallopian tube carcinoma using metronomic low-dose oral cyclophosphamide therapy for high-risk Gestational Trophoblastic Neoplasia (GTN) using etoposide, methotrexate, leucovorin (folinic acid), dactinomycin, cyclophosphamide and vincristine pelliative therapy for advanced salivary gland cancers using cyclophosphamide. Head and Neck pelliative therapy for advanced salivary gland cancers using cyclophosphamide. Teatment of drouncail treatment of drouncail treatment of trymomar/thymic carcinoma with cyclophosphamide, doxorubicin and cyclophosphamide cyclophosphamide vincristine reatment of thymomar/thymic carcinoma with cyclophosphamide tuged to treatment of thymomary thymic carcinoma with cyclophosphamide tuged to treatment of thymomary thymic carcinoma with cyclophosphamide tuged tuged to the cyclophosphamide tuged to the cyclophosphamide tuged tuged to the cyclophosphamide tuged to the cyclophosphamide tuged to the cyclophosphamide tuged tuged to the cyclophosphamide tuged tuged to the cyclophosphamide tuged tuged tuged tuged to the cyclophosphamide tuged tug					BRPCTAC	1	
Weekly CARBOplatin and Weekly PACLitaxel, Followed by DOXOrubicin and Cyclophosphamide palliative therapy for relapsed/progressing epithelial ovarian, primary peritoneal, or fallopian tube carcinoma using metronomic low-dose oral cyclophosphamide therapy for high-risk Gestational Trophoblastic Neoplasia (GTN) using eloposide, methotrexate, leucovorin (folinic acid), dactinomycin, cyclophosphamide and vincristine palliative therapy for advanced salivary gland cancers using cyclophosphamide, doxorubicin and fluorouracil treatment of advanced salivary gland cancers with platinum, doxorubicin and cyclophosphamide cyclophosphamide vincristine treatment of advanced salivary gland cancers with platinum, doxorubicin and cyclophosphamide vincristine treatment of advanced salivary gland cancers with platinum, doxorubicin and cyclophosphamide vincristine treatment of advanced salivary gland cancers with platinum, doxorubicin and cyclophosphamide vincristine treatment of advanced salivary gland cancers with platinum, doxorubicin and cyclophosphamide, doxorubicin and cyclophosphamide vincristine treatment of etymphoma with platinum, doxorubicin and cyclophosphamide vincristine and vincristine and vincristine and vincristine and vincristine and vincristine and retatment of tymphoma with doxorubicin, cyclophosphamide, vincristine, prednisone treatment of lymphoma (EHP) and brentuximab vedolin treatment of lymphocytic leukemia using cyclophosphamide, vincristine, prednisone using cyclophosphamide, vincristine and cyclophosphamide, vincristine and cyclophosphamide, vincristine and cyclophosphamid							
Gynecology palliative therapy for relapsed/progressing epithelial ovarian, primary peritoneal, or fallopian tube carrinoma using metronomic low-dose oral cyclophosphamide therapy for high-risk Gestational Trophoblastic Neoplasia (GTN) using etoposide, methotrexate, leucovorin (folinic acid), dactinomycin, cyclophosphamide and vincristine Head and Neck palliative therapy for advanced salivary gland cancers using cyclophosphamide, doxorubicin and fluorouracil treatment of advanced salivary gland cancers with platinum, doxorubicin and cyclophosphamide and vincristine treatment of thymoma/thymic carcinoma with cyclophosphamide, doxorubicin and vincristine treatment of thymoma with platinum, doxorubicin and vincristine treatment of thymoma with doxorubicin, cyclophosphamide, doxorubicin and vincristine treatment of tymphoma with doxorubicin, cyclophosphamide, vincristine and prednisone treatment of tymphoma with doxorubicin, cyclophosphamide, vincristine, prednisone treatment of tymphoma with doxorubicin, cyclophosphamide, vincristine, prednisone treatment of CD30-positive peripheral T-Cell Lymphoma (PTCL) with doxorubicin, cyclophosphamide, vincristine, prednisone cyclophosphamide, prednis				NEOAdjuvant Therapy for Triple Negative Breast Cancer using Pembrolizumab,			
Synecology palliative therapy for relapsed/progressing epithelial ovarian, primary pertoneal, or fallopian tube carcinoma using metronomic low-dose oral cyclophosphamide GOOVCYCPO I				Weekly CARBOplatin and Weekly PACLitaxel, Followed by DOXOrubicin and	BRPCWTAC	1	
Islippian tube carcinoma using metronomic low-dose oral cyclophosphamide GOUYCPPU I			L	Cyclophosphamide			
Interpretation of the carcinoma using metronomic low-dose oral cyclophosphamide therapy for hisr diseast into all Torphoblastic Neoplassia (GTN) using etoposide, methotrexate, leucovorin (folinic acid), dactinomycin, cyclophosphamide and vincristine Head and Neck			Gynecology	palliative therapy for relapsed/progressing epithelial ovarian, primary peritoneal, or	COOVEYERO	1	
methotrexate, leucovorin (folinic acid), dactinomycin, cyclophosphamide and vincristine Head and Neck Lung Lung			Gynecology		GOOVETEFO	'	
Head and Neck palliative therapy for advanced salivary gland cancers using cyclophosphamide, doxorubicin and fluorouracil reatment of advanced salivary gland cancers with platinum, doxorubicin and cyclophospahmide reatment of thymoma/thymic carcinoma with cyclophosphamide, doxorubicin and cyclophosphamide vincristine reatment of thymoma with platinum, doxorubicin and cyclophosphamide LUOTCAV I reatment of thymoma with platinum, doxorubicin and cyclophosphamide LUOTPAC I reatment of extensive small cell lung cancer with cyclophosphamide, doxorubicin and vincristine reatment of lymphoma with doxorubicin, cyclophosphamide, doxorubicin and cyclophosphamide, doxorubicin and cyclophosphamide, doxorubicin and cyclophosphamide, vincristine and prednisone reatment of lymphoma with doxorubicin, cyclophosphamide, vincristine, prednisone and rituximab reatment of lymphoma with doxorubicin, cyclophosphamide, vincristine, prednisone and rituximab reatment of CD30-positive peripheral T-Cell Lymphoma (PTCL) with doxorubicin, cyclophosphamide, vincristine, prednisone cyclophospham							
Head and Neck Palliative therapy for advanced salivary gland cancers using cyclophosphamide, doxorubicin and fluorouracil treatment of advanced salivary gland cancers with platinum, doxorubicin and cyclophosphamide Lung Treatment of thymoma/thymic carcinoma with cyclophosphamide, doxorubicin and vincristine Lung Treatment of thymoma with platinum, doxorubicin and cyclophosphamide LuoTCAV I LuoTCAV LuoTCAV I LuoTCAV LuoT				methotrexate, leucovorin (folinic acid), dactinomycin, cyclophosphamide and	GOTDEMACO	I	
doxorubicin and fluorouracil treatment of advanced salivary gland cancers with platinum, doxorubicin and cyclophosphamide treatment of thymoma/thymic carcinoma with cyclophosphamide, doxorubicin and vincristine treatment of thymoma with platinum, doxorubicin and cyclophosphamide treatment of extensive small cell lung cancer with cyclophosphamide, doxorubicin and vincristine treatment of extensive small cell lung cancer with cyclophosphamide, doxorubicin and vincristine Lymphoma treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine and prednisone treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine, prednisone treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine, prednisone treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine, prednisone treatment of CD30-positive peripheral T-Cell Lymphoma (PTCL) with doxorubicin, cyclophosphamide, vincristine, prednisone treatment of colora-positive peripheral T-Cell Lymphoma (PTCL) with doxorubicin, cyclophosphamide, vincristine, prednisone treatment of colora-positive peripheral T-Cell Lymphoma (PTCL) with doxorubicin, cyclophosphamide, or cyclophosphamide, prednisone colora-positive peripheral T-Cell Lymphoma (PTCL) with doxorubicin, cyclophosphamide, or cyclophosph							
doxorubicin and fluorouracii doxorubicin and tureatment of advanced salivary gland cancers with platinum, doxorubicin and cyclophospahmide Lung treatment of thymoma/thymic carcinoma with cyclophosphamide, doxorubicin and vincristine Luorcav I treatment of thymoma with platinum, doxorubicin and cyclophosphamide LuOrcav I Luorcav I treatment of textensive small cell lung cancer with cyclophosphamide, doxorubicin and vincristine Lymphoma treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine and prednisone Lychop I treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine, prednisone Lychop I treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine, prednisone Lychop I			Head and Neck		HNSAVFAC	1	
Cyclophospahmide							
Lung treatment of thymoma/thymic carcinoma with cyclophosphamide, doxorubicin and vincristine treatment of thymoma with platinum, doxorubicin and cyclophosphamide LUOTCAV I treatment of extensive small cell lung cancer with cyclophosphamide, doxorubicin and vincristine and vincristine and vincristine and treatment of I lymphoma with doxorubicin, cyclophosphamide, vincristine and prednisone treatment of I lymphoma with doxorubicin, cyclophosphamide, vincristine and prednisone treatment of I lymphoma with doxorubicin, cyclophosphamide, vincristine, prednisone and rituximab treatment of CD30-positive peripheral T-Cell Lymphoma (PTCL) with doxorubicin, cyclophosphamide, vincristine, prednisone treatment of CD30-positive peripheral T-Cell Lymphoma (PTCL) with doxorubicin, cyclophosphamide, prednisone (CHP) and brentuximab vedotin treatment of relapsed chronic lymphocytic leukemia using cyclophosphamide, prednisone treatment of relapsed chronic lymphocytic leukemia using cyclophosphamide, prednisone treatment of relapsed chronic lymphocytic leukemia using cyclophosphamide, prednisone treatment of relapsed chronic lymphocytic leukemia using cyclophosphamide, prednisone treatment of relapsed chronic lymphocytic leukemia using cyclophosphamide, prednisone treatment of relapsed chronic lymphocytic leukemia using cyclophosphamide, prednisone treatment of relapsed chronic lymphocytic leukemia using cyclophosphamide, prednisone treatment of relapsed chronic lymphocytic leukemia using cyclophosphamide, prednisone treatment of relapsed chronic lymphocytic leukemia using cyclophosphamide, prednisone treatment of contract treatment of cont				, ,	HNSAVPAC	1	
Lung vincristine LuOTCAV 1							
Vincristine Vincristine Ireatment of thymoma with platinum, doxorubicin and cyclophosphamide LUOTPAC I Ireatment of extensive small cell lung cancer with cyclophosphamide, doxorubicin and vincristine Lusccav I Lusccav I Lumphoma Lymphoma Lymphoma Lymphoma with doxorubicin, cyclophosphamide, vincristine and prednisone Lychop I Lychop I	1		Lung		LUOTCAV	1	
treatment of extensive small cell lung cancer with cyclophosphamide, doxorubicin and vincristine Lymphoma Lymphoma treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine and prednisone treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine, prednisone Itreatment of lymphoma with doxorubicin, cyclophosphamide, vincristine, prednisone and rituximab treatment of CD30-positive peripheral T-Cell Lymphoma (PTCL) with doxorubicin, cyclophosphamide, prednisone cyclophosphamide, prednisone (CHP) and brentuximab vedotin treatment of relapsed chronic lymphocytic leukemia using cyclophosphamide, treatment of relapsed chronic lymphocytic leukemia using cyclophosphamide, treatment of relapsed chronic lymphocytic leukemia using cyclophosphamide,					LUOTDAC		
Lymphoma treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine and prednisone treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine, prednisone treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine, prednisone and rituximab treatment of CD30-positive peripheral T-Cell Lymphoma (PTCL) with doxorubicin, cyclophosphamide, lychophosphamide, prednisone (CHP) and brentuximab vedotin treatment of relapsed chronic lymphocytic leukemia using cyclophosphamide, lychophosphamide, lychophospham					LUUTPAC	- 	
Lymphoma treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine and prednisone treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine, prednisone and rituximab treatment of CD30-positive peripheral T-Cell Lymphoma (PTCL) with doxorubicin, cyclophosphamide, prednisone (CHP) and brentuximab vedotin treatment of relapsed chronic lymphocytic leukemia using cyclophosphamide, IVCL CVPP	1			, , , ,	LUSCCAV	1	
prednisone LYCHOP I treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine, prednisone and rituximab Lychop I treatment of CD30-positive peripheral T-Cell Lymphoma (PTCL) with doxorubicin, cyclophosphamide, prednisone (CHP) and brentuximab vedotin treatment of relapsed chronic lymphocytic leukemia using cyclophosphamide, lychop I treatment of relapsed chronic lymphocytic leukemia using cyclophosphamide, lychopp							
treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine, prednisone and rituximab treatment of CD30-positive peripheral T-Cell Lymphoma (PTCL) with doxorubicin, cyclophosphamide, prednisone (CHP) and brentuximab vedotin treatment of relapsed chronic lymphocytic leukemia using cyclophosphamide, lycl CVPP	1		Lymphoma		LYCHOP	1	
and rituximab treatment of CD30-positive peripheral T-Cell Lymphoma (PTCL) with doxorubicin, cyclophosphamide, prednisone (CHP) and brentuximab vedotin treatment of relapsed chronic lymphocytic leukemia using cyclophosphamide, lycloppe							
treatment of CD30-positive peripheral T-Cell Lymphoma (PTCL) with doxorubicin, cyclophosphamide, prednisone (CHP) and brentuximab vedotin treatment of relapsed chronic lymphocytic leukemia using cyclophosphamide,	1				LYCHOPR	1	
cyclophosphamide, prednisone (CHP) and brentuximab vedotin LYCHPBV I treatment of relapsed chronic lymphocytic leukemia using cyclophosphamide,							
treatment of relapsed chronic lymphocytic leukemia using cyclophosphamide,					LYCHPBV	1	
				vincristine, prednisone and rituximab	LYCLLCVPR		



DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
cyclophosphamide (cont'd)	tablet, injectable	Lymphoma	treatment of Burkitt's Lymphoma and Leukemia with cyclophosphamide, vincristine, doxorubicin, methotrexate, leucovorin and rituximab	LYCODOXMR	l	
			advanced indolent lymphoma using cyclophosphamide, vincristine and prednisone	LYCVP	I	
			treatment of Hodgkin's disease with cyclophosphamide, vinblastine, procarbazine and prednisone	LYCVPPABO	ı	
			treatment of advanced indolent lymphoma using cyclophosphamide, vincristine, brednisone and rituximab	LYCVPR	ı	
		•••••	therapy of lymphoma, Hodgkin's disease, chronic lymphocytic leukemia or multiple Inveloma using cyclophosphamide	LYCYCLO	ı	***************************************
			Treatment of Previously Untreated Light Chain Amyloidosis and Not-Eligible for Stem Cell Transplant using Daratumumab, Cyclophosphamide, Bortezomib and	LYDARCBDF	ı	
			Dexamethasone treatment of lymphoma with dose-adjusted etoposide, doxorubicin, vincristine, cyclophosphamide, prednisone and rituximab with intrathecal methotrexate	LYEPOCHR	Ι	
			treatment of chronic lymphocytic leukemia (CLL) or prolymphocytic leukemia with fludarabine, cyclophosphamide and rituximab	LYFCR	ı	
			lymphoma palliative chemotherapy	LYPALL	l	
		Myeloma	Treatment of Multiple Myeloma using Bortezomib, Dexamethasone With or Without Cyclophosphamide as Induction Pre-Stem Cell Transplant	MYBORPRE	ı	
			Treatment of Relapsed Multiple Myeloma using Bortezomib, Dexamethasone With or Without Cyclophosphamide	MYBORREL	ı	
			Treatment of Multiple Myeloma using Bortezomib, Selinexor, and Dexamethasone With or Without Cyclophosphamide	MYBSD	I	
			Therapy of Multiple Myeloma using Carfilzomib and Dexamethasone With or Without Cyclophosphamide	MYCARDEX	I	
			treatment of relapsed and refractory multiple myeloma with daratumumab in combination with bortezomib and dexamethasone with or without cyclophosphamide	MYDARBD	ı	
			Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell Transplant using Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone	MYDARCBDF	I	
			Therapy of Multiple Myeloma using Carfilzomib, Dexamethasone and Isatuximab with or without Cyclophosphamide	UMYISACARD	R	***************************************
			Therapy of Multiple Myeloma using Pomalidomide, Dexamethasone and Isatuximab with or without Cyclophosphamide	UMYISAPOMD	R	
			treatment of multiple myeloma using melphalan, prednisone and weekly bortezomib with the option of substituting cyclophosphamide for melphalan	MYMPBOR	ı	
			single dose cyclophosphamide priming therapy for multiple myeloma prior to autologous stem cell transplant	MYHDC	I	
		Sarcoma	SAIME alternating with SAVAC or SAVACM with fligrastim support at <u>TWO</u> weekly interval for newly diagnosed Ewing's Sarcoma/Ewing's Family of Tumours, Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or	SAALT2W	I	
			Rhabdomyosarcoma SAIME alternating with SAVAC or SAVACM with filgrastim support at <u>THREE</u> weekly interval for newly diagnosed Ewing's Sarcoma/Ewing's Family of Tumours, Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or	SAALT3W	l	
			Rhabdomyosarcoma summary for treatment of recurrent/refractory neuroblastoma, ewing's sarcoma,	SAAVTC		
			osteogenic sarcoma or rhabdomyosarcoma with topotecan/cyclophosphamide treatment of sarcomas with vincristine, doxorubicin and cyclophosphamide	SAVAC	ļ	
			Treatment of Sarcomas with Pelvic Primaries or Chemotherapy-Induced Hematuria lusing Vincristine, Doxorubicin, Cyclophosphamide and Mesna	SAVACM	ı	
	tablet, injectable	Sarcoma	Adjuvant Therapy for Rhabdomyosarcoma using Vincristine, Dactinomycin and Cyclophosphamide	SAVDC	ı	



DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
cyclophosphamide (cont'd)	tablet, injectable	Pediatric	treatment of recurrent/refractory rhabdomysarcoma in pediatric patients with cyclophosphamide, vinorelbine and temsirolimus on the COG ARST0921 protocol		I	
		Not Otherwise Specified		Other tumour site code followed by 'NOS' (e.g. BRNOS)	I	
cyclosporine	capsule	Lymphoma	cytopenias associated with lymphoproliferative disorder of large granular lymphocytes	LYCSPA	ı	
			implications the state of hemophagocytic lymphohistic cytosis with etoposide, dexamethasone and cyclosporine	HLHETCSPA	- 1	
cytarabine	injectable	Leukemia & BMT	therapy of acute myeloid leukemia using low dose cytarabine Treatment of Acute Myeloid Leukemia using Gemtuzumab Ozogamicin with	LKAMLCYT	I	
				LKGEMOZ	- 1	
		Lymphoma	Induction and Consolidation Chemotherapy treatment of Burkitt's lymphoma and leukemia with cyclophosphamide, vincristine, doxorubicin, methotrexate, leucovorin and rituximab	LYCODOXMR	ı	
			Treatment of Lymphoma with Dexamethasone, Cytarabine, Platinum and riTUXimab	LYDHAPR	I	
			treatment of lymphoma using intrathecal methotrexate and cytarabine	LYIT	LI	
			treatment of Burkitt's lymphoma and leukemia with ifosfamide, mesna, etoposide, cytarabine and rituximab	LYIVACR	I	
		Miscellaneous Origins	therapy for solid tumours using intrathecal methotrexate and/or thiotepa and/or cytarabine	MOIT	I	
		Not Otherwise Specified		Other tumour site code followed by 'NOS' (e.g. LYNOS)	I	
dabrafenib	capsule	Skin & Melanoma	adjuvant treatment of stage III and IV, BRAF-mutated, fully resected melanoma using dabrafenib and trametinib	SMAJDT	1	
		• • • • • • • • • • • • • • • • • • • •	using dabratenib and trameunib treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma lusing dabrafenib	SMAVDAB	ı	• • • • • • • • • • • • • • • • • • • •
			treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma using dabrafenib and trametinib	SMAVDT	ı	
dacarbazine	injectable	Lymphoma	treatment of Hodgkin's disease with doxorubicin, bleomycin, vinblastine and dacarbazine	LYABVD	I	
			Treatment of Previously Untreated, Stage IV Hodgkin Lymphoma with Doxorubicin, Vinblastine, Dacarbazine and Brentuximab Vedotin	LYAVDBV	- 1	
			Treatment of Previously Untreated, Stage IV Hodgkin Lymphoma with Sequential Brentuximab Vedotin and DOXOrubicin, vinBLAStine and Dacarbazine in Patients 60 Years or Older	LYBVAVDBV	ı	
		Sarcoma	adjuvant treatment of patients with soft tissue sarcoma using doxorubicin and dacarbazine	SAAJADIC	ı	
			treatment of patients with soft tissue sarcoma using doxorubicin and dacarbazine	SAAVADIC	ı	
			high dose single agent dacarbazine for metastatic soft tissue sarcoma	SADTIC	l I	
		Skin & Melanoma	therapy for metastatic malignant melanoma using high dose single agent dacarbazine	SMDTIC	ı	
		Not Otherwise Specified		Other tumour site code followed by 'NOS' (e.g. SMNOS)	I	
dactinomycin	injectable	Gynecology	therapy for high-risk Gestational Trophoblastic Neoplasia (GTN) using etoposide, methotrexate, leucovorin (folinic acid), dactinomycin, cyclophosphamide and vincristine	GOTDEMACO	I	
		······	Therapy for Moderate Low-Risk Gestational Trophoblastic Cancer using Dactinomycin and Methotrexate	GOTDMR (previously GOTDLR)	ı	
		Gynecology	Therapy for Low-Risk Gestational Trophoblastic Cancer using Dactinomycin	GOTDLRA	<u> </u>	
		Sarcoma	Adjuvant Therapy for Rhabdomyosarcoma using Vincristine, Dactinomycin and Cyclophosphamide	SAVDC	1	
		Not Otherwise Specified		Other tumour site code followed by 'NOS' (e.g. SANOS)	ı	



DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
	1 Ortin	0.1.2	Treatment of Previously Untreated Light Chain Amyloidosis and Not-Eligible for	00020		
daratumumab	SC injectable only	Lymphoma	Stem Cell Transplant using Daratumumab, Cyclophosphamide, Bortezomib and	LYDARCBDF	1 1	
	oo iii,ootabio oiii,y	2,	Dexamethasone			
			Treatment of Relapsed and Refractory Multiple Myeloma with Daratumumab in			
	IV/SC injectable	Mveloma	Combination with Bortezomib and Dexamethasone with or without	MYDARBD	1 1	
	11700 injectable	, 5.5	Cyclophosphamide	57 11 15 5		
			Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell			
	IV/SC injectable		Transplant using Daratumumab, Cyclophosphamide, Bortezomib and	MYDARCBDF	1 1	
	1V/OO IIIJCCIADIC		Dexamethasone	WIBAROBBI		
			Treatment of Relapsed and Refractory Multiple Myeloma with Daratumumab in			
	IV/SC injectable		Combination with Lenalidomide and Dexamethasone	MYDARLD	1	
			Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell			
	IV/SC injectable			MYDARLDF	1	
	, ,		Transplant using Daratumumab, Lenalidomide and Dexamethasone			
darolutamide	tablet	Genitourinary	Treatment of Metastatic Castration Sensitive Prostate Cancer using Darolutamide	UGUMCSPDD	R	
			and DOCEtaxel			
			Treatment of Non-Metastatic Castration-Resistant Prostate Cancer using	UGUNMPDAR	R	
			Darolutamide	OGOININI DAIX	10	
dasatinib	tablet	Leukemia & BMT	treatment of chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia	LKCMLD	1	
daunorubicin	inicatable	Leukemia & BMT	first-line induction and consolidation therapy of acute promyelocytic leukemia using	LKATOP		
daunorubicin	injectable	Leukemia & bivi i	arsenic trioxide, tretinoin and daunorubicin	LKATOP	'	
			Treatment of Acute Myeloid Leukemia using Gemtuzumab Ozogamicin with		Ι .	
			Induction and Consolidation Chemotherapy	LKGEMOZ	'	
				Other tumour site code		
		Not Otherwise Specified		followed by 'NOS' (e.g.	1 1	
				KSNOS)	•	
				rtertee/	1	
daunorubicin liposomal-	injectable	Leukemia & BMT	Therapy of Acute Myeloid Leukemia using Daunorubicin Liposomal-Cytarabine	LKAMLDCYT	1 1	
cytarabine liposomal (Vyxeos®)	IIIJectable	Ecakemia & Bivi i	Liposomal	ERAMEBOTT		
decitabine-cedazuridine	tablet	Leukemia & BMT	Therapy of Myelodysplastic Syndrome using Decitabine-Cedazuridine	ULKMDSDC	R	
degarelix	injectable	Genitourinary	therapy for prostate cancer using LHRH antagonist	GUPLHRHA	ì	
<u> </u>		1	neoadjuvant use in patients with non-metastatic operable giant cell tumour of the			
denosumab (XGEVA®)	injectable	Sarcoma	bone	SANADENO	ı	
			Therapy for Metastatic Castration-Sensitive Prostate Cancer using Abiraterone and		1	
dexamethasone	tablet	Genitourinary	Prednisone	GUMCSPABI	1	
			Palliative Therapy for Metastatic Castration Resistant Prostate Cancer Using			
			Abiraterone and prednisone	UGUPABI	R	
				0110000		
			palliative therapy for metastatic hormone refractory prostate cancer	GUPDOC		
		Lymphoma	treatment of hemophagocytic lymphohistiocytosis with etoposide, dexamethasone	HLHETCSPA	1 1	Not reimbursed for:
			and cycloSPORINE	-		anti-emetic treatment, steroid
	1		treatment of refractory or relapsing extranodal natural killer or T-Cell lymphoma	LYASPMEDEX	l 1	replacement therapy, pre-taxane use,
		L	using pegaspargase, methotrexate and dexamethasone		.	or appetite stimulation
	1		Treatment of Previously Untreated Light Chain Amyloidosis and Not-Eligible for			or appoint ournation
	1		Stem Cell Transplant using Daratumumab, Cyclophosphamide, Bortezomib and	LYDARCBDF	1	
	.		Dexamethasone		L	
			treatment of lymphoma with gemcitabine, dexamethasone and platinum	LYGDP	L	
	Ī		treatment of lymphoma with gemcitabine, dexamethasone and platinum with	LVCDDD	T	1
		ĺ	rituximab	LYGDPR	'	l



DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
dexamethasone (cont'd)	tablet	Lymphoma	Treatment of Lymphoma with Dexamethasone, Cytarabine, Platinum and riTUXimab	LYDHAPR	ı	
			lymphoma palliative chemotherapy	LYPALL	i I	
			treatment of natural killer or T-Cell Lymphoma using dexamethasone, methotrexate,	LYSMILE	1	
			ifosfamide, pegaspargase and etoposide treatment of newly diagnosed nasal, extranodal natural killer (NK) or T-cell	L I OMILL		
				LYVIPDRT	1 .	
			by etoposide, ifosfamide, cisplatin and dexamethasone	ET VIII BIKT	l '	
		Myeloma	Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell	MYBLDF	I 1	
		,	Transplant using Bortezomib, Lenalidomide and Dexamethasone Treatment of Multiple Myeloma using Lenalidomide, Bortezomib and			
			Dexamethasone as Induction Pre-Stem Cell Transplant	MYBLDPRE	- 1	
			Treatment of Multiple Myeloma using Bortezomib, Dexamethasone With or Without	MYBORPRE		
			Cyclophosphamide as Induction Pre-Stem Cell Transplant	WITBURFRE	' '	
			Treatment of Relapsed Multiple Myeloma using Bortezomib, Dexamethasone With or Without Cyclophosphamide	MYBORREL	1	
			Treatment of Multiple Myeloma using Bortezomib, Selinexor, and Dexamethasone			
			With or Without Cyclophosphamide	MYBSD	<u> </u>	
			Therapy of Multiple Myeloma using Carfilzomib and Dexamethasone With or	MYCARDEX	ı	
			Without Cyclophosphamide			
			Therapy of Multiple Myeloma using Carfilzomib, Lenalidomide with Dexamethasone	MYCARLD	I	
			treatment of relapsed and refractory multiple myeloma with daratumumab in	MYDARBD	1	Not reimbursed for: anti-emetic treatment, steroid
			combination with bortezomib and dexamethasone with or without cyclophosphamide			
			Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell			
			Transplant using Daratumumab, Cyclophosphamide, Bortezomib and	MYDARCBDF	- 1	replacement therapy, pre-taxane use,
			Dexamethasone treatment of relapsed and refractory multiple myeloma with daratumumab in			or appetite stimulation
			combination with lenalidomide and dexamethasone	MYDARLD	- 1	
			Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell	MYDARLDF	1	
			Transplant using Daratumumab, Lenalidomide and Dexamethasone	WITDARLDF		
			Therapy of Multiple Myeloma using Carfilzomib, Dexamethasone and Isatuximab with or without Cyclophosphamide	UMYISACARD	R	
			treatment of previously untreated multiple myeloma and not eligible for stem cell			
			transplant using lenalidomide with low-dose dexamethasone	UMYLDF	R	
			therapy of relapsed multiple myeloma using lenalidomide with dexamethasone	MYLDREL	<u> </u>	
			treatment of multiple myeloma using melphalan, prednisone and weekly bortezomib with the option of substituting cyclophosphamide for melphalan	MYMPBOR	- 1	
			therapy of multiple myeloma using pomalidomide with dexamethasone	UMYPOMDEX	R	
			patients with primary or metastatic disease exhibiting cerebral edema or CNS			
		Not Otherwise Specified Not Otherwise Specified Tr	swelling; management of malignant brain tumours; management of CNS lymphoma	MODEXA	1	
				Other tumour site code		
				followed by 'NOS' (for	1	
				e.g. CNNOS)		
				Other tumour site code		
	injectable			followed by 'NOS' (e.g.	1	
			Treatment of Pediatric Patients with De Novo Acute Promyelocytic Leukemia using	BRNOS)		
	1		Arsenic Trioxide In Combination with Tretinoin and with or without Idarubicin and		1	
			Dexamethasone on the COG AAML1331 Study			

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
dexrazoxane	injectable	Pediatric	Pediatric patients with acute myeloid leukemia receiving anthracycline on the COG		1	
	····	- Calacilo	AAML1031 protocol			
			Pediatric patients with neuroblastoma treated on the COG AEWS1031 protocol			
			Pediatric patients with rhabdomyosarcoma treated on the COG ARST08P1 protocol		- 1	
			Dexrazoxane for pediatric patients with anticipated cumulative anthracycline dose			
			>150 mg/m2 or with past or anticipated radiotherapy including the pericardium		- 1	
			(including whole-abdomen or left flank irradiation)			
l			treatment of pediatric patients with high-risk neuroblastoma who achieve a			
dinutuximab	injectable	Pediatric	response to prior first-line multi-agent, multimodal therapy using dinutuximab in		ı	
			combination with sargramostim, aldesleukin and tretinoin			
			dinutuximab in combination with irinotecan, temozolomide and sargramostim for		1	
			high-risk neuroblastoma in first relapse or determination of refractory disease neoadjuvant or adjuvant therapy for breast cancer using cyclophosphamide,		+	
docetaxel	injectable	Breast	doxorubicin and docetaxel	BRAJDAC	1	
			neoadjuvant or adjuvant therapy for breast cancer using docetaxel and			
			cyclophosphamide	BRAJDC	1	
			neoadjuvant or adjuvant therapy for breast cancer using carboplatin, docetaxel and			
			trastuzumab	BRAJDCARBT		
			neoadjuvant or adjuvant therapy for breast cancer using fluorouracil, epirubicin and	BRAJFECD		
			cyclophosphamide and docetaxel	DRAJFECD	<u> </u>	
			neoadjuvant or adjuvant therapy for breast cancer using fluorouracil, epirubicin and	BRAJFECDT	1	
			cyclophosphamide followed by docetaxel and trastuzumab			
			neoadjuvant or adjuvant therapy for breast cancer using trastuzumab, docetaxel	BRAJTDC		
			and cyclophosphamide			
			combination with doxorubicin and cyclophosphamide as treatment of locally	BRLAACD	1	
			advanced breast cancer treatment of locally advanced breast cancer using doxorubicin and			
			cyclophosphamide followed by docetaxel and trastuzumab	BRLAACDT	1	
			first, second, or third line treatment of metastatic breast cancer patients with ECOG			
			performance status 0, 1, or 2, and greater than 3 month life expectancy	BRAVDOC	1	
			weekly docetaxel regimen for metastatic breast cancer patients with poor tolerance			
				BRAVDOC7	1	
			in BRAVDOC			
			palliative therapy for metastatic breast cancer using gemcitabine and docetaxel	BRAVGEMD	I .	
					<u>'</u>	
			palliative therapy for metastatic breast cancer using pertuzumab, trastuzumab and	BRAVPTRAD		
			docetaxel as first-line treatment for advanced breast cancer			
1		Gastrointestinal	palliative treatment of metastatic esophagogastric adenocarcinoma with docetaxel	GIAVDOC	1	
			perioperative treatment of resectable adenocarcinoma of the stomach.			
			gastroesophageal junction or lower 1/3 esophagus using docetaxel, oxaliplatin,	GIGFLODOC	1	
			infusional fluorouracil, and leucovorin	OIGI EODOO	1 '	
			combination with carboplatin as primary treatment of advanced/recurrent non-small			
		Gynecology	cell cancer of the cervix in ambulatory care settings	GOCXCAD	1	
			treatment of primarily advanced or recurrent endometrial cancer using carboplatin	00510010		
			and docetaxel	GOENDCAD	L '	
			primary treatment with visible or no visible residual tumour (moderate, high, or		Ī	
l			extreme risk) or treatment at relapse of invasive epithelial ovarian, fallopian tube,	GOOVCAD	1	
			and primary peritoneal cancer, using carboplatin and docetaxel			
1			treatment of progressive, platinum-refractory epithelial ovarian carcinoma, primary	GOOVDOC	1	
			peritoneal			
1			combination with gemcitabine for advanced or recurrent uterine sarcoma cancer	GOSADG	1	
			1		1	

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
docetaxel (cont'd)	injectable	Genitourinary	Intravesical Therapy for Non-Muscle Invasive Bladder Cancer using Gemcitabine	GUBGEMDOC	-	
L	IIIJectable	Geriilourinary	and Docetaxel	GODGLINDOC		
			Treatment of Metastatic Castration Sensitive Prostate Cancer using Darolutamide	UGUMCSPDD	R	
			and DOCEtaxel			
			intravesical use for bladder cancer if BCG and mitomycin C not available	GUNOS	l	
			palliative therapy for metastatic hormone refractory prostate cancer	GUPDOC		
			first-line treatment of castration sensitive, metastatic prostate cancer using			
			docetaxel and androgen deprivation therapy with LHRH agonist or LHRH	GUPDOCADT	'	
			antagonist with or without antiandrogen, or surgical castration			
		Head and Neck	treatment of recurrent or metastatic squamous cell carcinoma of the head and neck	HNAVDOC	1	
			with docetaxel			
			treatment of recurrent or metastatic squamous cell carcinoma of the head and neck	HNAVPD	1	
			with platinum and docetaxel			
			treatment of locally advanced squamous cell carcinoma of the head and neck with	HNLADCF	1	
			docetaxel, cisplatin and infusional fluorouracil			
		Lung	combination with cisplatin as first line treatment of advanced non-small lung cancer	LUAVDC	1	
			second-line treatment of non-small cell lung cancer	LUAVDOC	l I	
		Sarcoma	combination with gemcitabine as second or third line therapy for soft tissue	SAAVGEMD	1	
		Saiconia	sarcomas		'	
doxorubicin	injectable	Breast	adjuvant therapy for breast cancer using doxorubicin and cyclophosphamide	BRAJAC		
			neoadjuvant or adjuvant therapy for breast cancer using doxorubicin and cyclophosphamide followed by paclitaxel	BRAJACT	1	
			neoadjuvant or adjuvant therapy for breast cancer using dose dense therapy:			
			doxorubicin and cyclophosphamide followed by paclitaxel	BRAJACTG		
			neoadjuvant or adjuvant therapy for breast cancer using doxorubicin and			
			cyclophosphamide followed by paclitaxel and trastuzumab	BRAJACTT	1	
			neoadjuvant or adjuvant therapy for breast cancer using dose dense therapy:	DD 4 14 OTTO		
			doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab	BRAJACTTG	'	
			neoadjuvant or adjuvant therapy for early breast cancer using doxorubicin and	DDA IACTIAI		
			cyclophosphamide followed by weekly paclitaxel	BRAJACTW	'	
			neoadjuvant or adjuvant therapy for breast cancer using cyclophosphamide,	BRAJDAC		
			doxorubicin and docetaxel		'	
			palliative therapy for metastatic breast cancer using weekly doxorubicin	BRAVA7	I	
			palliative therapy for metastatic breast cancer using doxorubicin and	BRAVAC	1	
			cyclophosphamide	DIVAVAC		
			treatment of locally advanced breast cancer using doxorubicin and	BRLAACD	1 1	
			cyclophosphamide followed by docetaxel			
			treatment of locally advanced breast cancer using doxorubicin and	BRLAACDT	1 1	
			cyclophosphamide followed by docetaxel and trastuzumab			
			Alternative NEOAdjuvant Therapy for Triple Negative Breast Cancer using			
			CARBOplatin and PACLitaxel NAB (ABRAXANE) Followed by DOXOrubicin and	BRLACPNAC		
			Cyclophosphamide			
			Alternative NEOAdjuvant Therapy for Triple Negative Breast Cancer using Dose			
			Dense Therapy: CARBOplatin and PACLitaxel NAB (ABRAXANE) Followed by	BRLACPNACG	1	
			DOXOrubicin and Cyclophosphamide			
		1	NEOAdjuvant Therapy for Triple Negative Breast Cancer using Carboplatin and	BRLACTWAC	1	
			Weekly PACLitaxel Followed by DOXOrubicin and Cyclophosphamide			
		1	Neoadjuvant Therapy for Triple-Negative Breast Cancer using Dose-Dense	DDI ACTIVIACO	1 , 1	
			Therapy: Carboplatin and Weekly Paclitaxel Followed by Doxorubicin and Cyclophosphamide	BRLACTWACG		
			Alternative NEOAdjuvant Therapy for Locally Advanced Breast Cancer using		T	
	1			BRLAPNAC	1	
			PACLitaxel NAB (ABRAXANE) followed by DOXOrubicin and Cyclophosphamide			

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
			Alternative NEOAdjuvant Therapy for Breast Cancer using Dose Dense Therapy:			
doxorubicin (cont'd)	injectable	Breast	PACLitaxel NAB (ABRAXANE) followed by DOXOrubicin and Cyclophosphamide	BRLAPNACG	'	
			neoadjuvant therapy for breast cancer using dose dense therapy: paclitaxel	BRLATACG	T 1	
			followed by doxorubicin and cyclophosphamide			
			treatment of locally advanced breast cancer using doxorubicin and	BRLATWAC	1	
			cyclophosphamide followed by weekly paclitaxel NEOAdjuvant Therapy for Triple Negative Breast Cancer using Pembrolizumab with			
			CARBOplatin and Weekly PACLitaxel, Followed by DOXOrubicin and	BRPCTAC		
			Cyclophosphamide			
			NEOAdjuvant Therapy for Triple Negative Breast Cancer using Pembrolizumab,			
			Weekly CARBOplatin and Weekly PACLitaxel, Followed by DOXOrubicin and	BRPCWTAC	1	
			Cyclophosphamide			
		Gastrointestinal	palliative therapy for hepatoma using doxorubicin transarterial chemoembolization (TACE) of hepatocellular carcinoma using drug-	GIA		
			eluting bead (DEB) loaded with doxorubicin	GIDEBTACE	1	
			elding bead (DED) loaded with doxordbion			Note: only funded when prescribed by
			hepatic trans-arterial chemoembolization for primary liver cancer or liver metastasis	GIEMBOL	1	specialists at BC Cancer Vancouver
			<u>'</u>			and Royal Jubilee Hospital
			palliative therapy for pancreatic endocrine tumours using streptozocin and	GIENDO2	Ι	
			doxorubicin			
			hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with peritoneal	GIPMHIPEC	1	
		Genitourinary	mesothelioma using doxorubicin, cisplatin and paclitaxel palliative therapy for advanced adrenal cortical cancer using doxorubicin	GUAVD		
		Geriilourinary	Neoadjuvant Treatment of Urothelial Cancer using Dose-Dense Methotrexate,			
			Vinblastine. Doxorubicin and Cisplatin	GUBDDMVAC	I	
			treatment of metastatic adrenalcortical cancer with doxorubicin, etoposide, cisplatin	GUEDPM	1	Not reimbursed for bladder instillations
			and mitotane	GUEDPINI	_L'	
			therapy for transitional cell cancers of the urothelium using methotrexate,	GUMVAC		
			vinblastine, doxorubicin and cisplatin	GOENDD		
		Gynecology	for use in patients with advanced endometrial cancer for use in patients with advanced uterine sarcoma	GOSAD		
		Head and Neck	palliative therapy for advanced thyroid cancers using doxorubicin	HNOTAVD	+	
		Ticau and Ivcor	palliative therapy for advanced salivary gland cancers using cyclophosphamide,			
			doxorubicin and fluorouracil	HNSAVFAC		
			treatment of advanced salivary gland cancers with platinum, doxorubicin and	HNSAVPAC	Ι	
			cyclophospahmide treatment of thymoma/thymic carcinoma with cyclophosphamide, doxorubicin and	IIIIOAVEAG	'	
		Lung		LUOTCAV	1	
			vincristine treatment of thymoma with platinum, doxorubicin, and cyclophosphamide	LUOTPAC		
			treatment of extensive small cell lung cancer with cyclophosphamide, doxorubicin			
			and vincristine	LUSCCAV	I	
		Lymphomo	treatment of Hodgkin's disease with doxorubicin, bleomycin, vinblastine and	LYABVD	T	
		Lymphoma	dacarbazine	LYADVU		
			Treatment of Previously Untreated, Stage IV Hodgkin Lymphoma with Doxorubicin,	LYAVDBV	I 1	
			Vinblastine, Dacarbazine and Brentuximab Vedotin			
			Treatment of Previously Untreated, Stage IV Hodgkin Lymphoma with Sequential Brentuximab Vedotin and DOXOrubicin. vinBLAStine and Dacarbazine in Patients	LYBVAVDBV		
			60 Years or Older	LIDVAVDDV	1 '	
			treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine and	LVCLIOD	1	
			prednisone	LYCHOP		
	T		treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine, prednisone	LYCHOPR	I	
			and rituximab	2. 3. 101 10		



DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
doxorubicin (cont'd)	injectable	Lymphoma	central nervous system prophylaxis with high dose methotrexate, CHOP and	LYCHOPRMTX	1	
doxorubiciii (cont u)	injectable	Супірпопіа	rituximab in diffuse large B-cell lymphoma	LICHOPKWIX	<u>'</u>	
			treatment of CD30-positive peripheral T-Cell Lymphoma (PTCL) with doxorubicin,	LYCHPBV	1	
			cyclophosphamide, prednisone (CHP) and brentuximab vedotin			
			treatment of burkitt's lymphoma and leukemia with cyclophosphamide, vincristine,	LYCODOXMR	1	
			doxorubicin, methotrexate, leucovorin and rituximab			
			treatment of Hodgkin's Disease with cyclophosphamide, vinblastine, procarbazine	LYCVPPABO	1	
			and prednisone			
			treatment of lymphoma with dose-adjusted etoposide, doxorubicin, vincristine,	LYEPOCHR	1	
			cyclophosphamide, prednisone and rituximab with intrathecal methotrexate	LYPALL		
			lymphoma palliative chemotherapy	LYPALL	ļl	
		Sarcoma	therapy for advanced soft tissue sarcoma using doxorubicin, ifosfamide-mesna	SAAI	- 1	
			3-day doxorubicin, ifosfamide and mesna for use in patients with advanced soft	SAAI3		
			tissue sarcoma	SAAIS	<u>'</u>	
			doxorubicin for adjuvant use for patients with non-metastatic operable large high	SAAJA	1	
			grade soft tissue sarcoma	07407	L'	
			adjuvant treatment of patients with soft tissue sarcoma using doxorubicin and	SAAJADIC	1	
			dacarbazine		·	
			adjuvant therapy for osteosarcoma using doxorubicin and cisplatin	SAAJAP	<u> </u>	
			SAIME alternating with SAVAC or SAVACM with filgrastim support at <u>TWO</u> weekly			
			interval for newly diagnosed Ewing's Sarcoma/Ewing's Family of Tumours,	SAALT2W	1	
			Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or			
			Rhabdomyosarcoma			
			SAIME alternating with SAVAC or SAVACM with filgrastim support at THREE			
			weekly interval for newly diagnosed Ewing's Sarcoma/Ewing's Family of Tumours,	SAALT3W	1	
			Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or			
			Rhabdomyosarcoma	O A A V / A		
			therapy for advanced soft tissue sarcoma using doxorubicin	SAAVA	ļl	
			treatment of patients with soft tissue sarcoma using doxorubicin and dacarbazine	SAAVADIC	- 1	
			therapy of advanced osteosarcoma using doxorubicin and cisplatin	SAAVAP	I	
			treatment of sarcomas with vincristine, doxorubicin and cyclophosphamide	SAVAC	I	
			Treatment of Sarcomas with Pelvic Primaries or Chemotherapy-Induced Hematuria	SAVACM	1	
			using Vincristine, Doxorubicin, Cyclophosphamide and Mesna		<u>'</u>	
				Other tumour site code		
		Not Otherwise Specified		followed by 'NOS' (e.g.	1	Not reimbursed for bladder instillations
				BRNOS)		
doxorubicin pegylated	injectable	Gynecology	Resistant or Refractory Epithelial Ovarian Cancer with Bevacizumab and	GOOVBEVLD	1	
liposomal	·······		DOXOrubicin Pegylated Liposomal first line treatment of epithelial ovarian cancer using doxorubicin pegylated			
				GOOVFPLDC	1	
			liposomal and carboplatin treatment of epithelial ovarian cancer relapsing after primary treatment using			
			pegylated liposomal doxorubicin	GOOVLDOX	- 1	
			treatment of epithelial ovarian cancer relapsing after primary treatment using			
	ĺ		pegylated liposomal doxorubicin and carboplatin	GOOVPLDC	1	
		Kaposi's Sarcoma	Kaposi's sarcoma	KSLDO		
		1	Treatment of Relapsed or Refractory Hodgkin Lymphoma with Gemcitabine,	LVOV/LD		
		Lymphoma	Vinorelbine and Doxorubicin Pegylated Liposomal	LYGVLD	ı	
drug-eluting bead (DEB) loaded						
with doxorubicin (DC Bead® or	other	Gastrointestinal	transarterial chemoembolization (TACE) of hepatocellular carcinoma using drug-	GIDEBTACE	I 1	
HepaSphere™)	55.		eluting bead (DEB) loaded with doxorubicin		l .	
, , , , , , , , , , , , , , , , , , ,						



DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
durvalumab	injectable	Gastrointestinal	Treatment of Advanced Biliary Tract Cancer using Durvalumab	GIAVDUR4	I	
			First-line Palliative Treatment of Advanced Biliary Tract Cancer using Durvalumab,	GIAVDURPG	1	
			Gemcitabine and Platinum			
			First-Line Treatment of Advanced Hepatocellular Carcinoma using Tremelimumab	GITREMDUR	1	
			and Durvalumab Locally Advanced Non-Small Cell Lung Cancer Using Durvalumab	LULADUR		
		Lung	Treatment of Locally Advanced Non-Small Cell Lung Cancer Using Durvaluman Treatment of Locally Advanced Non-Small Cell Lung Cancer Using 4-Weekly		·	
			Durvalumab	LULADUR4	1	
			Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC) with Durvalumab,		•	
			Platinum and Etoposide	LUSCDURPE	1	
		0	Treatment of BRAF V600E-Mutated Metastatic Colorectal Cancer using	LIGIAN (BANIEN		
encorafenib	capsule	Gastrointestinal	Panitumumab and Encorafenib	UGIAVPANEN	R	
		Skin & Melanoma	Treatment of BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma	SMAVEB	I .	
			using Encorafenib and Binimetinib		'	
enfortumab vedotin	injectable	Genitourinary	Palliative Therapy for Urothelial Carcinoma using Enfortumab Vedotin	GUAVEV	ı	
entrectinib	capsule	Lung	First-Line Treatment of ROS1-Positive Advanced Non-Small Cell Lung Cancer	LUAVENT		
			(NSCLC) with Entrectinib			
		Tumour Agnostic	Treatment of Tumours with Neurotrophic Tyrosine Receptor Kinase (NTRK) Fusion	UTAAVENT	R	
		+	using Entrectinib		-	
enzalutamide	tablet	Genitourinary	Therapy for Metastatic Castration Sensitive Prostate Cancer using Enzalutamide	GUMCSPENZ	- 1	
			Therapy for Non-Metastatic Castration Resistant Prostate Cancer Using			
			Enzalutamide	UGUNMPENZ	R	
			Palliative Therapy for Metastatic Castration Resistant Prostate Cancer Using	UGUPENZ	R	
			Enzalutamide	UGUPENZ	K	
epirubicin	injectable	Breast	adjuvant therapy for breast cancer using fluorouracil, epirubicin and	BRAJFEC		
	·····		cyclophosphamide			
			neoadjuvant or adjuvant therapy for breast cancer using fluorouracil, epirubicin and	BRAJFECD	1	
			cyclophosphamide and docetaxel neoadjuvant or adjuvant therapy for breast cancer using fluorouracil, epirubicin and			
			cyclophosphamide followed by docetaxel and trastuzumab	BRAJFECDT	1	
			treatment of operable cancer of the stomach, stomach-esophagus junction or lower			
		Gastrointestinal	1/3 esophagus, given before and after surgery, using epirubicin, cisplatin and	GIGECC		
		Gastronitestinal	capecitabine	GIOLOG	'	
		Genitourinary	intravesical use for bladder cancer if BCG and mitomycin C not available	GUNOS	T	
				Other tumour site code		
1		Not Otherwise Specified		followed by 'NOS' (e.g.	1	
				BRNOS)		
eribulin	injectable	Breast	Palliative Therapy for Metastatic Breast Cancer using Eribulin	BRAVERIB	Ī	
		Sarcoma	Palliative Therapy for Metastatic Sarcoma using Eribulin	SAAVERIB		
erlotinib	tablet	Lung	second or third line treatment of advanced non-small cell lung cancer	LUAVERL	L	
1			maintenance therapy of advanced non-small cell lung cancer after first-line	LUAVMTNE	1	
			chemotherapy		1	



DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
etoposide capsule/ injectable	capsule/ injectable	Neuro-Oncology	carboplatin and etoposide in the treatment of recurrent ependymoma	CNCARV	1	
		palliative treatment of patients with recurrent malignant gliomas and ependymoma using low dose etoposide	CNETO	l		
			therapy for recurrent malignant brain tumours using temozolomide and etoposide	CNTMZETO	1	
		Gastrointestinal	palliative therapy of neuroendocrine tumours using cisplatin and etoposide	GIPE	I	
		Gynecology	therapy of non-dysgerminomatous ovarian germ cell cancer using bleomycin, etoposide and cisplatin	GOBEP	I	
			therapy of dysgerminomatous ovarian germ cell cancer using cisplatin and etoposide	GOEP	ı	
			treatment of relapsed/progressing epithelial ovarian, primary peritoneal, or fallopian tube carcinoma using etoposide	GOOVETO	ı	
			treatment of small-cell gynecologic cancer with cisplatin and etoposide	GOSCPE	1	
			treatment of small-cell gynecologic cancer with cisplatin and etoposide with radiation therapy	GOSCPERT	ı	
			therapy for high-risk Gestational Trophoblastic Neoplasia (GTN) using etoposide, methotrexate, leucovorin (folinic acid), dactinomycin, cyclophosphamide and vincristine	GOTDEMACO	I	
		Genitourinary	curative therapy for germ cell cancer using bleomycin, etoposide and cisplatin	GUBEP	I	
			treatment of metastatic adrenalcortical cancer with doxorubicin, etoposide, cisplatin and mitotane	GUEDPM	ı	***************************************
			therapy for nonseminoma germ cell cancer using etoposide-cisplatin	GUEP	ı	
			therapy of genitourinary small cell tumours with a platin and etoposide	GUSCPE	I	
			therapy of genitourinary small cell tumors with a platin and etoposide with radiation	GUSCPERT	ı	
			nonseminoma consolidation/salvage protocol using etoposide, cisplatin, ifosfamide, mesna	GUVIP2	ı	
		Head and Neck	treatment of recurrent and metastatic squamous cell cancer with platinum and etoposide	HNAVPE	ı	
			treatment of recurrent and/or metastatic nasopharyngeal cancer with platinum and etoposide	HNNAVPE	ı	
		Lung	treatment of locally advanced non-small cell lung cancer using cisplatin and etoposide with radiation	LULAPERT	I	
			treatment of locally advanced non-small cell lung cancer using alternative dosing of cisplatin and etoposide with radiation therapy	LULAPE2RT	ı	
			treatment of thymoma with cisplatin and etoposide	LUOTPE	ı	
			treatment of thymoma using cisplatin and etoposide with radiation therapy	LUOTPERT	ı	
			treatment of cancer of unknown primary involving the thorax with cisplatin and etoposide	LUPUPE	I	
			Treatment of Extensive Stage Small Cell Lung Cancer (SCLC) with Atezolizumab,	LUSCATPE	I	***************************************
			Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC) with Durvalumab, Platinum and Etoposide	LUSCDURPE	I	



DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
etoposide (cont'd)	capsule/ injectable	Lung	Treatment of Extensive Stage Small Cell Lung Cancer (SCLC) with Platinum and Etoposide	LUSCPE	I	
	capsule		Treatment of Extensive Stage Small Cell Lung Cancer with Platinum and Oral	LUSCPEPO	l	
	capsule		Treatment of Limited Stage Small Cell Lung Cancer using Platinum and Oral	LUSCPEPORT	ı	
			Treatment of Limited Stage Small Cell Lung Cancer using Platinum and Etoposide with Radiation Therapy palliative therapy of extensive stage small cell lung cancer with oral etoposide	LUSCPERT	I	
	capsule		palliative therapy of extensive stage small cell lung cancer with oral etoposide	LUSCPOE	l	
	capsule/ injectable	Lymphoma	treatment of hemophagocytic lymphohistiocytosis with etoposide, dexamethasone and cycloSPORINE	HLHETCSPA	I	
			treatment of lymphoma with dose-adjusted etoposide, doxorubicin, vincristine, cyclophosphamide, prednisone and rituximab with intrathecal methotrexate	LYEPOCHR	ı	
			treatment of burkitt's lymphoma and leukemia with ifosfamide, mesna, etoposide, cytarabine and rituximab	LYIVACR	ı	
			lymphoma palliative chemotherapy	LYPALL	I	
			treatment of relapsed or refractory advanced stage aggressive B-cell non-Hodgkin's lymphoma with ifosfamide, carboplatin, etoposide and rituximab	LYRICE	ı	
			treatment of natural killer or T-Cell Lymphoma using dexamethasone, methotrexate, ifosfamide, pegaspargase and etoposide	LYSMILE	ı	
			treatment of newly diagnosed nasal, extranodal natural killer (NK) or T-cell lymphoma, stage IE to IIE using concurrent radiation and weekly cisplatin followed by etopogical inspirite cisplatin and devembers one.	LYVIPDRT	I	
		Sarcoma	by explosive incisalines support at a trivial weekly interval for newly diagnosed Ewing's Sarcoma/Ewing's Family of Tumours, Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or Rhabdomyosarcoma	SAALT2W	I	
			SAIME alternating with SAVAC or SAVACM with filgrastim support at THREE	SAALT3W	l	
			3-Day etoposide & ifosfamide-mesna for patients with advanced soft tissue or bony sarcomas	SAAVIME3	ı	
			etoposide, ifosfamide-mesna (SAIME) for use in sarcomas	SAIME	ı	
		Skin & Melanoma	treatment of recurrent or metastatic Merkel cell carcinoma with cisplatin and etoposide	SMMCCPE	ı	
		Not Otherwise Specified		Other tumour site code followed by 'NOS' (e.g. HNNOS)	l	
etoposide phosphate (SAP)	injectable	Genitourinary	Curative Therapy for Germ Cell Cancer using Bleomycin, Etoposide and CISplatin	GUBEP	l	Approval from Health Canada Special
			Etoposide-CISplatin Protocol for Germ Cell Cancers	GUEP	ı	Access Programme is required for each patient
		Consolidation and Salvage Therapy for Nonseminoma Using Etoposide, CISplatin, Ifosfamide, Mesna	GUVIP2	ı	patient	

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
everolimus	tablet	Breast	therapy for advanced breast cancer using everolimus and exemestane	BRAVEVEX	I	
		Gastrointestinal	treatment of advanced neuroendocrine tumours of gastrointestinal origin (non-	UGINETEV	R	
		Gasti Officestifiai	functional) using everolimus			Note: AFINITOR® DISPERZ™
			palliative treatment of advanced pancreatic neuroendocrine tumours	GIPNEVER	l I	formulation not funded
		Genitourinary	therapy for advanced renal cancer using everolimus	GUEVER	l	iornidiation not randed
		Lung	treatment of advanced neuroendocrine tumours of lung origin (non-functional) using everolimus	LUNETEV	I	
exemestane	tablet	Breast	Treatment of Adjuvant Breast Cancer using Abemaciclib and Aromatase Inhibitor With or Without LHRH Agonist	UBRAJABEAI	R	
			neoadjuvant or adjuvant therapy for breast cancer using exemestane in	BRAJEXE	<u>.</u>	
			postmenopausal women Neoadjuvant or Adjuvant Ovarian Suppression and Aromatase Inhibitor in	BRAJLHRHAI		
			Premenopausal Women or In Men with High Risk Early Stage Breast Cancer	DRAJLIRITAI		
			therapy for advanced breast cancer using everolimus and exemestane	BRAVEVEX	l l	
			first or second line hormonal treatment for advanced breast cancer in	BRAVEXE	1	
			postmenopausal women	DIVAVLAL		
			therapy for advanced breast cancer using a LHRH agonist and an aromatase inhibitor	BRAVLHRHAI	ı	
		Gynecology	hormonal treatment for advanced endometrial cancer in postmenopausal women	GOENDAI	ı	
fedratinib	capsule	Leukemia & BMT	Treatment of Symptomatic Myelofibrosis with Fedratinib	ULKMFFED	R	
filgrastim (GRASTOFIL®, NIVESTYM®, NYPOZI®)	injectable		for inpatient administration only - see BC PharmaCare Special Authority Form for indications covered	FILGRASTIM		
fludarabine	injectable/ tablet	Leukemia & BMT	Indications serviced	BMTNOS		
				LKNOS	ı	
		Lymphoma	treatment of chronic lymphocytic leukemia or prolymphocytic leukemia with fludarabine and rituximab	LYCLLFLUDR	ı	
			treatment of chronic lymphocytic leukemia (CLL) or prolymphocytic leukemia with fludarabine, cyclophosphamide and rituximab	LYFCR	ı	
			chronic lymphocytic leukemia or low grade lymphoma	LYFLU		
			treatment of relapsed indolent lymphoma with fludarabine and rituximab	LYFLUDR	··· · ·····i	
				LYNOS	· · · · · · · · · · · · · · · · · · ·	
		Pediatric	pediatric patients with AML treated on the CCG-2961 study		ı	
fludrocortisone	tablet	Genitourinary	treatment of metastatic adrenalcortical cancer with doxorubicin, etoposide, cisplatin and mitotane	GUEDPM	I	
			mineralocorticoid deficiency associated with mitotane use	GUMITO	···	
fl	to to state to	D 4	adjuvant therapy for breast cancer using fluorouracil, epirubicin and		1 . 1	
fluorouracil	injectable	Breast	cyclophosphamide	BRAJFEC	'	
			neoadjuvant or adjuvant therapy for breast cancer using fluorouracil, epirubicin and	BRAJFECD	ı	
			neoadjuvant or adjuvant therapy for breast cancer using fluorouracil, epirubicin and	BRAJFECDT	ı	
			cyclophosphamide followed by docetaxel and trastuzumab palliative therapy for advanced breast cancer using cyclophosphamide,	BRAVCMF		
		Castraintestinal	methotrexate and fluorouracil adjuvant combination chemotherapy for stage III and stage IIB colon cancer using	GIAJFFOX		
		Gastrointestinal	oxaliplatin, fluorouracil and folinic acid (leucovorin) adjuvant therapy of colon cancer using fluorouracil injection and infusion and			
			leucovorin infusion	GIAJFL		
		palliative combination chemotherapy for metastatic colorectal cancer using fluorouracil injection and infusion and folinic acid (leucovorin) infusion	GIAVFL			
			combined modality therapy for locally advanced esophageal cancer using oxaliplatin, fluorouracil, leucovorin, and radiation therapy	GIEFFOXRT	ı	



DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
fluorouracil (cont'd)	injectable	Gastrointestinal	hepatic trans-arterial chemoembolization for primary liver cancer or liver metastasis	GIEMBOL	ı	Note: only funded when prescribed by specialists at BC Cancer Vancouver and Royal Jubilee Hospital
			palliative therapy for pancreatic endocrine tumours using streptozocin and doxorubicin	GIENDO2	l	
			palliative combination chemotherapy for metastatic colorectal cancer using irinotecan, fluorouracil, folinic acid (leucovorin) and bevacizumab	GIFFIRB	I	
			palliative combination chemotherapy for metastatic colorectal cancer using irinotecan, fluorouracil, leucovorin, and panitumumab	GIFFIRPAN	I	
			palliative combination chemotherapy for metastatic colorectal cancer using oxaliplatin, fluorouracil, leucovorin, and bevacizumab	GIFFOXB	l	
			palliative combination chemotherapy for metastatic colorectal cancer using oxaliplatin, fluorouracil, leucovorin, and panitumumab	GIFFOXPAN	l	
			palliative combination chemotherapy for advanced pancreatic adenocarcinoma using irinotecan, oxaliplatin, fluorouracil and folinic acid (leucovorin)	GIFIRINOX	I	
			palliative combination chemotherapy for metastatic colorectal cancer using irinotecan, fluorouracil and folinic acid (leucovorin)	GIFOLFIRI	ı	
			palliative combination chemotherapy for metastatic colorectal cancer using oxaliplatin, fluorouracil and folinic acid (leucovorin)	GIFOLFOX	ı	
			combined modality curative therapy for carcinoma of the anal canal using mitomycin, fluorouracil and radiation therapy	GIFUART	ı	
				GIFUC	I	
			Infusional fluorouracil and cisplatin Chemotherapy of Pseudomyxoma Peritonei Using Intraperitoneal Mitomycin and Fluorouracil	GIFUIP	l	
			combined modality curative therapy for carcinoma of the anal canal using cisplatin,	GIFUPART	l	
			adjuvant chemotherapy in gastric cancer patients with D2 resection (node negative) or ineligible for adjuvant chemoradiation using oxaliplatin, fluorouracil, and	GIGAJFFOX	I	
			leucovorin palliative treatment of metastatic or inoperable, locally advanced gastric or qastroesophaqeal junction adenocarcinoma using cisplatin, infusional fluorouracil	GIGAVCFT		
			and trastuzumab		' 	
			Junction or Esophageal Carcinoma using Oxaliplatin, Fluorouracil and Leucovorin	GIGAVFFOX	ı	
			First-Line Treatment of Locally Advanced or Metastatic Esophageal, Gastroesophageal, or Gastric Cancer using Oxaliplatin, Fluorouracil, Leucovorin and Nivolumab	GIGAVFFOXN	ı	
			and nivoluman First-Line Treatment of Locally Advanced or Metastatic Gastroesophageal Cancer lusing Oxaliolatin. Fluorouracil. Leucovorin and Pembrolizumab	GIGAVFFOXP	I	
			palliative treatment of metastatic or locally advanced HER-2 positive gastric, gastroesophageal junction, or esophageal adenocarcinoma using oxaliplatin,	GIGAVFFOXT	I	
			fluorouracil, leucovorin, and trastuzumab perioperative treatment of resectable adenocarcinoma of the stomach,			
			gastroesophageal junction or lower 1/3 esophagus using docetaxel, oxaliplatin, infusional fluorouracil, and leucovorin	GIGFLODOC	l	
			palliative combination chemotherapy for metastatic gastric or esophageal adenocarcinoma using irinotecan, fluorouracil and folinic acid (leucovorin)	GIGFOLFIRI	ı	



DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
			hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with peritoneal			
fluorouracil (cont'd)	injectable	Gastrointestinal	carcinomatosis from limited advanced colorectal and appendiceal carcinomas using	GIHIPEC	- 1	
		oxaliplatin and fluorouracil				
			adjuvant chemotherapy for resected pancreatic adenocarcinoma using irinotecan,	GIPAJFIROX		
			lovaliniatin fluorouracil and loucovorin	GIF AUI INOX	<u>'</u>	
			Second-Line Treatment for Metastatic Pancreatic Cancer using Irinotecan,	GIPAVFFIRI	1	
			Fluorouracil and Leucovorin	GIFAVI I IIXI	'	
			Palliative Combination Chemotherapy for Metastatic Pancreatic Cancer using	GIPAVFFOX	1	
			Oxaliplatin, Fluorouracil and Leucovorin	OII AVI I OX	L	
			Adjuvant or Neoadjuvant Combination Chemotherapy for Stage III Rectal Cancer	GIRAJFFOX		
			using Oxaliplatin, Fluorouracil and Leucovorin	OII VAUIT OX	L	
			combined modality adjuvant therapy for high risk rectal carcinoma using	GIRINFRT		
			capecitabine, infusional fluorouracil and radiation therapy combined modality therapy for squamous cell cancer of the genitourinary system	Oliviivi ivi	L	
		Genitourinary		GUFUPRT		
		Geriilourinary	using fluorouracil and cisplatin with radiation	GOLOFICI	L	
		Head and Neck	fluorouracil and leucovorin for recurrent head and neck cancer (squamous cell	HNAVFUFA	1	
		nead and Neck	carcinoma)		'	
			treatment of advanced squamous cell carcinoma of the head and neck cancer using	LINIAN/ELID		
		L	fluorouracil and platinum First-Line Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck	HIVAVEUE	'	
			First-Line Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck	HNAVPFPMB		
		L	using Platinum, Fluorouracil and Pembrolizumab	HIVAVEFEIVID	'	
			combined chemotherapy (carboplatin and fluorouracil) and radiation treatment for	HNLACAFRT		
			locally advanced squamous cell carcinoma of the head and neck	HNLACAFKI	'	
			treatment of locally advanced squamous cell carcinoma of the head and neck with	HNLADCF		
			docetaxel, cisplatin and infusional fluorouracil	HNLADCF	'	
			fluorouracil and leucovorin for recurrent head and neck cancer (nasopharyngeal)	HNNAVFUFA		
			illuorouracii and leucovonii lor recurrent nead and neck cancer (nasopnaryngear)	HININAVFUFA	'	
			treatment for advanced nasopharyngeal cancer of the head and neck using	HNNAVFUP		
				HININAVFUP	'	
			palliative therapy for advanced salivary gland cancers using cyclophosphamide,	LINICAL/EAG		
			doxorubicin and fluorouracil	HNSAVFAC	'	
				HNSAVFUP	I	
			Α	Other tumour site code		
		Not Otherwise Specified		followed by 'NOS' (e.g.	1	
				HNNOS)		
	eyedrops	Ocular	Topical Therapy for Ocular Malignancies using Fluorogracil Eve Drops	OCFU	l l	
	topical cream	Skin & Melanoma	skin cancer	SMNOS		
flutamide	tablet	Genitourinary		GUPNSAA		Not reimbursed for vasomotor
IIIutailiiue	lablet	Geriilourinary	·	GUFINOAA	'	symptoms (hot flashes)
fulvestrant	injectable	Breast	Therapy of Advanced Breast Cancer using Palbociclib and Fulvestrant with or	BRAVPBFLV	1	
I a roomant	Injudiable	I Di Gast	without LHRH Agonist	DIGITI DI LV	<u> </u>	
			Therapy of Advanced Breast Cancer using Ribociclib and Fulvestrant with or	BRAVRBFLV		
			without LHRH Agonist	DIAMINDI EA	'	
gefitinib	tablet	Lung	first-line treatment of epidermal growth factor receptor mutation-positive advanced	LUAVGEFF		
gentinib	lablet	Lung	NSCLC	LUAVUEFF	'	



DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
gemcitabine	injectable	Breast	palliative therapy for metastatic breast cancer using gemcitabine	BRAVGEM	l	
			palliative therapy for metastatic breast cancer using gemcitabine and docetaxel	BRAVGEMD	ı	
			F	BRAVGEMP	ı	
			treatment of metastatic breast cancer using gemcitabine and paclitaxel	BRAVGEMT	l I	
			(Gemeitabline and CARROnlatin	BRAVPGC	ı	
		Gastrointestinal	Gemcitabine and Platinum	GIAVDURPG	ı	
			Carcinoma and Cholangiocarcinoma using Gemcitabine and Cisplatin	GIAVPG	ı	
			and gemoitabline	GIPAJGCAP	ı	
			GIPAJGEM	<u> </u>		
			palliative chemotherapy for pancreatic adenocarcinoma, gallbladder cancer, and cholangiocarcinoma using gemcitabine	GIPGEM	1	
			Inaclitate NAR (ARRAXANE) and demotabline	GIPGEMABR	ı	
		Gynecology	Treatment of Platinum Resistant or Refractory Epithelial Ovarian Cancer with	GOOVBEVG	ı	
			carbonlatin and generations for the treatment of recurrent platinum-sensitive	GOOVCAG	ı	
			palliative chemotherapy for re-treatment of ovarian, tubal, and peritoneal cancer using gemcitabine	GOOVGEM	ı	
				GOSADG	<u> </u>	
		Genitourinary	adjuvant therapy for urothelial carcinoma using cisplatin and gemcitabine	GUAJPG	<u> </u>	
			combination with cisplatin for advanced transitional cell carcinoma of the bladder	GUAVPG	ı	
				GUBGEM	l I	
		Intravesical Therapy for Non-Muscle Invasive Bladder Cancer using Gemcitabine and Docetaxel	GUBGEMDOC	1		
			combination with cisplatin as neoadjuvant therapy for urothelial carcinoma	GUNAJPG	I	
	Head and Neck g	palliative therapy for germ cell cancers using paclitaxel and gemcitabine	GUTAXGEM	I I		
		treatment of loco-regionally recurrent and/or metastatic nasopharyngeal cancer with gemcitabine	HNNAVGEM	ı		
		treatment of local-regionally recurrent and/or metastatic nasopharyngeal cancer with platinum and gemcitabine	HNNAVPG	ı		



DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
gemcitabine (cont'd)	injectable	Head and Neck	as induction treatment of locally advanced nasopharyngeal cancer with cisplatin and gemcitabine	HNNLAPG	ı	
		Lung	combination with cisplatin or carboplatin as treatment of advanced non-small cell lung cancer	LUAVPG	ı	***************************************
			first-line treatment of advanced squamous non-small cell lung cancer with platinum, gemcitabine and pembrolizumab	LUAVPGPMB	l	***************************************
			treatment of malignant mesothelioma with platinum and gemcitabine	LUMMPG	· · · · · · · · · · · · · · · · · · ·	
		Lymphoma	treatment of lymphoma with gemcitabine, dexamethasone and platinum	LYGDP	ı	
			treatment of lymphoma with gemcitabine, dexamethasone and platinum with rituximab	LYGDPR	ı	
			Treatment of Newly Diagnosed or Relapsed/Refractory Natural Killer or T-Cell Lymphoma using Gemcitabine, Oxaliplatin and Pegaspargase	LYGEMOXPEG	ı	
			Treatment of Relapsed or Refractory Hodgkin Lymphoma with Gemcitabine, Vinorelbine and Doxorubicin Pegylated Liposomal	LYGVLD	ı	
			palliative chemotherapy of lymphomas	LYPALL	l	
		Pediatric	treatment of pediatric patients with relapsed Hodgkin lymphoma with a combination of ifosfamide, mesna, gemcitabine and vinorelbine (IGEV)		ı	
		Sarcoma	combination with docetaxel as second or third line therapy for soft tissue sarcomas	SAAVGEMD	I	
gemtuzumab ozogamicin	injectable	Leukemia & BMT	Treatment of Acute Myeloid Leukemia using Gemtuzumab Ozogamicin with Induction and Consolidation Chemotherapy	LKGEMOZ	I	
		Pediatric	Pediatric patients with de novo acute myeloid leukemia (AML) in the first induction chemotherapy cycle, in combination with standard chemotherapy		R	
gilteritinib	tablet	Leukemia & BMT	Therapy of Relapsed or Refractory FLT3+ Acute Myeloid Leukemia using Gilteritinib	ULKAMLGIL	R	
goserelin	long acting injectable	Breast	Treatment of Adjuvant Breast Cancer using Abemaciclib and Aromatase Inhibitor With or Without LHRH Agonist	UBRAJABEAI	R	
	***************************************		Treatment of Adjuvant Breast Cancer using Abemaciclib and Tamoxifen With or Without LHRH Agonist	UBRAJABET	R	
***************************************			Neoadjuvant or Adjuvant Ovarian Suppression and Aromatase Inhibitor in Premenopausal Women or In Men with High Risk Early Stage Breast Cancer	BRAJLHRHAI	ı	
			neoadjuvant or adjuvant therapy for breast cancer using a LHRH agonist and tamoxifen	BRAJLHRHT	ı	
			therapy for advanced breast cancer using a LHRH agonist and an aromatase inhibitor	BRAVLHRHAI	ı	
			combination therapy with tamoxifen palliative therapy for metastatic breast cancer	BRAVLHRHT	ı	Not reimbursed for endometriosis
			therapy of advanced breast cancer using palbociclib and aromatase inhibitor with or without LHRH agonist	BRAVPALAI	ı	
			Therapy of Advanced Breast Cancer using Palbociclib and Fulvestrant with or without LHRH Agonist	BRAVPBFLV	ı	
			Therapy of Advanced Breast Cancer using Ribociclib and Fulvestrant with or without LHRH Agonist	BRAVRBFLV	ı	
			therapy of advanced breast cancer using ribociclib and aromatase inhibitor with or without LHRH agonist	BRAVRIBAI	I	
		Genitourinary	Therapy for Prostate Cancer using LHRH Agonist (Goserelin or Leuprolide)	GUPLHRH	ı	
hydrocortisone	tablet, injectable	Lymphoma	treatment of hemophagocytic lymphohistiocytosis with etoposide, dexamethasone and cycloSPORINE	HLHETCSPA	I	
		Not Otherwise Specified		Other tumour site code followed by 'NOS' (e.g. LYNOS)	I	Not reimbursed for supportive care
hydroxyurea	capsule	Leukemia & BMT	Myeloid neoplasms, including but not limited to: Acute myeloid leukemia, Myelodysplastic syndromes (e.g. Refractory anemia), Myeloproliferative disease (e.g. Chronic myeloid leukemia, Polycythemia, Essential thrombocythemia)	LKNOS	ı	
hydroxyurea (cont'd)	capsule	Lymphoma	Lymphoid neoplasms, including but not limited to: Lymphoproliferative disease, Myeloma	LYNOS	I	
ibritumomab tiuxetan 90Y (ZEVALIN®)	injectable	Lymphoma	Palliative Therapy For Lymphoma Using Radioimmunotherapy: riTUXimab-Priming for 90Y-Ibritumomab tiuxetan (ZEVALIN®)	LYRITZ	I	



DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
ibrutinib	capsule	Lymphoma	treatment of previously untreated chronic lymphocytic leukemia or small	LYFIBRU	-	
	Capsuic	Lymphoma	lymphocytic lymphoma using ibrutinib	LITIBINO		
			treatment of relapsed or refractory chronic lymphocytic leukemia or small	LYIBRU	1	
			lymphocytic lymphoma using ibrutinib		ļ	
			treatment of relapsed/refractory mantle-cell lymphoma using ibrutinib	LYMIBRU	ı	
l				Tumour site code		
idarubicin	injectable	Not Otherwise Specified		followed by 'NOS' (e.g.	'	
			Treatment of Pediatric Patients with De Novo Acute Promyelocytic Leukemia using	BRNOS)		
		Arsenic Trioxide In Combination with Tretinoin and with or without Idarubicin and				
		Pediatric	Dexamethasone on the COG AAML1331 Study		'	
			treatment of relapsed/refractory chronic lymphocytic leukemia or small lymphocytic			
idelalisib	tablet	Lymphoma	lymphoma using idelalisib and rituximab	LYIDELAR	1	
			advanced therapy for relapsed testicular germ cell cancer using paclitaxel,			
ifosfamide	injectable	Genitourinary	ifosfamide and cisplatin	GUTIP	1	
		consolidation/ salvage treatment for germ cell cancer using vinblastine, cisplatin,				
			ifosfamide and mesna	GUVEIP	1	
			nonseminoma consolidation/salvage protocol using etoposide, cisplatin, ifosfamide.			
			mesna	GUVIP2	l l	
			treatment of burkitt's lymphoma and leukemia with ifosfamide, mesna, etoposide.			
		Lymphoma	cytarahina and rituyimah	LYIVACR		
			treatment of relapsed or refractory advanced stage aggressive B-cell non-Hodgkin's			
			lymphoma with ifosfamide, carboplatin, etoposide and rituximab	LYRICE	1	
			treatment of natural killer or T-Cell Lymphoma using dexamethasone, methotrexate,		·	
			ifosfamide, pegaspargase and etoposide	LYSMILE	'	
			treatment of newly diagnosed nasal, extranodal natural killer (NK) or T-cell	LYVIPDRT		
			lymphoma, stage IE to IIE using concurrent radiation and weekly cisplatin followed		1	
			by etoposide, ifosfamide, cisplatin and dexamethasone			
		Pediatric	treatment of pediatric patients with relapsed Hodgkin lymphoma with a combination			
		rediatile	of ifosfamide, mesna, gemcitabine and vinorelbine (IGEV)		L	
		Sarcoma	therapy for advanced soft tissue sarcoma using doxorubicin, ifosfamide-mesna	SAAI	1	
			3-day doxorubicin, ifosfamide and mesna for use in patients with advanced soft			
			tissue sarcoma	SAAI3	ı	
			SAIME alternating with SAVAC or SAVACM with filgrastim support at TWO weekly			
			interval for newly diagnosed Ewing's Sarcoma/Ewing's Family of Tumours,			
			Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or	SAALT2W	1	
			Rhabdomyosarcoma			
			SAIME alternating with SAVAC or SAVACM with filgrastim support at THREE			
1			weekly interval for newly diagnosed Ewing's Sarcoma/Ewing's Family of Tumours,	CAAL TOW	Ι.	
1		Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or	SAALT3W	'		
l		1	Rhabdomyosarcoma			
			therapy for advanced soft tissue sarcoma using ifosfamide	SAAVI	l l	
			3-day ifosfamide for use in patients with advanced soft tissue sarcoma	SAAVI3	I i	
			3-Day etoposide & ifosfamide-mesna for patients with advanced soft tissue or bony	SAAVIME3	I	
			sarcomas	SAAVIME3	L '	
	T	T	etoposide, ifosfamide-mesna (SAIME) for use in sarcomas	SAIME	I i	



DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
	1 OIGH	- OII L		Other tumour site code		
ifosfamide (cont'd)	injectable	Not Otherwise Specified		followed by 'NOS' (e.g.	- 1	
	,	·		LYNOS)		
imatinib	tablet	Leukemia & BMT	therapy for chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia	LKCMLI		
		Pediatric	pediatric patients with Philadelphia chromosome positive acute lymphoblastic		1	
			leukemia			
		Sarcoma	adjuvant therapy of C-Kit positive high risk gastrointestinal stromal cell tumours	SAAJGI	ı	
			advanced c-kit positive and c-kit negative gastrointestinal stromal cell tumours	SAAVGI	ı	
			advanced c-kit positive gastrointestinal stromal cell tumors using 800 mg dosing of imatinib	SAAVGIDD	ı	
		Skin & Melanoma	treatment of advanced c-kit melanoma using imatinib	SMAVI	i I	
lood ood oo a	4		topical immunotherapy for in-transit melanoma metastases, cutaneous lymphoma,	CNAINAI		
imiquimod	topical cream	Skin & Melanoma	basal cell carcinoma using imiquimod	SMIMI	ı	
inotuzumab ozogamicin	injectable	Leukemia & BMT	treatment of relapsed or refractory pre-B-cell acute lymphoblastic leukemia with	ULKINOZ	R	
Illotuzulliab özögaillicili	Injectable	Leukeiiiia & Divi i	inotuzumab ozogamicin	ULKINOZ	K	
ipilimumab	injectable	Genitourinary	treatment of metastatic or advanced renal cell carcinoma using ipilimumab and nivolumab	GUAVIPNI	- 1	
		1	First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer with	L LIAV/DCIDNII		
		Lung	Paclitaxel, Carboplatin, Ipilimumab and Nivolumab	LUAVPCIPNI	l !	
			First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer with	LUAVPPIPNI	1	
			Platinum, Pemetrexed, Ipilimumab and Nivolumab			
			Treatment of Malignant Mesothelioma using Ipilimumab and Nivolumab	LUMMIPNI	I	
			Treatment of Malignant Mesothelioma using Ipilimumab and 3-Weekly Nivolumab	LUMMIPNI3	ı	
		Skin & Melanoma	Treatment of Unresectable or Metastatic Melanoma Using Alternative Dosing	SMAVALIPNI		
		Okiii & Wcianoma	Regimen of Ipilimumab and Nivolumab			
			first-line treatment of unresectable or metastatic melanoma using ipilimumab	SMAVFIPI	ļ	
			treatment of advanced and metastatic melanoma after prior systemic therapy	SMAVIPI	ļl	
			treatment of unresectable or metastatic melanoma using ipilimumab and nivolumab	SMAVIPNI	I	
irinotecan	injectable	Gastrointestinal	palliative third line treatment of metastatic colorectal cancer with wild-type KRAS	GIAVCETIR	1	
			using cetuximab and irinotecan		ļ	
1			Palliative Therapy of Metastatic Colorectal Cancer using Irinotecan and Raltitrexed	GIAVRALIR	- 1	
			in Patients Intolerant to Fluorouracil or Capecitabine palliative combination chemotherapy for metastatic colorectal cancer using			
1			irinotecan and capecitabine in patients unsuitable for GIFOLFIRI	GICAPIRI	- 1	
			palliative combination chemotherapy for metastatic colorectal cancer using	0.0.00		
1			irinotecan, bevacizumab and capecitabine	GICIRB	'	
		T	palliative combination chemotherapy for metastatic colorectal cancer using	GIFFIRB	i .	
		.	irinotecan, fluorouracil, folinic acid (leucovorin) and bevacizumab		L'	
1			palliative combination chemotherapy for metastatic colorectal cancer using	GIFFIRPAN	1	
			irinotecan, fluorouracil, leucovorin, and panitumumab			
			palliative combination chemotherapy for advanced pancreatic adenocarcinoma using irinotecan, oxaliplatin, fluorouracil and folinic acid (leucovorin)	GIFIRINOX	I	
			palliative combination chemotherapy for metastatic colorectal cancer using			
			irinotecan, fluorouracil and folinic acid (leucovorin)	GIFOLFIRI	'	
			second line palliative combination chemotherapy for metastatic gastric or			
1			esophageal adenocarcinoma using irinotecan, fluorouracil and folinic acid	GIGFOLFIRI	- 1	
			(leucovorin)			

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
irinotecan (cont'd)	injectable	Gastrointestinal	palliative chemotherapy of metastatic colorectal cancer using irinotecan	GIIR	I	
			palliative therapy of metastatic colorectal cancer in patients who may not tolerate	GIIRINALT		
			the 3-weekly irinotecan schedule of GIIR	GIRINALI	' '	
			adjuvant chemotherapy for resected pancreatic adenocarcinoma using irinotecan,	CIDA IEIDOV		
			oxaliplatin, fluorouracil and leucovorin	GIPAJFIROX	' '	
			Second-Line Treatment for Metastatic Pancreatic Cancer using Irinotecan,	OIDAVEEIDI		
			Fluorouracil and Leucovorin	GIPAVFFIRI	' '	
		1.	second line treatment of extensive stage small cell lung cancer (SCLC) with			
		Lung	irinotecan with or without platinum	LUSCPI	' '	
			pediatric patients treated on the COG protocol ARST0531 for intermediate-risk			
		Pediatric	which down to a program		'	
			pediatric patients with recurrent pediatric neuroblastoma treated on the COG			
			protocol ANBL0421		ı	
			pediatric patients with high risk renal tumors treated on the COG protocol			
			AREN0321		1	
			pediatric patients with high risk rhabdomyosarcoma treated on the COG protocol			
			ARSTO431		1	
			AR31U431			
			pediatric patients with rhabdomyosarcoma treated on the COG ARST08P1 protocol		1	
			pediatric patients with recurrent/refractory medulloblastomas/CNS PNET of			
			childhood treated on the COG ACNS0821 protocol		'	
isatuximab	ininetable	Mveloma	Therapy of Multiple Myeloma using Carfilzomib, Dexamethasone and Isatuximab	UMYISACARD	R	
Isatuximab	injectable	iviyeioma	with or without Cyclophosphamide	UMYISACARD	ĸ	
			Therapy of Multiple Myeloma using Pomalidomide, Dexamethasone and Isatuximab	UMYISAPOMD	R	
			with or without Cyclophosphamide	UMITISAPUMD	ĸ	
isotretinoin	capsule	Pediatric	pediatric patients with high risk neuroblastoma			
			pediatric patients treated on the COG protocol ACNS0332 for above average risk			
			medulloblastoma/PNE		'	
lanreotide	injectable	Neuro-Oncology	treatment of growth hormone secreting pituitary adenoma using lanreotide	CNLAN		
			symptomatic management of functional carcinoid and neuroendocrine tumours of			
		Gastrointestinal	the GI Tract using lanreotide	UGILAN	R	
lapatinib	tablet	Breast	therapy for metastatic breast cancer using capecitabine and lapatinib	BRAVLCAP	1	
	capsule, oral		Treatment of Solid Tumours with Neurotrophic Tyrosine Receptor Kinase (NTRK)			
larotrectinib	solution	Tumour Agnostic	Fusion using Larotrectinib	UTAAVLAR	R	
			Treatment of Solid Tumours with Neurotrophic Tyrosine Receptor Kinase (NTRK)			
		Pediatric	Fusion using Larotrectinib		R	
lenalidomide	capsule	Leukemia & BMT	therapy of myelodysplastic syndrome using lenalidomide	LKMDSL		
			Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell			
		Myeloma	Transplant using Bortezomib, Lenalidomide and Dexamethasone	MYBLDF	ı	
			Treatment of Multiple Myeloma using Lenalidomide, Bortezomib and			
			Dexamethasone as Induction Pre-Stem Cell Transplant	MYBLDPRE	I	
			Dexametriasone as induction Fre-Stem Cell Transplant			
			Therapy of Multiple Myeloma using Carfilzomib, Lenalidomide with Dexamethasone	MYCARLD	1	
			treatment of relapsed and refractory multiple myeloma with daratumumab in	1.0/D.4.D.1.D		
			combination with lenalidomide and dexamethasone	MYDARLD		
			Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell			
			Transplant using Daratumumab, Lenalidomide and Dexamethasone	MYDARLDF		
			treatment of previously untreated multiple myeloma and not eligible for stem cell			
			transplant using lenalidomide with low-dose dexamethasone	UMYLDF	R	
			therapy of relapsed multiple myeloma using lenalidomide with dexamethasone	MYLDREL		
			Maintenance Therapy of Multiple Myeloma using Lenalidomide	MYLENMTN		
			IMaintenance Therapy of Multiple Myeloma using Lenandomide	IVI I LEINIVI I IN		

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
lenvatinib	capsule	Gastrointestinal	Therapy of Advanced Hepatocellular Carcinoma using Lenvatinib	GILEN	1	
		Cumanalamu	Treatment of Endometrial Cancer With Microsatellite Stability or Mismatch Repair	COEVIDAVIDI	1	
		Gynecology	Proficiency using Pembrolizumab and Lenvatinib	GOENDAVPL	'	
			Treatment of Endometrial Cancer With Microsatellite Stability or Mismatch Repair	GOENDAVPL6		
			Proficiency using 6-weekly Pembrolizumab and Lenvatinib	GOLINDAVELO	'	
		Genitourinary	Treatment of Metastatic Renal Cell Carcinoma using Pembrolizumab and	GUAVPEML	1 1	
		Contournary	Lenvatinib			
			Treatment of Metastatic Renal Cell Carcinoma using 6-weekly Pembrolizumab and	GUAVPEML6	1 1	
			Lenvatinib therapy for locally recurrent or metastatic, RAI-refractory differentiated thyroid			
		Head and Neck		HNOTLEN	1	
	+		cancer using lenvatinib Treatment of Adjuvant Breast Cancer using Abemaciclib and Aromatase Inhibitor		_	
letrozole	tablet	Breast	With or Without LHRH Agonist	UBRAJABEAI	R	
			neoadjuvant or adjuvant therapy for breast cancer using letrozole in			
			postmenopausal women	BRAJLET	1	
			Neoadjuvant or Adjuvant Ovarian Suppression and Aromatase Inhibitor in			
			Premenopausal Women or In Men with High Risk Early Stage Breast Cancer	BRAJLHRHAI	1	
			first or second line hormonal treatment for advanced breast cancer in			
			postmenopausal women	BRAVLET	'	
			therapy for advanced breast cancer using a LHRH agonist and an aromatase	DDAY/LUDUAL		
			inhibitor	BRAVLHRHAI	'	
			therapy of advanced breast cancer using palbociclib and aromatase inhibitor with or	BRAVPALAI	Ι	
			without LHRH agonist	DRAVFALAI	'	
			therapy of advanced breast cancer using ribociclib and aromatase inhibitor with or	BRAVRIBAI		
			without LHRH agonist	DIGATION		
		Gynecology	hormonal treatment for advanced endometrial cancer in postmenopausal women	GOENDAI	1 1	
			with contraindications to tamoxifen or intolerant of tamoxifen			
			hormonal treatment for advanced ovarian cancer in postmenopausal women	GOOVAI		
leucovorin calcium	tablet, injectable	Breast	treatment of meningeal disease using high-dose methotrexate with leucovorin	BRAVHDMTX	1	
			rescue adjuvant combination chemotherapy for Stage III and Stage IIB colon cancer using			
		Gastrointestinal	oxaliplatin, fluorouracil and folinic acid (Leucovorin)	GIAJFFOX	1	
			adjuvant therapy of colon cancer using fluorouracil injection and infusion and			
			leucovorin infusion	GIAJFL	1	
			palliative combination chemotherapy for metastatic colorectal cancer using			
			fluorouracil injection and infusion and folinic acid (leucovorin) infusion	GIAVFL	1	
			combined modality therapy for locally advanced esophageal cancer using			
			oxaliplatin, fluorouracil, leucovorin, and radiation therapy	GIEFFOXRT	'	
			palliative combination chemotherapy for metastatic colorectal cancer using	CIECIDD	1	
			irinotecan, fluorouracil, folinic acid (leucovorin) and bevacizumab	GIFFIRB		
			palliative combination chemotherapy for metastatic colorectal cancer using	GIFFIRPAN		
			irinotecan, fluorouracil, leucovorin, and panitumumab	OILL HAFAIN	'	
			palliative combination chemotherapy for metastatic colorectal cancer using	GIFFOXB	1 1	
			oxaliplatin, fluorouracil, leucovorin, and bevacizumab			
			palliative combination chemotherapy for metastatic colorectal cancer using	GIFFOXPAN	1	
			oxaliplatin, fluorouracil, leucovorin, and panitumumab	-		
			palliative combination chemotherapy for advanced pancreatic adenocarcinoma	OLEIDINOV	1 .	
			using irinotecan, oxaliplatin, fluorouracil and folinic acid (leucovorin)	GIFIRINOX	'	
			palliative combination chemotherapy for metastatic colorectal cancer using			
			irinotecan. fluorouracil and folinic acid (leucovorin)	GIFOLFIRI	- 1	
			palliative combination chemotherapy for metastatic colorectal cancer using			
			oxaliplatin, fluorouracil and folinic acid (leucovorin)	GIFOLFOX	1	
			adjuvant chemotherapy in gastric cancer patients with D2 resection (node negative)			
			or ineligible for adjuvant chemoradiation using oxaliplatin, fluorouracil, and	GIGAJFFOX	1	
			leucovorin		1	



DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
			Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal	010 11 (550)	١.	
leucovorin calcium (cont'd) tablet, injectable	Gastrointestinal		GIGAVFFOX	'		
			Junction or Esophageal Carcinoma using Oxaliplatin, Fluorouracil and Leucovorin First-Line Treatment of Locally Advanced or Metastatic Esophageal,			
			Gastroesophageal, or Gastric Cancer using Oxaliplatin, Fluorouracil, Leucovorin and Nivolumab	GIGAVFFOXN	I	
			First-Line Treatment of Locally Advanced or Metastatic Gastroesophageal Cancer			
			using Oxaliplatin, Fluorouracií, Leucovorin and Pembrolizumab palliative treatment of metastatic or locally advanced HER-2 positive gastric,	GIGAVFFOXP	 	
			gastroesophageal junction, or esophageal adenocarcinoma using oxaliplatin,	GIGAVFFOXT		
			fluorouracil, leucovorin, and trastuzumab	Olo/Will Oxi		
			perioperative treatment of resectable adenocarcinoma of the stomach,			
			gastroesophageal junction or lower 1/3 esophagus using docetaxel, oxaliplatin,	GIGFLODOC	1	
			infusional fluorouracil, and leucovorin	0.0.20200		
			palliative combination chemotherapy for metastatic gastric or esophageal	OLOFOL FIDI		
			adenocarcinoma using irinotecan, fluorouracil and folinic acid (leucovorin)	GIGFOLFIRI	'	
			adjuvant chemotherapy for resected pancreatic adenocarcinoma using irinotecan,	GIPAJFIROX		
			oxaliplatin, fluorouracil and leucovorin	GIPAJFIKUX	'	
			Second-Line Treatment for Metastatic Pancreatic Cancer using Irinotecan,	GIPAVFFIRI		
			Fluorouracil and Leucovorin	GIFAVFFIKI	l	
			Palliative Combination Chemotherapy for Metastatic Pancreatic Cancer using	GIPAVFFOX	1	
			Oxaliplatin, Fluorouracil and Leucovorin	GIFAVITOA	L	
			Adjuvant or Neoadjuvant Combination Chemotherapy for Stage III Rectal Cancer	GIRAJFFOX		
			using Oxaliplatin, Fluorouracil and Leucovorin			
			therapy for high-risk Gestational Trophoblastic Neoplasia (GTN) using etoposide,			
		Gynecology	methotrexate, leucovorin (folinic acid), dactinomycin, cyclophosphamide and	GOTDEMACO	ı	
			vincristine			
				GOTDMR (previously	1	
			Dactinomycin and Methotrexate	GOTDLR)		
		Head and Neck	fluorouracil and leucovorin for recurrent head and neck cancer (squamous cell carcinoma)	HNAVFUFA	I	
			fluorouracil and leucovorin for recurrent head and neck cancer (nasopharyngeal)	HNNAVFUFA	ı	
		1	treatment of refractory or relapsing extranodal natural killer or T-Cell lymphoma	LVAODMEDEV		
		Lymphoma	using pegaspargase, methotrexate and dexamethasone	LYASPMEDEX	'	!
			central nervous system prophylaxis with high dose methotrexate, CHOP and	LYCHOPRMTX		
			rituximab in diffuse large B-cell lymphoma	LYCHOPKWIX	<u> </u>	
			treatment of Burkitt's lymphoma and leukemia with cyclophosphamide, vincristine,	LYCODOXMR	1	
			doxorubicin, methotrexate, leucovorin and rituximab		L	
l			Treatment of Primary and Secondary CNS Lymphoma with High-Dose	LYHDMRTEM	1 1	
		Methotrexate, Rituximab and Temozolomide				
l		treatment of natural killer or T-Cell lymphoma using dexamethasone, methotrexate,	LYSMILE	1		
			ifosfamide, pegaspargase and etoposide			
1		Net Otherwise One 15		Other tumour site code	Ι.	
1		Not Otherwise Specified		followed by 'NOS' (e.g.	'	
		1		LYNOS)	I	

BC CAN CER Provincial Health Services Authority

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
leuprolide	long acting	Breast	Treatment of Adjuvant Breast Cancer using Abemaciclib and Aromatase Inhibitor	UBRAJABEAI	R	
	injectable		With or Without LHRH Agonist	00.00.00.		
			Treatment of Adjuvant Breast Cancer using Abemaciclib and Tamoxifen With or Without LHRH Agonist	UBRAJABET	R	
			Neoadjuvant or Adjuvant Ovarian Suppression and Aromatase Inhibitor in			•
			Premenopausal Women or In Men with High Risk Early Stage Breast Cancer	BRAJLHRHAI	I	
			neoadjuvant or adjuvant therapy for breast cancer using a LHRH agonist and	DDA II LIDLIT		
			tamoxifen	BRAJLHRHT	<u> </u>	
			therapy for advanced breast cancer using a LHRH agonist and an aromatase	BRAVLHRHAI	ı	Not reimbursed for endometriosis.
			inhibitor			Leuprolide acetate IM (LUPRON®) and
			combination therapy with tamoxifen palliative therapy for metastatic breast cancer	BRAVLHRHT	1	SC (ELIGARD®) injectables are both
			therapy of advanced breast cancer using palbociclib and aromatase inhibitor with or	DDA) (DAL AL		reimbursable for prostate cancer
			without LHRH agonist	BRAVPALAI	ı	indications (GUPLHRH).
			Therapy of Advanced Breast Cancer using Palbociclib and Fulvestrant with or	BRAVPBFLV	1	
			without LHRH Agonist Therapy of Advanced Breast Cancer using Ribociclib and Fulvestrant with or			•
				BRAVRBFLV	1	
			without LHRH Agonist therapy of advanced breast cancer using ribociclib and aromatase inhibitor with or			
			without LHRH agonist	BRAVRIBAI	- 1	
		Genitourinary	Therapy for Prostate Cancer using LHRH Agonist (Goserelin or Leuprolide)	GUPLHRH	1	
I a manual in a						
lomustine	capsule	Neuro-Oncology	Iomustine for treatment of recurrent malignant brain tumors adjuvant Iomustine, cisplatin and vincristine in adult high-risk medulloblastoma or	CNCCNU	ļl	
			other primitive neuroectodermal tumour	CNCCV	- 1	
			modified PCV chemotherapy of brain tumours using procarbazine, lomustine and			
			vincristine	CNMODPCV		
		Lymphoma	lymphoma palliative chemotherapy	LYPALL	l	
				Other tumour site code		
		Not Otherwise Specified		followed by 'NOS' (e.g.	ı	
			Peptide Receptor Radionuclide Therapy (PRRT) using Lutetium 177Lu-Dotatate	CNNOS)		
¹⁷⁷ Lu-Dotatate	radio-	Gastrointestinal	(LUTATHERA) for Treatment in Patients with Somatostatin Receptor Positive	UGIPRRT	R	
Eu-Dotatate	pharmaceutical	Castronitestinal	Neuroendocrine Tumours	OGII TUTU	11	
la datinih	4-61-4	Longo	Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with	LUAV# OD		
lorlatinib	tablet	Lung	Lorlatinib	LUAVLOR		
medroxyprogesterone	tablet	Gynecology	non-aromatase inhibitor hormonal treatment of endometrial cancer	GOENDH	1	Not reimbursed for appetite stimulation
		, ,,	I		<u> </u>	or replacement therapy. Not reimbursed for appetite stimulation
megestrol	tablet	Breast Gynecology	breast cancer non-aromatase inhibitor hormonal treatment of endometrial cancer	BRAVMEG GOENDH	<u> </u>	or symptom management
			conditioning therapy for autologous stem cell transplant using high dose melphalan	1	<u> </u>	or symptom management
melphalan	tablet, injectable	Leukemia & BMT	in the treatment of multiple myeloma	BMTMM0301	ı	
		Myeloma	Treatment of Multiple Myeloma using Melphalan and Prednisone	MYMP	I	
			treatment of multiple myeloma using melphalan, prednisone and weekly bortezomib	MYMPBOR	Ι ι	
			with the option of substituting cyclophosphamide for melphalan		ļ	
1		Not Othomuson Consider a		Other tumour site code	Ι.	
l		Not Otherwise Specified		followed by 'NOS' (e.g. LKNOS)	'	
	+			Tumour site code		
6-mercaptopurine	tablet	Not Otherwise Specified		followed by 'NOS' (e.g.	L	
				LKNOS)	l '	1



DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
mesna	iniectable	Genitourinary	therapy for relapsed testicular germ cell cancer using paclitaxel, ifosfamide and	GUTIP		
	IIIJCCIADIC	Contournary	cisplatin (TIP)			
			consolidation/ salvage treatment for germ cell cancer using vinblastine, cisplatin,	GUVEIP	1	
			ifosfamide and mesna			1
			nonseminoma consolidation/salvage protocol using etoposide, cisplatin, ifosfamide,	GUVIP2	1	
			Treatment of Burkitt's lymphoma and leukemia with ifosfamide, mesna, etoposide,			
		Lymphoma	cytarabine and rituximab	LYIVACR	- 1	
			treatment of relapsed or refractory advanced stage aggressive B-Cell Non-			
			Hodgkin's Lymphoma with ifosfamide, carboplatin, etoposide and rituximab	LYRICE	1	
			treatment of Natural Killer or T-Cell Lymphoma using dexamethasone,			
			methotrexate, ifosfamide, pegaspargase and etoposide	LYSMILE		
			treatment of newly diagnosed Nasal, Extranodal Natural Killer (NK) or T-cell			
			lymphoma, using concurrent radiation and weekly cisplatin followed by etoposide,	LYVIPDRT	- 1	
			ifosfamide, cisplatin and dexamethasone			
		Pediatric	treatment of pediatric patients with relapsed Hodgkin lymphoma with a combination		ı	
		Culaulo	of ifosfamide, mesna, gemcitabine and vinorelbine (IGEV)			
		Sarcoma	therapy for advanced soft tissue sarcoma using doxorubicin, ifosfamide-mesna	SAAI	1 1	
		.,,			Approved for use ONLY as an uro-	
			3-day doxorubicin, ifosfamide and mesna for use in patients with advanced soft	SAAI3	1	protector for ifosfamide or high dose
			tissue sarcoma SAIME alternating with SAVAC or SAVACM with filgrastim support at TWO weekly			cyclophosphamide
			interval for newly diagnosed Ewing's Sarcoma/Ewing's Family of Tumours,			
			Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or	SAALT2W	1	
			Rhabdomyosarcoma			
			SAIME alternating with SAVAC or SAVACM with filgrastim support at THREE			
			weekly interval for newly diagnosed Ewing's Sarcoma/Ewing's Family of Tumours,			
			Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or	SAALT3W	1	
			Rhabdomyosarcoma			
			therapy for advanced soft tissue sarcoma using ifosfamide	SAAVI	I	
			3-day ifosfamide for use in patients with advanced soft tissue sarcoma	SAAVI3	I	
			3-day etoposide & ifosfamide-mesna for patients with advanced soft tissue or bony	SAAVIME3		
		L	sarcomas	-	<u>'</u>	
			etoposide, ifosfamide-mesna (SAIME) for use in sarcomas	SAIME	l	
			Treatment of Sarcomas with Pelvic Primaries or Chemotherapy-Induced Hematuria	SAVACM	1	
			using Vincristine, Doxorubicin, Cyclophosphamide and Mesna			
		Supportive Care	mesna dosage modification for hematuria secondary to oxazaphosphorines	SCMESNA	<u>l</u>	
				Other tumour site code		
		Not Otherwise Specified		followed by 'NOS' (e.g.		
			palliative therapy for advanced breast cancer using cyclophosphamide,	SANOS)	1	
methotrexate	tablet, injectable	Breast	methotrexate and fluorouracil	BRAVCMF	1	
			treatment of meningeal disease using high-dose methotrexate with leucovorin			
			rescue	BRAVHDMTX	- 1	
			therapy for high-risk Gestational Trophoblastic Neoplasia (GTN) using etoposide,			
		Gynecology	methotrexate, leucovorin (folinic acid), dactinomycin, cyclophosphamide and	GOTDEMACO	Li	
		-,00.09,	vincristine	22.32	l .	
			Therapy for Low-Risk Gestational Trophoblastic Cancer using Methotrexate	GOTDLRM	i I	
	Contouring	•	Therapy for Moderate Low-Risk Gestational Trophoblastic Cancer using	GOTDMR (previously	1	
			Destinantial and Mathetraviate	GOTDLR)	'	
		Genitourinary	Neoadjuvant Treatment of Urothelial Cancer using Dose-Dense Methotrexate,	GUBDDMVAC	1	
	Genitourinary	Vinblastine, Doxorubicin and Cisplatin	GUBUDINIVAC	<u> </u>		
		therapy for transitional cell cancers of the urothelium using methotrexate,	GUMVAC	I i		
			vinblastine, doxorubicin and cisplatin	CONIVAC		



DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
methotrexate (cont'd)	tablet, injectable	Head and Neck	treatment of head and neck cancer using methotrexate as standard therapy	HNAVM	1	
		Kaposi's Sarcoma	therapy for Kaposi's Sarcoma using vinblastine-vincristine	KSVB	I	
		Lymphoma	treatment of hemophagocytic lymphohistiocytosis with etoposide, dexamethasone and cycloSPORINE	HLHETCSPA	ı	
			treatment of refractory or relapsing extranodal natural killer or T-Cell lymphoma lusing pegaspargase, methotrexate and dexamethasone	LYASPMEDEX	ı	
			central nervous system prophylaxis with high dose methotrexate, CHOP and rituximab in diffuse large B-cell lymphoma	LYCHOPRMTX	I	
			treatment of burkitt's lymphoma and leukemia with cyclophosphamide, vincristine, doxorubicin, methotrexate, leucovorin and rituximab	LYCODOXMR	I	
			treatment of lymphoma with dose-adjusted etoposide, doxorubicin, vincristine, cyclophosphamide, prednisone and rituximab with intrathecal methotrexate	LYEPOCHR	I	
			Treatment of Primary and Secondary CNS Lymphoma with High-Dose Methotrexate, Rituximab and Temozolomide	LYHDMRTEM	ı	
			Central Nervous System Prophylaxis with High-Dose Methotrexate in Diffuse Large B-Cell Lymphoma	LYHDMTXPRO	ı	
		1	treatment of lymphoma using intrathecal methotrexate and cytarabine	LYIT	i I	
			treatment of Burkitt's Lymphoma and Leukemia with ifosfamide, mesna, etoposide, cytarabine and rituximab	LYIVACR	ı	
			lymphoma palliative chemotherapy	LYPALL	l	
			treatment of natural killer or T-Cell Lymphoma using dexamethasone, methotrexate, ifosfamide, pegaspargase and etoposide	LYSMILE	ı	
		Miscellaneous Origins	therapy for solid tumours using intrathecal methotrexate and/or thiotepa and/or cytarabine	MOIT	ı	
		Sarcoma	palliative therapy for aggressive fibromatosis using weekly or alternate week methotrexate and vinblastine intravenously	SAMV	ı	
		Not Otherwise Specified		Other tumour site code followed by 'NOS' (e.g. MYNOS)	ı	
methoxsalen	injectable	Lymphoma	Treatment of Cutaneous T-Cell Lymphoma (Sézary Syndrome) with Extracorporeal Photopheresis	LYMFECP	I	
methyl aminolevulinate (METVIX®)	topical cream	Skin & Melanoma	topical therapy for skin cancer with PDT (Photodynamic Therapy)	SMPDT	I	Only reimbursable when prescribed by physicians in the Skin Tumour Group within the Skin PDT Program of the BC Cancer Agency
midostaurin	capsule	Leukemia & BMT	therapy of FLT3+ acute myeloid leukemia using midostaurin in combination with induction and consolidation chemotherapy	LKAMLMIDO	1	
mitomycin	injectable	Gastrointestinal	combined modality therapy for carcinoma of the anal canal using mitomycin, capecitabine and radiation therapy	GICART	ı	
			hepatic trans-arterial chemoembolization for primary liver cancer or liver metastasis	GIEMBOL	I	Note: only funded when prescribed by specialists at BC Cancer Vancouver and Royal Jubilee Hospital
			combined modality curative therapy for carcinoma of the anal canal using mitomycin, fluorouracil and radiation therapy	GIFUART	ı	
			chemotherapy of pseudomyxoma peritonei using intraperitoneal mitomycin and fluorouracil	GIFUIP	I	
			hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with peritoneal carcinomatosis from limited advanced colorectal and appendiceal carcinomas using	GIHIPEC	ı	
		Genitourinary	oxaliplatin and fluorouracil combined modality therapy for squamous cell cancer of the genitourinary system using fluorouracil and cisplatin with radiation	GUFUPRT	ı	



DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
mitomycin (cont'd)	injectable	Genitourinary	intravesical therapy for non-muscle invasive cell bladder cancer using mitomycin	GUBMITO	I	
	eye drops	Ocular	eye drops as topical therapy for ocular malignancies	OCMITO	I	
	injectable	Not Otherwise Specified		Other tumour site code followed by 'NOS' (e.g. GUNOS)	ı	
mitotane	tablet	Genitourinary	treatment of advanced adrenal cortical cancer	GUMITO	l	
			treatment of metastatic adrenalcortical cancer with doxorubicin, etoposide, cisplatin and mitotane	GUEDPM	I	
mitoxantrone	injectable	Genitourinary	palliative therapy for hormone-refractory prostate cancer using mitoxantrone and prednisone	GUPMX	- 1	
		Not Otherwise Specified		Other tumour site code followed by 'NOS' (e.g. BRNOS)	l	
nilotinib	tablet	Leukemia & BMT	Treatment of Chronic Myeloid Leukemia using Nilotinib	LKCMLN		
nilutamide	tablet	Genitourinary	prostate carcinoma patients who are intolerant to bicalutamide or flutamide, at 150 mg po daily	GUPNSAA	I	Not reimbursed for vasomotor symptoms (hot flashes)
niraparib	capsule	Gynecology	Ovarian Cancer using Niraparib	GOOVFNIRM	I	
			Maintenance Treatment of Relapsed Platinum Sensitive and Responsive Epithelial Ovarian Cancer using Niraparib	GOOVNIRAM	- 1	



DRUG	DOSAGE	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
nivolumab	injectable	Gastrointestinal	Adjuvant Treatment of Resected Esophageal or Gastroesophageal Junction Cancer	GIAJNIV		
	Oddironicatinal	using Nivolumab	CIAGINIV			
		First-Line Treatment of Locally Advanced or Metastatic Esophageal,	OLO ALVOOVAL			
			Gastroesophageal, or Gastric Cancer using Oxaliplatin, Capecitabine and Nivolumab	GIGAVCOXN	'	
			First-Line Treatment of Locally Advanced or Metastatic Esophageal,			
			Gastroesophageal, or Gastric Cancer using Oxaliplatin, Fluorouracil, Leucovorin	GIGAVFFOXN	1	
			and Nivolumab			
		Genitourinary	Adjuvant Treatment of Resected Urothelial Carcinoma using Nivolumab	UGUAJNIV	R	
			Adjuvant Treatment of Resected Urothelial Carcinoma using 4-Weekly Nivolumab	UGUAJNIV4	R	
			treatment of metastatic or advanced renal cell carcinoma using ipilimumab and	GUAVIPNI	1	
			nivolumab		!	
			treatment of metastatic or advanced renal cell carcinoma using nivolumab	GUAVNIV		
			treatment of metastatic or advanced renal cell carcinoma using 4-weekly nivolumab	GUAVNIV4	- 1	
			Palliative Therapy for Unresectable, Platinum-Refractory, Recurrent or Metastatic			
		Head and Neck	Squamous Cell Cancer of the Head and Neck using Nivolumab	HNAVNIV		
			Palliative Therapy for Unresectable, Platinum-Refractory, Recurrent or Metastatic			
			Squamous Cell Cancer of the Head and Neck using 4-Weekly Nivolumab	HNAVNIV4	'	
			Neoadjuvant Treatment of Non-Small Cell Lung Cancer with Nivolumab,			
		Lung	CARBOnlatin and PACI itaxel	LUAJNIVPC	1	
			Neoadjuvant Treatment of Non-Squamous Non-Small Cell Lung Cancer with	LUAJNIVPP		
			Nivolumab, Pemetrexed and Platinum			
			treatment of advanced non-small cell lung cancer using nivolumab	LUAVNIV	!	
			treatment of advanced non-small cell lung cancer using 4-weekly nivolumab	LUAVNIV4		
			First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer with Paclitaxel, Carboplatin, Ipilimumab and Nivolumab	LUAVPCIPNI	1	
			First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer with			
			Platinum, Pemetrexed, Ipilimumab and Nivolumab	LUAVPPIPNI	1	
			Treatment of Malignant Mesothelioma using Ipilimumab and Nivolumab	LUMMIPNI	ı	
			Treatment of Malignant Mesothelioma using Ipilimumab and 3-Weekly Nivolumab	LUMMIPNI3	ı	
		Lymphoma	treatment of relapsed or refractory Hodgkin lymphoma using nivolumab	LYNIV	····	
			treatment of relapsed or refractory Hodgkin lymphoma using 4-weekly nivolumab	LYNIV4		
			, , , , , , , , , , , , , , , , , , , ,	I	!	
		Skin & Melanoma	adjuvant treatment of resected stage III-IV NED melanoma using nivolumab	SMAJNIV		
			adjuvant treatment of resected stage III-IV NED melanoma using 4-weekly nivolumab	SMAJNIV4	1	
			Treatment of Unresectable or Metastatic Melanoma Using Alternative Dosing			
			Regimen of Ipilimumab and Nivolumab	SMAVALIPNI	1	
			treatment of unresectable or metastatic melanoma using ipilimumab and nivolumab	CMAN/IDNII		
			<u> </u>			
			treatment of unresectable or metastatic melanoma using nivolumab	SMAVNIV	!	
		+	treatment of unresectable or metastatic melanoma using 4-weekly nivolumab treatment of previously untreated chronic lymphocytic leukemia using obinutuzumab	SMAVNIV4		
obinutuzumab	injectable	Lymphoma	in combination with chlorambucil	LYOBCHLOR	1	
			treatment of rituximab-refractory follicular lymphoma with obinutuzumab in	LVODDEND		
			combination with bendamustine	LYOBBEND		
			Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small	LYVENOB	1	
1			Lymphocytic Lymphoma using Venetoclax and Obinutuzumab	LIVLINOD	'	



DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
octreotide	short acting injectable	Neuro-Oncology	treatment of growth hormone secreting pituitary adenoma	CNNOS	ı	
	Gastrointestinal	management of non-functional neuroendocrine tumours of the GI tract; symptomatic management of functional carcinoid and neuroendocrine tumours of the GI tract	GINOS	I		
	long acting injectable	Neuro-Oncology	Treatment of Growth Hormone Secreting Pituitary Adenoma using Octreotide Long Acting	CNOCTLAR	ı	
		Gastrointestinal	Management of Non-Functional Neuroendocrine Tumours of the GI Tract using Octreotide Long Acting	GINFOCLAR	ı	
			Symptomatic Management of Functional Carcinoid and Neuroendocrine Tumors of the GI Tract using Octreotide Long Acting	GIOCTLAR	I	
olaparib	tablet	Breast	Treatment of BRCA-Mutated High-Risk Early Breast Cancer using Olaparib	UBRAJOLA	R	
		Genitourinary	Metastatic Castration-Resistant Prostate Cancer using Olaparib	UGUPOLAP	R	
		Gynecology	Maintenance Treatment of Newly Diagnosed BRCA-Mutated Platinum Responsive Epithelial Ovarian Cancer using Olaparib	GOOVFOLAM	ı	
			Maintenance Treatment of Relapsed, BRCA-Mutated, Platinum Sensitive and Responsive Epithelial Ovarian Cancer using Olaparib	GOOVOLAPM	ı	
osimertinib	tablet	Lung	Adjuvant Treatment of Epidermal Growth Factor Receptor (EGFR) Mutation- Positive Non-Small Cell Lung Cancer (NSCLC) with Osimertinib	LUAJOSI	. I	
			treatment of EGFR T790M mutation-positive advanced non-small cell lung cancer with osimertinib	LUAVOSI	I	
			first-line treatment of EGFR mutation-positive advanced non-small cell lung cancer with osimertinib	LUAVOSIF	1	
oxaliplatin	injectable	Gastrointestinal	adjuvant combination chemotherapy for stage III and IIB colon cancer with capecitabine	GIAJCAPOX	I	
			adjuvant combination chemotherapy for stage III and IIB colon cancer with fluorouracil and folinic acid	GIAJFFOX	. I	
			adjuvant combination chemotherapy for node-positive colon cancer using oxaliplatin and rallitrexed in patients intolerant to fluorouracil or capecitabine	GIAJRALOX	I	
			Palliative Therapy of Metastatic Colorectal Cancer using Oxaliplatin and Raltitrexed in Patients Intolerant to Fluorouracil or Capecitabine	GIAVRALOX	I	
			palliative combination chemotherapy for metastatic colorectal cancer using oxaliplatin and capecitabine palliative combination chemotherapy for metastatic colorectal cancer using	GICAPOX	I	
			paniative combination chemotherapy for metastatic colorectal cancer using oxaliplatin, bevacizumab and capecitabine combined modality therapy for locally advanced esophageal cancer using	GICOXB	I	
			oxaliplatin, fluorouracil, leucovorin, and radiation therapy palliative combination chemotherapy for metastatic colorectal cancer using	GIEFFOXRT	l	
			palliative combination celemotherapy for metastatic colorectal cancer using oxaliplatin, fluorouracil, leucovorin, and bevacizumab palliative combination chemotherapy for metastatic colorectal cancer using	GIFFOXB	l	
			oxaliplatin, fluorouracil, leucovorin, and panitumumab	GIFFOXPAN	1	
			palliative combination chemotherapy for advanced pancreatic adenocarcinoma using irinotecan, oxaliplatin, fluorouracil and folinic acid (leucovorin)	GIFIRINOX	I	
			palliative combination chemotherapy for metastatic colorectal cancer with fluorouracil and folinic acid	GIFOLFOX	ı	
			adjuvant chemotherapy in gastric cancer patients with D2 resection (node negative) or ineligible for adjuvant chemoradiation using oxaliplatin and capecitabine	GIGAJCOX	ı	
			adjuvant chemotherapy in gastric cancer patients with D2 resection (node negative) or ineligible for adjuvant chemoradiation using oxaliplatin, fluorouracil, and leucovorin	GIGAJFFOX	1	



DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
oxaliplatin (cont'd)	injectable	Gastrointestinal		GIGAVCOX	1	
			Junction or Esophageal Carcinoma using Capecitabine and Oxaliplatin			
			First-Line Treatment of Locally Advanced or Metastatic Esophageal,			
			1 3 7 - 3 - 1 7 - 1	GIGAVCOXN		
			Nivolumab			
			First-Line Treatment of Locally Advanced or Metastatic Gastroesophageal Cancer	GIGAVCOXP	1	
			using Oxaliplatin. Capecitabine and Pembrolizumab		·	
			palliative treatment of metastatic or locally advanced gastric, gastroesophageal			
			junction, or esophageal adenocarcinoma using capecitabine, oxaliplatin and	GIGAVCOXT	1	
			trastuzumab			
				GIGAVFFOX	1	
			Junction or Esophageal Carcinoma using Oxaliplatin, Fluorouracil and Leucovorin			
			First-Line Treatment of Locally Advanced or Metastatic Esophageal,			
				GIGAVFFOXN	1	
			and Nivolumab			
			First-Line Treatment of Locally Advanced or Metastatic Gastroesophageal Cancer	GIGAVFFOXP	1 1	
			using Oxaliplatin, Fluorouracil, Leucovorin and Pembrolizumab		·	
			palliative treatment of metastatic or locally advanced HER-2 positive gastric,			
				GIGAVFFOXT	1	
			fluorouracil, leucovorin, and trastuzumab		1	
			perioperative treatment of resectable adenocarcinoma of the stomach,			
				GIGFLODOC	1	
			infusional fluorouracil, and leucovorin			
			hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with peritoneal			
			carcinomatosis from limited advanced colorectal and appendiceal carcinomas using	GIHIPEC	1	
			oxaliplatin and fluorouracil			
			adjuvant chemotherapy for resected pancreatic adenocarcinoma using irinotecan,	GIPAJFIROX	1	
			oxalinlatin fluorouracil and leucovorin	GIF AUT INOX	<u>'</u>	
			Palliative Combination Chemotherapy for Metastatic Pancreatic Cancer using	GIPAVFFOX	1	
			Oxaliplatin, Fluorouracil and Leucovorin	GIFAVEFUX	'	
			Adjuvant or Neoadjuvant Combination Chemotherapy for Stage III Rectal Cancer	GIRAJCOX		
			using Oxaliplatin and Capecitabine	GIIVAJOOA		
			Adjuvant or Neoadjuvant Combination Chemotherapy for Stage III Rectal Cancer	GIRAJFFOX		
		using Oxaliplatin, Fluorouracil and Leucovorin	GIKAJFFUX	l '		
		Lymphomo	Treatment of Newly Diagnosed or Relapsed/Refractory Natural Killer or T-Cell	LYGEMOXPEG	Ī	
		Lymphoma	Lymphoma using Gemcitabine, Oxaliplatin and Pegaspargase	LIGENIUAPEG	'	



DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
			neoadjuvant or adjuvant therapy for breast cancer using doxorubicin and			
paclitaxel	injectable	Breast	cyclophosphamide followed by paclitaxel	BRAJACT	' '	
			neoadjuvant or adjuvant therapy for breast cancer using dose dense therapy:	BRAJACTG		
		L	doxorubicin and cyclophosphamide followed by paclitaxel	BRAJACIG	'	
			neoadjuvant or adjuvant therapy for breast cancer using doxorubicin and	BRAJACTT		
		L	cyclophosphamide followed by paclitaxel and trastuzumab	BRAJACTI	'	
			neoadjuvant or adjuvant therapy for breast cancer using dose dense therapy:	BRAJACTTG	1	
			doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab	DIVADACTIO		
			neoadjuvant or adjuvant therapy for early breast cancer using doxorubicin and	BRAJACTW	1	
			cyclophosphamide followed by weekly paclitaxel			
			adjuvant therapy for breast cancer using weekly paclitaxel and trastuzumab	BRAJTTW		
			treatment of metastatic breast cancer using gemcitabine and paclitaxel	BRAVGEMT	l I	
			Palliative Therapy for Metastatic Breast Cancer using Pembrolizumab with	BRAVPP	1	
			PACLitaxel	DIVAVEE		
			Palliative Therapy for Metastatic Breast Cancer using Pertuzumab, Trastuzumab			
			and Paclitaxel as First-Line Treatment for Advanced Breast Cancer	BRAVPTRAT	1	
			and I aditaxi as I iist-Line Treatment to Advanced breast dancer			
			palliative therapy for metastatic breast cancer using paclitaxel	BRAVTAX		
			palliative therapy for metastatic breast cancer using weekly paclitaxel (given weekly	BRAVTW	1	
			for 3 weeks out of 4 weeks) (replaces BRAVT7)	DIVAVIV		
			NEOAdjuvant Therapy for Triple Negative Breast Cancer using Carboplatin and	BRLACTWAC	1 1	
			Weekly PACLitaxel Followed by DOXOrubicin and Cyclophosphamide	DILACTWAC		
			Neoadjuvant Therapy for Triple-Negative Breast Cancer using Dose-Dense			
			Therapy: Carboplatin and Weekly Paclitaxel Followed by Doxorubicin and	BRLACTWACG	I	
			Cyclophosphamide			
			neoadjuvant therapy for breast cancer using dose dense therapy: paclitaxel	BRLATACG	1 1	
			followed by doxorubicin and cyclophosphamide	DI LE CITACO		
			treatment of locally advanced breast cancer using doxorubicin and	BRLATWAC	1	
			cyclophosphamide followed by weekly paclitaxel			
			NEOAdjuvant Therapy for Triple Negative Breast Cancer using Pembrolizumab with			
			CARBOplatin and Weekly PACLitaxel, Followed by DOXOrubicin and	BRPCTAC	1	
			Cyclophosphamide			
			NEOAdjuvant Therapy for Triple Negative Breast Cancer using Pembrolizumab,			
			Weekly CARBOplatin and Weekly PACLitaxel, Followed by DOXOrubicin and	BRPCWTAC	ı	
			Cyclophosphamide			
		Gastrointestinal	First-Line Palliative Treatment of Metastatic Anal Squamous Cell Carcinoma using	GIAAVCT	1 1	
			Carboplatin and Weekly Paclitaxel			
			neoadjuvant treatment of esophageal and gastroesophageal carcinomas using	GIENACTRT	1	
			carboplatin, paclitaxel and radiation therapy			
			second-line therapy for metastatic or locally advanced gastric or gastroesophageal	GIGAVRAMT	1	
			junction cancer using weekly paclitaxel and ramucirumab			
			hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with peritoneal	GIPMHIPEC	1	
			mesothelioma using doxorubicin, cisplatin and paclitaxel			
		Gynecology	alternative treatment of gynecological malignancies using cisplatin and paclitaxel	GOCISP		
		1	Alternative Treatment of Gynecological Malignancies using Bevacizumab, Cisplatin	GOCISPBEV		
			and Paclitaxel			
		1	combination with carboplatin as primary treatment of advanced/recurrent non-small	GOCXCAT		
			cell cancer of the cervix in ambulatory care settings			
		1	Neoadjuvant or Adjuvant Treatment of Endometrial Cancer using CARBOplatin and	GOENDAJCAT		
			PACLitaxel			
		1	Treatment of Advanced or Recurrent Endometrial Cancer using CARBOplatin and	GOENDAVCAT		
			PACLitaxel		·	



DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
paclitaxel (cont'd)	injectable	Gynecology	primarily advanced or recurrent endometrial cancer	GOENDCAT	1	
·		1	primary treatment of invasive epithelial ovarian, fallopian tube and primary			
			peritoneal cancer with high risk of relapse using bevacizumab, carboplatin and	GOOVCATB		
			paclitaxel			
		•	primary treatment of invasive epithelial ovarian, fallopian tube and primary			
			peritoneal cancer, with no visible residual tumour (moderate-high risk)	GOOVCATM	l I	
			ovarian cancer relapsing after complete remission of at least 4 months' duration in			
			response to primary treatment with carboplatin and paclitaxel	GOOVCATR	I	
			primary treatment of visible residual (extreme risk) invasive epithelial ovarian			
			cancer	GOOVCATX	1	
			primary treatment of metastatic/recurrent cancer of the cervix with bevacizumab,			
			carboplatin and paclitaxel	GOCXCATB	1	
			Primary Treatment of Squamous, Adenocarcinoma, or Adenosquamous Cancer of	LICOCYCATER	_	
			the Cervix with Bevacizumab, CARBOplatin, PACLitaxel and Pembrolizumab	UGOCXCATBP	R	
			Primary Treatment of Squamous, Adenocarcinoma, or Adenosquamous Cancer of	UGOCXCATP	R	
			the Cervix with CARBOplatin, PACLitaxel, and Pembrolizumab			
			Platinum Resistant or Refractory Epithelial Ovarian Cancer with Bevacizumab and	GOOVBEVP	1	
			PACLitaxel	COOVEEV.		
			primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian	GOOVDDCAT		
			tube carcinoma using carboplatin and weekly paclitaxel	GOOVDDCAT	'	
			primary treatment of stage III less than or equal to 1 cm visible residual invasive			
			epithelial ovarian cancer using intravenous and intraperitoneal paclitaxel and	GOOVIPPC	1	
			intraperitoneal carboplatin			
			progressive, platinum-refractory ovarian carcinoma, primary peritoneal carcinoma	0000/741/0		
			or fallopian tube carcinoma	GOOVTAX3	1	
		Genitourinary	palliative therapy for germ cell cancers using paclitaxel and gemcitabine	GUTAXGEM		
			advanced therapy for relapsed testicular germ cell cancer using paclitaxel,			
			ifosfamide and cisplatin	GUTIP	' '	
		Head and Neck	treatment for unresectable, locoregionally recurrent or metastatic squamous cell	HNAVPC	1	
			carcinoma of the head and neck using paclitaxel and cisplatin or carboplatin	TINAVEC		
			First-Line Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck			
			with Paclitaxel, Carboplatin and Pembrolizumab	HNAVPCPMB	ı	
			treatment of recurrent or metastatic nasopharyngeal carcinoma with carboplatin and			
			paclitaxel	HNNAVPC	1	
			Neoadjuvant Treatment of Non-Small Cell Lung Cancer with Nivolumab,			
		Lung	CARBOplatin and PACLitaxel	LUAJNIVPC	1	
			adjuvant carboplatin and paclitaxel following resection of stage I, II and IIIA non-	LUAJPC	1	
			small cell lung cancer			
			combination with carboplatin as first line treatment of advanced non-small cell lung	LUAVPC	1	
			cancer			
			First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer with	LUAVPCIPNI		
			Paclitaxel, Carboplatin, Ipilimumab and Nivolumab			
			first-line treatment of advanced squamous non-small cell lung cancer with	LUAVPCPMB	1	
			paclitaxel, carboplatin and pembrolizumab			
			treatment of locally advanced non-small cell lung cancer using carboplatin and	LULACATRT		
			paclitaxel with radiation therapy	LODIOMINI		
		Primary Unknown	primary treatment of cancer of unknown primary origin using carboplatin and	PUCAT		
		Filliary Officiowii	paclitaxel	FUCAI		
		Dadiatria	treatment of recurrent or resistant pediatric malignant germ cell tumors with			
		Pediatric	paclitaxel, ifosfamide and carboplatin (COG protocol AGCT0521)		'	
		1_	Metastatic or Unresectable Angiosarcoma using Weekly Paclitaxel (3 Weeks out of	0 A A V (T) A /		
		Sarcoma	4 Weeks Schedule)	SAAVTW		



DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
paclitaxel NAB (ABRAXANE)	injectable	Breast	Alternative Adjuvant Therapy for Breast Cancer using Paclitaxel NAB (ABRAXANE)	BRAJPN	- 1	
			Alternative Neoadjuvant or Adjuvant Therapy for Breast Cancer using PACLitaxel NAB (ABRAXANE), CARBOplatin and Trastuzumab	BRAJPNCT	I	
			Alternative Adjuvant Therapy for Breast Cancer using Paclitaxel NAB (ABRAXANE) and Trastuzumab	BRAJPNT	I	
			Palliative Therapy for Metastatic Breast Cancer using PACLitaxel NAB (ABRAXANE)	BRAVABR	1	
			Palliative Therapy for Metastatic Breast Cancer using Pembrolizumab and PACI itaxel NAR (ABRAXANE)	BRAVPPN	ı	
			Alternative NEOAdjuvant Therapy for Triple Negative Breast Cancer using CARBOplatin and PACLitaxel NAB (ABRAXANE) Followed by DOXOrubicin and Cyclophosphamide	BRLACPNAC	ı	
			Alternative NEOAdjuvant Therapy for Triple Negative Breast Cancer using Dose Dense Therapy: CARBOplatin and PACLitaxel NAB (ABRAXANE) Followed by DOXOrubicin and Cyclophosphamide	BRLACPNACG	ı	
			Alternative NEOAdjuvant Therapy for Locally Advanced Breast Cancer using PACLitaxel NAB (ABRAXANE) followed by DOXOrubicin and Cyclophosphamide	BRLAPNAC	ı	
			Alternative NEOAdjuvant Therapy for Breast Cancer using Dose Dense Therapy: PACLitaxel NAB (ABRAXANE) followed by DOXOrubicin and Cyclophosphamide	BRLAPNACG	1	
		Gastrointestinal	First Line Treatment of Locally Advanced and Metastatic Pancreatic Cancer with PACLitaxel NAB (ABRAXANE) and Gemcitabine	GIPGEMABR	I	
		Gynecology	Alternative Treatment of Gynecological Malignancies Using CARBOplatin and PACLitaxel NAB (ABRAXANE)	GOCABR	ı	
			Alternative Treatment of Gynecological Malignancies Using Bevacizumab, CARBOplatin and PACLitaxel NAB (ABRAXANE)	GOCABRBEV	I	
			Pembrolizumah	GOCXCPNBP	1	
			Alternative Treatment of Squamous, Adenocarcinoma, or Adenosquamous Cancer of the Cervix with CARBOplatin, PACLitaxel NAB (ABRAXANE), and Pembrolizumab	GOCXCPNP	ı	
palbociclib	capsule	Breast	Therapy of Advanced Breast Cancer using Palbociclib and Aromatase Inhibitor with or without LHRH Agonist	BRAVPALAI	I	
			Therapy of Advanced Breast Cancer using Palbociclib and Fulvestrant with or without LHRH Agonist	BRAVPBFLV	ı	
pamidronate	injectable	Breast	adjuvant therapy for breast cancer in post-menopausal women using pamidronate	BRAJPAM	I	
			bony metastases associated with breast cancer for patients who do not tolerate oral clodronate	BRAVCLOD	ı	Not reimbursed for hypercalcemia
			prevention of skeletal related events secondary to breast cancer using pamidronate	BRAVPAM	I	
		Myeloma	multiple myeloma	MYPAM	I	
panitumumab	injectable	Gastrointestinal	Treatment of BRAF V600E-Mutated Metastatic Colorectal Cancer using Panitumumab and Encorafenib	UGIAVPANEN	R	
			palliative third-line treatment of metastatic colorectal cancer using panitumumab with wild type KRAS	GIAVPANI	ı	
			palliative combination chemotherapy for metastatic colorectal cancer using irinotecan, fluorouracil, leucovorin, and panitumumab	GIFFIRPAN	ı	
			palliative combination chemotherapy for metastatic colorectal cancer using oxaliplatin, fluorouracil, leucovorin, and panitumumab	GIFFOXPAN	I	

BC CAN CER Provincial Health Services Authority

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
pazopanib	tablet	Genitourinary	palliative therapy for renal cell carcinoma using pazopanib	GUPAZO		
4		,	treatment of refractory or relapsing extranodal natural killer or T-Cell lymphoma	LYACDMEDEY		
pegaspargase (ONCASPAR®)	injectable	Lymphoma	using pegaspargase, methotrexate and dexamethasone	LYASPMEDEX	'	
		Treatment of Newly Diagnosed or Relapsed/Refractory Natural Killer or T-Cell	LYGEMOXPEG			
		Lymphoma using Gemcitabine, Oxaliplatin and Pegaspargase	LYGEWOXPEG	'		
			treatment of natural killer or T-Cell Lymphoma using dexamethasone, methotrexate,	LYSMILE		
			ifosfamide, pegaspargase and etoposide	LISIVIILE	'	
			treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma using	LKNOS, LYNOS		
			pegaspargase (ONCOSPAR)	LKNOS, LTNOS	'	
		Pediatric	pediatric patients with leukemia or lymphoma		ı	
peginterferon alfa-2a	injectable	Leukemia & BMT	therapy of chronic myeloid neoplasms and hypereosinophilic syndrome	LKPEGIFN	1	
	to to skelete	Donata	Adjuvant Treatment of Resected Triple Negative Breast Cancer using	BRAJPEM		
pembrolizumab	injectable	Breast	Pembrolizumab	BRAJPEM	'	
			Treatment of Metastatic Breast Cancer using Pembrolizumab	BRAVPEM	I	
			Treatment of Metastatic Breast Cancer using 6-Weekly Pembrolizumab	BRAVPEM6	I I	
			Palliative Therapy for Metastatic Breast Cancer using Pembrolizumab,	BRAVPGC	1	
			Gemcitabine, and CARBOplatin	DIVAVI GO		
			Palliative Therapy for Metastatic Breast Cancer using Pembrolizumab with	BRAVPP	1	
			PACLitaxel	DIVAVII		
			Palliative Therapy for Metastatic Breast Cancer using Pembrolizumab and	BRAVPPN	1	
			PACLitaxel NAB (ABRAXANE)			
			NEOAdjuvant Therapy for Triple Negative Breast Cancer using Pembrolizumab with			
			CARBOplatin and Weekly PACLitaxel, Followed by DOXOrubicin and	BRPCTAC	1	
			Cyclophosphamide			
			NEOAdjuvant Therapy for Triple Negative Breast Cancer using Pembrolizumab,			
			Weekly CARBOplatin and Weekly PACLitaxel, Followed by DOXOrubicin and	BRPCWTAC	1	
			Cyclophosphamide			
		Gastrointestinal	First-Line Treatment of dMMR/MSI-H Metastatic Colorectal Cancer using	UGIAVPEM	R	
			Pembrolizumab			
			First-Line Treatment of dMMR/MSI-H Metastatic Colorectal Cancer using 6-Weekly	UGIAVPEM6	R	
			Pembrolizumab First-Line Treatment of Locally Advanced or Metastatic Gastroesophageal Cancer			
			using Oxaliplatin, Capecitabine and Pembrolizumab	GIGAVCOXP	- 1	
			First-Line Treatment of Locally Advanced or Metastatic Gastroesophageal Cancer			
			using Oxaliplatin, Fluorouracil, Leucovorin and Pembrolizumab	GIGAVFFOXP	- 1	
			Maintenance Therapy of Squamous, Adenocarcinoma, or Adenosquamous Cancer			
		Gynecology	of the Cervix with Pembrolizumab with or without Bevacizumab	GOCXBP	1	
			Maintenance Therapy of Squamous, Adenocarcinoma, or Adenosquamous Cancer	GOCXBP6	1	
			of the Cervix with 6-Weekly Pembrolizumab with or without Bevacizumab	000/12/10		
			Primary Treatment of Squamous, Adenocarcinoma, or Adenosquamous Cancer of	UGOCXCATBP	R	
			the Cervix with Bevacizumab, CARBOplatin, PACLitaxel and Pembrolizumab			
			Primary Treatment of Squamous, Adenocarcinoma, or Adenosquamous Cancer of	LICOOYOATS		
			the Cervix with CARBOplatin, PACLitaxel, and Pembrolizumab	UGOCXCATP	R	
			Alternative Treatment of Squamous, Adenocarcinoma, or Adenosquamous Cancer			
1			of the Cervix with Bevacizumab, CARBOplatin, PACLitaxel NAB (ABRAXANE) and	GOCXCPNBP	- 1	
			Pembrolizumab			
		T	Alternative Treatment of Squamous, Adenocarcinoma, or Adenosquamous Cancer		1	
1			of the Cervix with Bevacizumab, CARBOplatin, PACLitaxel NAB (ABRAXANE) and	GOCXCPNP	- 1	
			Pembrolizumab	<u> </u>		
			Treatment of Microsatellite Instability-High or Mismatch Repair Deficient	UGOENDAVP	R	
			Endometrial Cancer using Pembrolizumab	UGUENDAVP	l K	
		T	Treatment of Endometrial Cancer With Microsatellite Stability or Mismatch Repair	COENDAVD	1	
		1	Proficiency using Pembrolizumab and Lenvatinib	GOENDAVPL	_1'	
			Treatment of Endometrial Cancer With Microsatellite Stability or Mismatch Repair	COENDAY/DLC		
l			Proficiency using 6-weekly Pembrolizumab and Lenvatinib	GOENDAVPL6	'	



DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
pembrolizumab (cont'd)	injectable	Gynecology	Treatment of Microsatellite Instability-High or Mismatch Repair Deficient	UGOENDAVP6	R	
penibronzumab (cont u)	Injectable	Gyriecology	Endometrial Cancer using 6-Weekly Pembrolizumab		18	
		Genitourinary	Adjuvant Treatment of Resected Renal Cell Carcinoma using Pembrolizumab	GUAJPEM	<u>l</u>	
			Adjuvant Treatment of Resected Renal Cell Carcinoma using 6-Weekly	GUAJPEM6	1	
			Pembrolizumab			
			treatment of locally advanced or metastatic urothelial carcinoma using	GUAVPEM	1	
			pembrolizumab Treatment of Metastatic Renal Cell Carcinoma using Pembrolizumab and			
			Lenvatinib	GUAVPEML	1	
			Treatment of Metastatic Renal Cell Carcinoma using 6-weekly Pembrolizumab and			
			Lamuatimih	GUAVPEML6	ı	
			treatment of locally advanced or metastatic urothelial carcinoma using 6-weekly	01147/202140		
			pembrolizumab	GUAVPEM6	ļ ļ	
			Treatment of Metastatic Renal Cell Carcinoma Using Pembrolizumab and Axitinib	GUAVPEMAX		
			3	GUAVFEINIAA		
		Head and Neck	First-Line Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck	HNAVPCPMB	1	
		Tiodd diid 1400K	with Paclitaxel, Carboplatin and Pembrolizumab	THE COLUMN		
			First-Line Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck	HNAVPFPMB	1	
			using Platinum, Fluorouracil and Pembrolizumab			
			First-Line Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck	HNAVPMBF	1	
			with Pembrolizumab First-Line Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck			
			using 6-Weekly Pembrolizumab	HNAVPMBF6	1	
		***	Maintenance Treatment of Advanced Squamous Cell Carcinoma of the Head and			
			Neek with Dembrolizumeh	HNAVPMBM	I	
		***	Maintenance Treatment of Advanced Squamous Cell Carcinoma of the Head and			
			Neck using 6-Weekly Pembrolizumab	HNAVPMBM6	l l	
		1	first-line treatment of advanced squamous non-small cell lung cancer with	L LIAV/DODA/D		
		Lung	paclitaxel, carboplatin and pembrolizumab	LUAVPCPMB	'	
			first-line treatment of advanced squamous non-small cell lung cancer with platinum,	LUAVPGPMB	1	
			gemcitabine and pembrolizumab	LUAVEGENID		
			second-line treatment of advanced non-small cell lung cancer using pembrolizumab	LUAVPMB	1	
			treatment of advanced non-small cell lung cancer using 6-weekly pembrolizumab	LUAVPMB6	1	
			first-line treatment of advanced non-small cell lung cancer using pembrolizumab	LUAVPMBF	1	
			first-line treatment of advanced non-small cell lung cancer using 6-weekly			
			pembrolizumab	LUAVPMBF6	ı	
			maintenance therapy of advanced non-small cell lung cancer with pembrolizumab	LUAVPMBM	ļ ļ	
			maintenance therapy of advanced non-small cell lung cancer with 6-weekly	LUAVPMBM6		
			pembrolizumab	LUAVFIVIDIVIO	'	
			maintenance therapy of advanced non-squamous non-small cell lung cancer with	LUAVPPMBM	1	
			pemetrexed and pembrolizumab			
			first-line treatment of advanced non-squamous non-small cell lung cancer with	LUAVPPPMB		
		I vers be seen	platinum, pemetrexed and pembrolizumab			
		Lymphoma	treatment of relapsed or refractory hodgkin lymphoma using pembrolizumab treatment of relapsed or refractory hodgkin lymphoma using 6-weekly	LYPEM		
			pembrolizumab	LYPEM6	1	
			peribrolizurian			

BC CAN CER Provincial Health Services Authority

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
pembrolizumab (cont'd)	injectable	Skin & Melanoma	Adjuvant Treatment of Resected Stage IIB to IV NED Melanoma Using Pembrolizumab	SMAJPEM	1	
			Adjuvant Treatment of Resected Stage IIB to IV NED Melanoma Using 6-Weekly Pembrolizumab	SMAJPEM6	I	
			treatment of unresectable or metastatic melanoma using pembrolizumab	SMAVPEM		
			treatment of unresectable or metastatic melanoma using 6-weekly pembrolizumab	SMAVPEM6	ı	
pemetrexed	injectable	Lung	Neoadjuvant Treatment of Non-Squamous Non-Small Cell Lung Cancer with Nivolumab, Pemetrexed and Platinum	LUAJNIVPP	1	
			Adjuvant Cisplatin and Pemetrexed Following Resection of Non-Small Cell Lung	LUAJPP	<u>.</u>	
			Cance second-line treatment of advanced non-small cell lung cancer	LUAVPEM		
			maintenance therapy of advanced non-small cell lung cancer after first-line	LUAVPENI		
			chemotherapy	LUAVPMTN	1	
			first-line treatment of advanced non-small cell lung cancer with platinum and	LUAVPP	ı	
			pemetrexed			
			First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer with Platinum, Pemetrexed, Ipilimumab and Nivolumab	LUAVPPIPNI	I	
			maintenance therapy of advanced non-squamous non-small cell lung cancer with pemetrexed and pembrolizumab	LUAVPPMBM	ı	
			first-line treatment of advanced non-squamous non-small cell lung cancer with	LUAVPPPMB		
			platinum, pemetrexed and pembrolizumab treatment of malignant mesothelioma with platinum and pemetrexed	LUMMPP		
				LOMINIFF	-	
pertuzumab	injectable	Breast	Palliative Therapy for Metastatic Breast Cancer using Pertuzumab, Trastuzumab and Docetaxel as First-Line Treatment for Advanced Breast Cancer	BRAVPTRAD	1	
			Palliative Therapy for Metastatic Breast Cancer using Pertuzumab, Trastuzumab and Paclitaxel as First-Line Treatment for Advanced Breast Cancer	BRAVPTRAT	ı	
			Palliative Therapy for Metastatic Breast Cancer using Pertuzumab, Trastuzumab, and Vinorelbine as First-Line Treatment for Advanced Breast Cancer	BRAVPTRVIN	I	
plerixafor	injectable		hematopoietic stem cell mobilization	PLERIXAFOR		
polatuzumab vedotin	injectable	Lymphoma	Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Not Eligible for Transplant using Polatuzumab Vedotin, Bendamustine and Rituximab	LYPOLABR	1	
pomalidomide	capsule	Myeloma	Therapy of Multiple Myeloma using Pomalidomide, Dexamethasone and Isatuximab with or without Cyclophosphamide	UMYISAPOMD	R	
			therapy of multiple myeloma using pomalidomide with dexamethasone	UMYPOMDEX	R	
ponatinib	tablet	Leukemia & BMT	treatment of chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia using ponatinib	ULKCMLP	R	
pralatrexate	injectable	Lymphoma	treatment of relapsed or refractory Peripheral T-Cell lymphoma (PTCL) with pralatrexate	LYPRA	1	
prednisolone	suspension	Pediatric	pediatric patients			
prednisone			palliative therapy for metastatic castration resistant prostate cancer sing cabazitaxel	GUPCABA	 	
hieniiisoiie	tablet	Genitourinary	and prednisone Therapy for Metastatic Castration-Sensitive Prostate Cancer using Abiraterone and	GUPCADA	-+'	
			Prednisone	GUMCSPABI		
			Palliative Therapy for Metastatic Castration Resistant Prostate Cancer Using Abiraterone and prednisone	UGUPABI	R	
			Therapy for Castration Sensitive Very High-Risk Non-Metastatic Prostate Cancer	UGUPAJABI	R	
			using Abiraterone and predniSONE palliative therapy for metastatic hormone refractory prostate cancer	GUPDOC		
			palliative therapy for metastatic normone retractory prostate cancer palliative therapy for hormone-refractory prostate cancer using mitoxantrone and			
			prednisone	GUPMX		***************************************
		Lymphoma	treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine and prednisone	LYCHOP	- 1	



DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
prednisone (cont'd)	tablet	Lymphoma	treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine, prednisone and rituximab	LYCHOPR	ı	
			central nervous system prophylaxis with high dose methotrexate, CHOP and rituximab in diffuse large B-cell lymphoma	LYCHOPRMTX	ı	
			treatment of CD30-positive peripheral T-Cell Lymphoma (PTCL) with doxorubicin,	LYCHPBV		
			cyclophosphamide, prednisone (CHP) and brentuximab vedotin	LICHEDV		
			treatment of relapsed chronic lymphocytic leukemia using cyclophosphamide, vincristine, prednisone and rituximab	LYCLLCVPR	ı	
			advanced indolent lymphoma using cyclophosphamide, vincristine and prednisone	LYCVP	ı	
			treatment of Hodgkin's Disease with cyclophosphamide, vinblastine, procarbazine and prednisone	LYCVPPABO	I	
			treatment of advanced indolent lymphoma using cyclophosphamide, vincristine, brednisone and rituximab	LYCVPR	l	
			therapy of lymphoma, Hodgkin's disease, chronic lymphocytic leukemia or multiple			
			myeloma using cyclophosphamide	LYCYCLO		
			Treatment of Previously Untreated Light Chain Amyloidosis and Not-Eligible for			
			Stem Cell Transplant using Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone	LYDARCBDF	'	
			treatment of lymphoma with dose-adjusted etoposide, doxorubicin, vincristine,			
			cyclophosphamide, prednisone and rituximab with intrathecal methotrexate	LYEPOCHR	1	
			lymphoma palliative chemotherapy	LYPALL	l	
		Myeloma	Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell	MYBLDF	1	
			Transplant using Bortezomib, Lenalidomide and Dexamethasone Treatment of Multiple Myeloma using Lenalidomide, Bortezomib and			
			Dexamethasone as Induction Pre-Stem Cell Transplant	MYBLDPRE	- 1	
			Treatment of Multiple Myeloma using Bortezomib, Dexamethasone With or Without Cyclophosphamide as Induction Pre-Stem Cell Transplant	MYBORPRE	ı	
			Treatment of Relapsed Multiple Myeloma using Bortezomib, Dexamethasone With or Without Cyclophosphamide	MYBORREL	1	
			treatment of relapsed and refractory multiple myeloma with daratumumab in			
			combination with bortezomib and dexamethasone with or without cyclophosphamide	MYDARBD	1	
			Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell			
			Transplant using Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone	MYDARCBDF	1	
			treatment of relapsed and refractory multiple myeloma with daratumumab in	MYDARLD	1	
			combination with lenalidomide and dexamethasone	WII DAILLD		
			Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell Transplant using Daratumumab, Lenalidomide and Dexamethasone	MYDARLDF	- 1	
			Treatment of Multiple Myeloma using Melphalan and Prednisone	MYMP	· · · · · · · · · · · · · · · · · · ·	***************************************
			treatment of multiple myeloma using melphalan, prednisone and weekly bortezomib	MYMPBOR		
			with the option of substituting cyclophosphamide for melphalan			
		Nat Otlannia - On a ifind		Other tumour site code		
		Not Otherwise Specified		followed by 'NOS' (e.g. LKNOS)	'	
procarbazine	capsule	Neuro-Oncology	modified PCV chemotherapy of brain tumours using procarbazine, lomustine and vincristine	CNMODPCV	I	
			standard procarbazine for second-line treatment of recurrent brain tumor	CNPROC	†	***************************************
		Lymphoma	treatment of Hodgkin's Disease with cyclophosphamide, vinblastine, procarbazine and prednisone	LYCVPPABO	1	
			lymphoma palliative chemotherapy	LYPALL	ı	
				Other tumour site code	Ī	
		Not Otherwise Specified		followed by 'NOS' (e.g. CNNOS)	I	
radium-223	radio- pharmaceutical	Genitourinary	therapy for metastatic castration resistant prostate cancer using radium-223	GUPRAD	1	



DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
raltitrexed	injectable	Gastrointestinal	adjuvant combination chemotherapy for node-positive colon cancer using oxaliplatin	GIAJRALOX	ı	
			and raltitrexed in patients intolerant to fluorouracil or capecitabine Palliative Therapy of Metastatic Colorectal Cancer using Irinotecan and Raltitrexed			
			in Patients Intolerant to Fluorouracil or Capecitabine	GIAVRALIR		
			Palliative Therapy of Metastatic Colorectal Cancer using Oxaliplatin and Raltitrexed	GIAVRALOX	1	
			in Patients Intolerant to Fluorouracil or Capecitabine unresectable or metastatic colorectal adenocarcinoma for patients with previous			
			fluorouracil toxicity	GIRALT	I	
ramucirumab iniectable	Gastrointestinal	second-line therapy for metastatic or locally advanced gastric or gastroesophageal	GIGAVRAMT			
	,		junction cancer using weekly paclitaxel and ramucirumab			
regorafenib	tablet	Sarcoma	third line treatment of advanced gastrointestinal stromal cell tumours (GIST's) using regorafenib	SAAVGR	ı	
			Treatment of Relapsed or Refractory Advanced Osteosarcoma using Regorafenib	SAAVOR	ı	
		Gastrointestinal	treatment of advanced hepatocellular carcinoma using regorafenib	GIREGO	···	
ribociclib	tablet	Breast	Therapy of Advanced Breast Cancer using Ribociclib and Fulvestrant with or	BRAVRBFLV	1 ,	
			without LHRH Agonist Therapy of Advanced Breast Cancer using Ribociclib and Aromatase Inhibitor with			
			or without LHRH Agonist	BRAVRIBAI	1	
ripretinib ta	tablet	Sarcoma	Fourth-Line Therapy of Advanced Gastrointestinal Stromal Cell Tumours (GIST)	SAAVGRIP		
			Using Ripretinib			
rituximab	IV injectable only	Leukemia & BMT	pre-emptive rituximab therapy of Epstein-Barr virus related post-transplant lymphoproliferative disease	BMTLPDRIT	1	
	IV / 1400 mg SC	Lymphoma	treatment of Non-Hodgkin Lymphoma with bendamustine and rituximab	LYBENDR	1	
	injectable IV / 1400 mg SC					
	injectable		treatment of indolent B-cell lymphoma with chlorambucil and rituximab	LYCHLRR	1	
	IV / 1400 mg SC		in combination with CHOP (cyclophosphamide, doxorubicin, prednisone,			1
	injectable		vincristine), in all stages of newly diagnosed diffuse large B-cell lymphoma and	LYCHOPR	1	Note: Biosimilar rituximab (RIXIMYO®,
	IV / 1400 mg SC		mantle cell lymphoma, advanced stage at diagnosis			RUXIENCE®) is funded for intravenous
	injectable		central nervous system prophylaxis with high dose methotrexate, CHOP and rituximab in diffuse large B-cell lymphoma	LYCHOPRMTX	- 1	rituximab started on or after August 1st,
	IV / 1600 mg SC		treatment of relapsed/refractory chronic lymphocytic leukemia or small lymphocytic	LYCLLBENDR		2020. RITUXAN® is funded for
	injectable		lymphoma with bendamustine and rituximab	LYCLLBENDR		intravenous rituximab started prior to and continue beyond August 1st, 2020.
	IV / 1600 mg SC		treatment of chronic lymphocytic leukemia with chlorambucil and rituximab	LYCLLCHLR	1	
	injectable IV / 1600 mg SC		treatment of relapsed chronic lymphocytic leukemia using cyclophosphamide,			
	injectable		vincristine, prednisone and rituximab	LYCLLCVPR		
	IV / 1600 mg SC		treatment of previously untreated chronic lymphocytic leukemia (CLL) with	LYCLLFBR		
	injectable		bendamustine and rituximab	LI OLLI DIX		
	IV / 1600 mg SC injectable		treatment of chronic lymphocytic leukemia or prolymphocytic leukemia with fludarabine and rituximab	LYCLLFLUDR	- 1	
	mjeciable		וועעמומטוויכ מווע וונעגוווומט			



DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
rituximab (cont'd)	IV / 1400 mg SC injectable	Lymphoma	treatment of Burkitt's lymphoma and leukemia with cyclophosphamide, vincristine, doxorubicin, methotrexate, leucovorin and rituximab	LYCODOXMR	ı	
	IV / 1400 mg SC injectable		combination with CVP for advanced stage indolent lymphoma at diagnosis	LYCVPR	ı	
	IV / 1400 mg SC injectable		Treatment of Lymphoma with Dexamethasone, Cytarabine, Platinum and riTUXimab	LYDHAPR	ı	
	IV / 1400 mg SC injectable		treatment of lymphoma with dose-adjusted etoposide, doxorubicin, vincristine, cyclophosphamide, prednisone and rituximab with intrathecal methotrexate	LYEPOCHR	I	
	IV / 1600 mg SC injectable		treatment of chronic lymphocytic leukemia (CLL) or prolymphocytic leukemia with fludarabine, cyclophosphamide and rituximab	LYFCR	ı	
	IV / 1400 mg SC iniectable		treatment of relapsed indolent lymphoma with fludarabine and rituximab	LYFLUDR	ı	
	IV / 1400 mg SC iniectable		treatment of lymphoma with gemcitabine, dexamethasone and platinum with rituximab	LYGDPR	ı	
	IV / 1400 mg SC injectable		Treatment of Primary and Secondary CNS Lymphoma with High-Dose Methotrexate. Rituximab and Temozolomide	LYHDMRTEM	ı	
	IV / 1600 mg SC iniectable		treatment of relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma using idelalisib and rituximab	LYIDELAR	ı	Note: Biosimilar rituximab (RIXIMYO®, RUXIENCE®) is funded for intravenous
	IV / 1400 mg SC injectable		treatment of Burkitt's lymphoma and leukemia with ifosfamide, mesna, etoposide, cytarabine and rituximab	LYIVACR	ı	rituximab started on or after August 1st, 2020. RITUXAN® is funded for
	IV / 1400 mg SC injectable		Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Not Eligible for Transplant using Polatuzumab Vedotin, Bendamustine and Rituximab	LYPOLABR	ı	intravenous rituximab started prior to and continue beyond August 1st, 2020.
	IV / 1400 mg SC injectable		treatment of relapsed or refractory advanced stage aggressive B-cell non-Hodgkin's lymphoma with ifosfamide, carboplatin, etoposide and rituximab	LYRICE	ı	
	IV / 1400 mg SC injectable		diagnosed (within 6 months) asymptomatic advanced follicular lymphoma	LYRITUX	I	
	IV injectable only		Palliative Therapy For Lymphoma Using Radioimmunotherapy: riTUXimab-Priming for 90Y-Ibritumomab tiuxetan (ZEVALIN®)	LYRITZ	ı	
	IV / 1400 mg SC injectable		maintenance treatment of indolent lymphoma	LYRMTN	ı	
	IV / 1600 mg SC injectable		treatment of relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma using venetoclax and rituximab	LYVENETOR	I	
	IV injectable only	Pediatric	pediatric patients treated on the COG protocols ANHL0221 for CD20 positive post- transplant lymphoproliferative disease following solid organ transplantation and ANHL01P1 for newly diagnosed advanced B-cell leukemia/lymphoma		ı	
romidepsin	injectable	Lymphoma	treatment of relapsed or refractory Peripheral T-Cell lymphoma (PTCL) with romidepsin	ULYROMI	R	
ruxolitinib	tablet	Leukemia & BMT	Treatment of Symptomatic Myelofibrosis with Ruxolitinib Treatment of Polycythemia Vera with Ruxolitinib	LKMFRUX LKPCVRUX	! I	
sacituzumab govitecan	injectable	Breast	Palliative Therapy for Metastatic Triple Negative Breast Cancer	BRAVSG		



DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
sargramostim (SAP)	injectable	Pediatric	pediatric patients with neuroblastoma treated on the COG ANBL0032 protocol		ı	
			pediatric patients with relapsed neuroblastoma treated on the COG ANBL1021 protocol		ı	Approval from Health Canada Special Access Programme is required for each
			treatment of pediatric patients with high-risk neuroblastoma who achieve a			patient
			response to prior first-line multi-agent, multimodal therapy using dinutuximab in		- 1	patient
			combination with sargramostim, aldesleukin and tretinoin			
selinexor	tablet	Myeloma	With or Without Cyclophosphamide	MYBSD	- 1	
selpercatinib	capsule	Head and Neck	Therapy of Advanced RET Fusion-Positive Differentiated Thyroid Cancer using Selpercatinib	HNOTDSEL	l	
			Treatment of Advanced RET-Mutant Medullary Thyroid Cancer using Selpercatinib	HNOTMSEL	I	
		Lung	Treatment of RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Selpercatinib	LUAVSEL	I	
siltuximab	injectable	Lymphoma	treatment of Multicentric Castleman's Disease (MCD) negative for Human Immunodeficiency Virus (HIV) and Human Herpes Virus-8 (HHV-8) Using siltuximab	LYSILTUX	I	
sorafenib	tablet	Gastrointestinal	Therapy for Advanced Hepatocellular Carcinoma using Sorafenib	GISORAF		
		Genitourinary	palliative therapy for renal cell carcinoma in patients after cytokine failure	GUSORAF	l l	
		Leukemia & BMT	therapy of acute myeloid leukemia using azacitidine and sorafenib	LKAMLAS	I	
streptozocin	injectable	Gastrointestinal	palliative therapy for pancreatic endocrine tumours using streptozocin and doxorubicin	GIENDO2	I	Approval from Health Canada Special
				Other tumour site code		Access Programme is required for each
		Not Otherwise Specified		followed by 'NOS' (e.g. GINOS)	I	patient
sunitinib	capsule	Gastrointestinal	as palliative treatment of advance pancreatic neuroendocrine tumours	GIPNSUNI	ı	
		Genitourinary	palliative therapy for renal cell carcinoma in patients who are not suitable candidates for interferon	GUSUNI	I	
			second line treatment of advanced c-kit positive gestrointestinal stromal cell			
		Sarcoma	tumours (GIST's) after imatinib	SAAVGS	I	
		 	Treatment of Adinvent Preset Consequencing Above sight and Tomovifer With a			
tamoxifen	tablet	Breast	Without LHRH Agonist	UBRAJABET	R	
			Adjuvant Treatment of Resected Ductal Carcinoma in Situ using Tamoxifen	BRAJLDTAM	I	
			Neoadjuvant or Adjuvant Therapy for Breast Cancer Using a LHRH Agonist and Tamoxifen	BRAJLHRHT	- 1	
			Neoadjuvant or Adjuvant Therapy for Breast Cancer Using Tamoxifen	BRAJTAM	ı	
			Palliative Therapy for Breast Cancer Using a LHRH agonist and tamoxifen	BRAVLHRHT	l I	
			Palliative Therapy for Breast Cancer Using Tamoxifen	BRAVTAM	l I	
		Gynecology		GOENDH	l I	
			Therapy for Advanced Ovarian Cancer Using Tamoxifen	GOOVTAM	I I	
		Head and Neck	Treatment of Recurrent/Metastatic Salivary Gland Cancers of the Head and Neck With Tamoxifen	HNSAVTAM	I	
		Sarcoma	Therapy for Recurrent Desmoid Tumours/Aggressive Fibromatosis Using Tamoxifen	SATAM	I	
tebentafusp	injectable	Skin & Melanoma	Treatment of Metastatic Uveal Melanoma using Tebentafusp	USMAVTEB	R	



DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
temozolomide	capsule	Neuro-Oncology	Concomitant (Dual Modality) and 12 Cycles of Adjuvant Temozolomide for Newly	CNAJ12TZRT	ı	
			Diagnosed Malignant Gliomas with Radiation Concomitant (Dual Modality) and Adjuvant Temozolomide for Newly Diagnosed			
	1	1	Concomitant (Dual Modality) and Adjuvant Temozolomide for Newly Diagnosed Malignant Gliomas with Radiation	CNAJTZRT	1	
			Treatment of Elderly Newly Diagnosed Glioma Patient with Concurrent and			
	1	1	Adjuvant Temozolomide and Radiation Therapy	CNELTZRT	I	
			Therapy for Newly Diagnosed Malignant Brain Tumours with MGMT Methylation in	CNTEM60	1	
			Elderly Patients using Temozolomide			
			Therapy for Malignant Brain Tumours Using Temozolomide	CNTEMOZ	l	
			Therapy for Malignant Brain Tumours using Metronomic Dosing of Temozolomide	CNTEMOZMD	- 1	
			Therapy for Recurrent Malignant Brain Tumours using Temozolomide and Etoposide	CNTMZETO	ı	
		Gastrointestinal	Palliative Therapy of Metastatic Neuroendocrine Cancer Using Temozolomide and Capecitabine	GIAVTZCAP	ı	
			Treatment of Primary and Secondary CNS Lymphoma with High-Dose			
		Lymphoma	Methotrexate, Rituximab and Temozolomide	LYHDMRTEM	I	
		Pediatric	pediatric patients with brain tumours		l	
	T		pediatric patients treated on the COG protocol ANBL0421 for recurrent		ı	
			neuroblastoma			
			pediatric patients with rhabdomyosarcoma treated on the COG ARST08P1 protocol		- 1	
		Sarcoma	Therapy for Advanced Solitary Fibrous Tumours and Hemangiopericytoma Using Temozolomide and Bevacizumab	SATEMBEV	I	
		Ckin 9 Malanama	Palliative Therapy for Malignant Melanoma with Brain Metastases Using	SMAVTMZ		
		Skin & Melanoma	Temozolomide		'	
temsirolimus	injectable	Genitourinary	therapy for advanced renal cancer using temsirolimus	GUTEM	l	
		Pediatric	treatment of recurrent/refractory rhabdomysarcoma in pediatric patients with			
		Pediatric	cyclophosphamide, vinorelbine and temsirolimus on the COG ARST0921 protocol		'	
				Tumour site code		
teniposide	injectable	Not Otherwise Specified		followed by 'NOS' (e.g.	- 1	
				GUNOS)		
testosterone enanthate	injectable	Breast	palliative therapy for metastatic breast cancer	BRAVTEST	- 1	Not reimbursed for symptom
	'		,	Tumour site code		management or appetite stimulation
thioguanine	tablet	Not Otherwise Specified		followed by 'NOS' (e.g.	1	
anoguannic .	tablet	rtot Othorwide Opcomed		LYNOS)		
thiotepa	iniectable	Miscellaneous Origins	therapy for solid tumours using intrathecal methotrexate and/or thiotepa and/or	MOIT		
	IIIJectable	wiscellaneous Origins	cytarabine		<u> </u>	
		Not Otherwise One if		Other tumour site code	I , I	
	1	Not Otherwise Specified		followed by 'NOS' (e.g. GUNOS)	'	
thyrotropin alfa	injectable	Head and Neck	radioiodine imaging in patients with thyroid cancer and treatment	HNOTTSH		
	,50,000		Treatment of pediatric and young adult patients up to and including 25 years of age			
tisagenlecleucel (KYMRIAH)	CAR T-cell	Dodietrie	with B-cell acute lymphocytic leukemia (ALL) refractory to or relapsed after	PECARTALL	R	
usagemecieucei (KTWKIAH)	CAR 1-ceil	Pediatric	allogeneic stem cell transplantation (SCT) or otherwise ineligible for SCT, or	FECARIALL	ĸ	
			experienced second or later relapse Third line treatment of adults with diffuse large B cell lymphoma (DLBCL) and high-			
	1	Lymphoma		LYCARTDL3	R	
	1	1 .	grade B-cell lymphoma (HGBL) treatment of relapsed/progressive epithelial ovarian, fallopian tube or primary			
topotecan	injectable	Gynecology	peritoneal cancer using topotecan	GOOVTOP	I	
	injectable	Lung	second line treatment of recurrent small cell lung cancer	LUSCTOP	l I	
		Pediatric	pediatric sarcoma		l I	
1	1		intermediate-risk (COG ANBL0532) and high risk (COG ANBL0531) pediatric		1 1	
			neuroblastoma			
	1	Sarcoma	summary for treatment of recurrent/refractory neuroblastoma, ewing's sarcoma,	SAAVTC		!
	1	Carooma	osteogenic sarcoma or rhabdomyosarcoma with topotecan/cyclophosphamide	5, 17, 10	'	



DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
trametinib	tablet	Skin & Melanoma	adjuvant treatment of stage III and IV, BRAF-mutated, fully resected melanoma	SMAJDT		
		Okin a wolanoma	using dabrafenib and trametinib			
			treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma	SMAVDT	1 1	
			using dabrafenib and trametinib			
			treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma	SMAVTRA		
			using trametinib			
trastuzumab	injectable	Breast	neoadjuvant or adjuvant therapy for breast cancer using doxorubicin and	BRAJACTT	1	
			cyclophosphamide followed by paclitaxel and trastuzumab			
			neoadjuvant or adjuvant therapy for breast cancer using dose dense therapy:	BRAJACTTG	1	
			doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab			
			neoadjuvant or adjuvant therapy for breast cancer using carboplatin, docetaxel and	BRAJDCARBT	1	
			trastuzumab			
			neoadjuvant or adjuvant therapy for breast cancer using fluorouracil, epirubicin and cyclophosphamide followed by docetaxel and trastuzumab	BRAJFECDT	1	!
			Alternative Adjuvant Therapy for Breast Cancer using Paclitaxel NAB (ABRAXANE)			
			and Trastuzumab	BRAJPNT	1	
			Alternative Neoadjuvant or Adjuvant Therapy for Breast Cancer using PACLitaxel			
				BRAJPNCT	1	
			NAB (ABRAXANE), CARBOplatin and Trastuzumab neoadjuvant or adjuvant therapy for breast cancer using trastuzumab, docetaxel			
			, , , , , , , , , , , , , , , , , , , ,	BRAJTDC	1	
			and cyclophosphamide Adjuvant Therapy for Breast Cancer using Trastuzumab Following the Completion			
			of Chemotherapy (Sequential)	BRAJTR	1	Note: Biosimilar trastuzumab
			adjuvant therapy (Sequential) adjuvant therapy for breast cancer using weekly paclitaxel and trastuzumab	BRAJTTW		(HERZUMA®, TRAZIMERA®, ONTRUZANT®) is funded for treatment
				DRAJIIW		
			Palliative Therapy for Metastatic Breast Cancer using Pertuzumab, Trastuzumab	BRAVPTRAD		started on or after February 1st, 2020.
			and Docetaxel as First-Line Treatment for Advanced Breast Cancer	DIVIVI IIVID		HEDCEDTIN® is only funded for:
						HERCEPTIN® is only funded for: treatment started prior to February
			Palliative Therapy for Metastatic Breast Cancer using Pertuzumab, Trastuzumab	BRAVPTRAT	1	
			and Paclitaxel as First-Line Treatment for Advanced Breast Cancer			1st, 2020, or
			Dellistics Theorem for Materialis Decret Occurrence in Destruction Destruction			treatment started prior to September
			Palliative Therapy for Metastatic Breast Cancer using Pertuzumab, Trastuzumab,	BRAVPTRVIN	1	1, 2022 when used with pertuzumab for
			and Vinorelbine as First-Line Treatment for Advanced Breast Cancer			advanced breast cancer
			- III - E	DDAV/TOAD	Τ .	(BRAVPTRAD, BRAVPTRAT)
			palliative therapy for metastatic breast cancer using trastuzumab and capecitabine	BRAVTCAP	'	
		T	single agent therapy for metastatic breast cancer progressing after 1 prior regimens		1	
			(e.g., taxane) and responding to trastuzumab in combination with paclitaxel, with	BRAVTR	1	
			paclitaxel and carboplatin, or with vinorelbine			
			Palliative Therapy for Metastatic Breast Cancer using Trastuzumab, Tucatinib and	UBRAVTTCAP	R	
			Capecitabine	UBRAVITCAP	, r	
			treatment of locally advanced breast cancer using doxorubicin and	BRLAACDT	1	
			cyclophosphamide followed by docetaxel and trastuzumab	DILLAACDI	L	l
			Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal			
1		Gastrointestinal	Junction or Esophageal Adenocarcinoma using Cisplatin, Capecitabine and	GIGAVCCT	- 1	
			Trastuzumab			
			palliative treatment of metastatic or inoperable, locally advanced gastric or			
1			gastroesophageal junction adenocarcinoma using cisplatin, infusional fluorouracil	GIGAVCFT	- 1	
			and trastuzumab			
1			palliative treatment of metastatic or locally advanced gastric, gastroesophageal			
1			junction, or esophageal adenocarcinoma using capecitabine, oxaliplatin and	GIGAVCOXT		
I	1	1	trastuzumab	ĺ	1	



DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
trastuzumab (cont'd)	Injectable	Gastrointestinal	Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction or Esophageal Carcinoma using Oxaliplatin, Fluorouracil and Leucovorin	GIGAVFFOXT	l	Note: Biosimilar trastuzumab (HERZUMA®, TRAZIMERA®, ONTRUZANT®) is funded for treatment
			continuation of palliative treatment of metastatic or inoperable, locally advanced gastric or gastroesophageal junction adenocarcinoma using trastuzumab	GIGAVTR	1	started on or after February 1st, 2020. (See above)
trastuzumab emtansine (KADCYLA)	injectable	Breast	adjuvant therapy for breast cancer using trastuzumab emtansine (KADCYLA)	UBRAJKAD	R	
			palliative therapy for metastatic breast cancer using trastuzumab emtansine (KADCYLA)	BRAVKAD	I	
trastuzumab deruxtecan (ENHERTU)	injectable	Breast	Palliative Therapy for Metastatic Breast Cancer using Trastuzumab Deruxtecan (ENHERTU)	BRAVENH	I	
tremelimumab	injectable	Gastrointestinal	First-Line Treatment of Advanced Hepatocellular Carcinoma using Tremelimumab and Durvalumab	GITREMDUR	1	
treosulfan	injectable	Leukemia & BMT	pre-conditioning therapy with treosulfan for pediatric patients at risk for busulfan-	BMTNOS		
		Pediatric	related toxicity prior to hematopoietic stem cell transplantation for malignant conditions		R	
tretinoin (VESANOID®)	capsule	Leukemia & BMT	acute promyelocytic leukemia first-line induction and consolidation therapy of acute promyelocytic leukemia using	LKNOS	I	
			arsenic trioxide and tretinoin	LKATOATRA	I	
			first-line induction and consolidation therapy of acute promyelocytic leukemia using	LKATOP	ı	
			induction and consolidation therapy of relapsed acute promyelocytic leukemia using arsenic trioxide and tretinoin (All-Trans Retinoic Acid)	LKATOR	ı	
		Pediatric	Treatment of Pediatric Patients with De Novo Acute Promyelocytic Leukemia using Arsenic Trioxide In Combination with Tretinoin and with or without Idarubicin and Dexamethasone on the COG AAML1331 Study		1	
			treatment of pediatric patients with high-risk neuroblastoma who achieve a response to prior first-line multi-agent, multimodal therapy using dinutuximab in		ı	
			combination with sargramostim, aldesleukin and tretinoin Third- or Later-Line Therapy for Advanced Gastroesophageal Carcinoma using		<u> </u>	
trifluridine-tipiracil	tablet	Gastrointestinal	Trifluridine-Tipiracil	GIGAVTRFT	1	
tucatinib	tablet	Breast	Palliative Therapy for Metastatic Breast Cancer using Trastuzumab, Tucatinib and Capecitabine	UBRAVTTCAP	R	
vandetanib	tablet	Head and Neck	treatment for locally advanced or metastatic medullary thyroid cancer using vandetanib	HNOTVAN	I	
vemurafenib	tablet	Skin & Melanoma	treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma using vemurafenib	SMAVVEM	1	
			treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma using vemurafenib and cobimetinib	SMAVVC	1	
venetoclax	tablet	Leukemia & BMT	Therapy of Acute Myeloid Leukemia using Azacitidine and Venetoclax	ULKAMLAVEN	R	
***************************************		Lymphoma	treatment of relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma using venetoclax	ULYVENETO	R	
			treatment of relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma using venetoclax and rituximab	LYVENETOR	ı	
			Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma using Venetoclax and Obinutuzumab	LYVENOB	ı	



DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
vinblastine	injectable	Genitourinary	therapy for transitional cell cancers of the urothelium using methotrexate,	GUMVAC	1	
VIIIDIastille	IIIJectable	Geriilourinary	vinblastine, doxorubicin and cisplatin	GOWIVAC	<u>'</u>	
			consolidation/ salvage treatment for germ cell cancer using vinblastine, cisplatin,	GUVEIP	1 1	
			ifosfamide and mesna		L'	
		Kaposi's Sarcoma	therapy for Kaposi's Sarcoma using vinblastine-vincristine	KSVB	l I	
		Lymphoma	treatment of Hodgkin's disease with doxorubicin, bleomycin, vinblastine and	LYABVD	1	
		Lymphoma	dacarbazine	LIADVD	L'	
			Treatment of Previously Untreated, Stage IV Hodgkin Lymphoma with Doxorubicin,	LYAVDBV	1	
			Vinblastine, Dacarbazine and Brentuximab Vedotin			
			Treatment of Previously Untreated, Stage IV Hodgkin Lymphoma with Sequential			
			Brentuximab Vedotin and DOXOrubicin, vinBLAStine and Dacarbazine in Patients	LYBVAVDBV	1	
			60 Years or Older			
			treatment of Hodgkin's Disease with cyclophosphamide, vinblastine, procarbazine	LYCVPPABO	1 1	
			and prednisone		ļ	
			lymphoma palliative chemotherapy	LYPALL	LI	
		Sarcoma	palliative therapy for aggressive fibromatosis using weekly or alternate week	SAMV	1 1	
			methotrexate and vinblastine intravenously			
				Other tumour site code		
		Not Otherwise Specified		followed by 'NOS' (e.g.	I	
				LYNOS)		
vincristine	iniectable	Neuro-Oncology	adjuvant lomustine, cisplatin and vincristine in adult high-risk medulloblastoma or	CNCCV	1	
	,000		other primitive neuroectodermal tumour			
			modified PCV chemotherapy of brain tumours using procarbazine, lomustine and	CNMODPCV	1 1	
			vincristine			
		Genitourinary	Neoadjuvant Treatment of Urothelial Cancer using Dose-Dense Methotrexate,	GUBDDMVAC	1 1	
			Vinblastine, Doxorubicin and Cisplatin			
		I	therapy for high-risk Gestational Trophoblastic Neoplasia (GTN) using etoposide,		l .	
		Gynecology	methotrexate, leucovorin (folinic acid), dactinomycin, cyclophosphamide and	GOTDEMACO	1	
			vincristine			
		Kaposi's sarcoma	therapy for Kaposi's Sarcoma using vinblastine-vincristine	KSVB	 	
		Lung	treatment of thymoma/thymic carcinoma with cyclophosphamide, doxorubicin and	LUOTCAV	1 1	
			vincristine			
			treatment of extensive small cell lung cancer with cyclophosphamide, doxorubicin	LUSCCAV	1 1	
			and vincristine			
		Lymphoma	treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine and	LYCHOP	1 1	
			prednisone			
l			treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine, prednisone	LYCHOPR	1 1	
			and rituximab			
l			central nervous system prophylaxis with high dose methotrexate, CHOP and	LYCHOPRMTX	1 1	
			rituximab in diffuse large B-cell lymphoma		.	
l			treatment of relapsed chronic lymphocytic leukemia using cyclophosphamide,	LYCLLCVPR	Li	
I	ľ	1	vincristine, prednisone and rituximab		I '	ĺ



DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
vincristine (cont'd)	iniectable	Lymphoma	treatment of Burkitt's Lymphoma and Leukemia with cyclophosphamide, vincristine,	LYCODOXMR	1	
,			doxorubicin, methotrexate, leucovorin and rituximab			
			advanced indolent lymphoma using cyclophosphamide, vincristine and prednisone	LYCVP	ı	
			treatment of Hodgkin's Disease with cyclophosphamide, vinblastine, procarbazine and prednisone	LYCVPPABO	I	
			treatment of advanced indolent lymphoma using cyclophosphamide, vincristine, prednisone and rituximab	LYCVPR	ı	
			treatment of lymphoma with dose-adjusted etoposide, doxorubicin, vincristine,	LYEPOCHR	1	
			cyclophosphamide, prednisone and rituximab with intrathecal methotrexate			
			lymphoma palliative chemotherapy SAIME alternating with SAVAC or SAVACM with filgrastim support at TWO weekly	LYPALL		
		Sarcoma	interval for newly diagnosed Ewing's Sarcoma/Ewing's Family of Tumours, Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or Rhabdomyosarcoma	SAALT2W	I	
			SAIME alternating with SAVAC or SAVACM with filgrastim support at THREE			
			weekly interval for newly diagnosed Ewing's Sarcoma/Ewing's Family of Tumours, Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or	SAALT3W	1	
			Rhabdomyosarcoma treatment of sarcomas with vincristine, doxorubicin and cyclophosphamide	SAVAC		
			Treatment of Sarcomas with Pelvic Primaries or Chemotherapy-Induced Hematuria			
			using Vincristine, Doxorubicin, Cyclophosphamide and Mesna	SAVACM	· · · · · · · · · · · · · · · · · · ·	
			Adjuvant Therapy for Rhabdomyosarcoma using Vincristine, Dactinomycin and Cyclophosphamide	SAVDC	- 1	
		Not Otherwise Specified	Cyclopinospiralina	Other tumour site code followed by 'NOS' (e.g.	1	
		Not Otherwise openied		LYNOS)		
vinorelbine	injectable	Breast	palliative therapy for metastatic breast cancer	BRAVNAV	l	
			Palliative Therapy for Metastatic Breast Cancer using Pertuzumab, Trastuzumab, and Vinorelbine as First-Line Treatment for Advanced Breast Cancer	BRAVPTRVIN	1	
		Gynecology	Treatment of Platinum Resistant or Refractory Epithelial Ovarian Cancer with Bevacizumab and Vinorelbine	GOOVBEVV	ı	
			palliative chemotherapy for re-treatment of ovarian, tubal, and peritoneal cancer	GOOVVIN	- 1	
		Head and Neck	combination with cisplatin as treatment of advanced salivary gland cancers with cisplatin and vinorelbine	HNSAVNP	1	
		Lung	adjuvant cisplatin and vinorelbine following resection of stage I, II and IIIA non- small cell lung cancer	LUAJNP	I	
			combination with cisplatin as treatment for advanced non-small cell lung cancer	LUAVNP	ı	
			advanced non-small cell lung cancer in elderly patients malignant mesothelioma	LUAVVIN LUMMVIN		
			Treatment of Relapsed or Refractory Hodgkin Lymphoma with Gemcitabine,		············	
		Lymphoma	Vinorelbine and Doxorubicin Pegylated Liposomal	LYGVLD	l	
		Pediatric	pediatric patients treated on the COG protocol AHOD0521 for refractory/recurrent Hodgkin's disease		ı	
			Hodgkin's disease treatment of pediatric patients with relapsed Hodgkin lymphoma with a combination of ifosfamide, mesna, gemcitabine and vinorelbine (IGEV)		I	
	injectable	Pediatric	treatment of recurrent/refractory rhabdomysarcoma in pediatric patients with cyclophosphamide, vinorelbine and temsirolimus on the COG ARST0921 protocol		I	



DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
vismodegib	capsule	Skin & Melanoma	treatment of metastatic or locally advanced basal cell carcinoma	SMAVVIS		
yttrium-90	injectable	Gastrointestinal	or Gallbladder Carcinoma Not Amenable for Surgical Resection	GIBYTT	1	
			Neuroendocrine Tumours with Hepatic Disease	GIYTT	ı	
zanubrutinib	capsule	Lymphoma	Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma using Zanubrutinib	LYCLLZANU	ı	
				ULYWMZANU (previously ULYZANU)	R	
zoledronic acid	injectable	Breast		BRAJZOL5	I	
				BRAJZOL2	ı	
			treatment of acute bone pain secondary to breast cancer metastases using IV zoledronic acid	BRAVZOL	ı	
		Myeloma	treatment of multiple myeloma with zoledronic acid	MYZOL		
Protocol Code Definitions						
Bone Marrow Transplantation		BMT				
Breast		BR				
Gastrointestinal		GI				
Genitourinary		GU				
Gynecologic		GO				
Head and Neck		HN				
Kaposi's sarcoma		KS				
Leukemia		LK				
Lung		LU				
Lymphoma		LY				
Miscellaneous Origin		MO				
Myeloma		MY				
Neuro-Oncology		CN				
Ocular		OC				
Primary Unknown		PU				
Sarcoma		SA				
Skin & Melanoma		SM				
Tumour Agnostic		TA				
					1	